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Abstract 
 
Phosphodiesterase 4 enzymes hydrolyse the second messenger cyclic AMP and 
therefore are set to play an important role in cell signaling. In this thesis I investigate the 
phosphorylation  and  protein-protein  interactions  of  the  cAMP  hydrolyzing 
phosphodiesterase isoform, PDE4A4/5.  
In  the  first  of  my  studies  I  show  that  PDE4A4/5  can  be  phosphorylated  by 
MAPKAPK2 (MK2) the downstream kinase of the p38 MAPK signalling pathway. This 
phosphorylation reaction attenuates the degree of activation of PDE4A5 elicited through 
phosphorylation by Protein Kinase A. I also show that MAPKAPK2 can bind directly to 
PDE4A4/5 and map the two binding sites required by peptide array technology.  
In the second of my studies I show that PDE4A4/5 interacts with the low affinity 
neurotrophin receptor, p75NTR.  This interaction inhibits normal fibrin breakdown in an 
in vitro model. I also show that phosphorylation of PDE4A5 by MAPKAPK2 enhances 
the inhibition of fibrin breakdown and increases PDE4A5:p75NTR complex formation.  
In the final study described in this thesis I show that long form PDE4 isoforms 
contain a potential multi-functional docking site where several partner proteins are able 
to bind.  
In conclusion, the work described in this thesis provides a valuable insight into 
PDE4A4/5,  its  interacting  proteins,  phosphorylation  status  and  the  potential  for 
exploitation of this novel information therapeutically.   3 
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Chapter 1                     Introduction 
 
 
Understanding how cells communicate with each other in health and disease is a 
major topical issue that will impact considerably on human health. The mechanisms that 
underpin signal transduction in cells are complex and unravelling them provides a major 
challenge. 
 
With the exception of steroid hormones, most hormones and neurotransmitters 
cannot penetrate the cell membrane and must therefore elicit their response within the 
cell via signal transduction pathways that traverse the cell plasma membrane, radiate 
through the cell interior and, where appropriate, into intracellular organelles such as the 
nucleus. This process involves the conversion of an extracellular biological signal to an 
intracellular response. Initiation of this pathway begins through activation of a cell-
surface receptor by an agonist.  
 
The  second  messenger  concept  was  developed  through  studies  on  the  3’,  5’ 
cyclic adenosine monophosphate (cyclic AMP or cAMP) signalling system [Beavo and 
Brunton, 2002]. The receptor-mediated stimulation of cAMP generation (Figure 1.1) 
[Beavo and Brunton, 2002] envisages that when an agonist binds to a G Protein Coupled 
Receptor (GPCR) it is able to associate with a specific G-Protein, called Gs. This causes 
activation of Gs through GDP/GTP exchange, with the release of GTP-bound γ-subunit 
of Gs and a αβ complex. The GTP-bound, Gs γ-subunit, in turn, activates the membrane 
bound enzyme adenylyl cyclase, which leads to the production of cAMP from ATP and 
therefore an increase in intracellular levels of cAMP. Cyclic AMP can then activate 
important proteins like Protein Kinase A (PKA), Exchange Protein Activated by cAMP 
(EPAC) and cyclic nucleotide gated ion channels. This confers regulation on a myriad of 
fundamental  cellular  processes  such  as  transcription,  proliferation,  cardiac  function, 
learning and memory and apoptosis [Tasken and Aandahl, 2004].  
   18 
Cyclic  nucleotide  phosphodiesterases,  which  degrade  cAMP  to  5’-AMP,  are 
pivotal  to  signal  transduction,  not  only  as  regards  signal  termination  and  therefore 
negative regulation of cAMP within the cell, but also in shaping gradients of cAMP for 
compartmentalised cAMP signalling [Houslay. 2010]. 
 
 
 
 
 
 
 
 
Figure 1.1 -  cAMP cascade (adapted from Prof Miles Houslay). 
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1.1 G-Protein Coupled Receptors  
 
For the cAMP signalling pathway to be fully understood each of its components 
must be looked at in depth. Signalling is initiated by an agonist binding to G-Protein 
Coupled  Receptors.  GPCRs  are  the  widest  and  most  diverse  family  of  cell  surface 
receptors [Fredholm et al., 2007]. Structurally they consist of seven transmembrane α-
helices that span the plasma membrane. These seven α-helices are linked by alternate 
intracellular and extracellular loops. They can vary in length and can be subjected to N-
linked glycosylation at their extracellular surface [Hollmann et al., 2005]. The third 
transmembrane domain contains an amino acid essential for ligand specificity, which is 
situated C-terminally to a conserved cysteine residue [Yin et al., 2004]. If the ‘ligand 
specificity’ amino acid is basic the agonist binding the GPCR will most likely be a 
peptide but if the ‘ligand specificity’ amino acid is acidic then the agonist will most 
likely be an amine [Simon, Strathmann and Gautam, 2001]. The C terminal region of a 
GPCR consists of approximately 50 amino acids that are reasonably conserved through 
most GPCRs. The second and third cytoplasmic loop work in conjunction with the C-
terminal to confer ligand binding specificity [Simon, Strathmann, Gautam, 2001]. 
 
G-Protein  Coupled  Receptors  are  now  widely  thought  to  form  dimers  which 
confer important functional attributes such as signal transduction and plasma membrane 
localisation [Milligan, 2004]. 
 
 
1.1.1  Desensitisation of GPCRs 
 
Continuous  exposure  of  GPCRs  to  their  ligand  causes  a  profound  and  rapid 
desensitization of signalling [Kohout and Lefkowitz, 2003].  Desensitization occurs as a 
result  of  phosphorylation  of  the  C-terminal  by  G-protein  coupled  receptor  kinases 
(GRK). Indeed, GRK activity can itself be regulated by PKA and Extracellular-signal 
Regulated  Kinase  (ERK)  phosphorylation.  The  functional  consequence  of   20 
phosphorylation  by  GRK  is  to  trigger  the  binding  of  cytosolic  β-arrestin  to  the 
membrane-localised GPCR, which sterically blocks its G-protein coupling, causing a 
rapid desensitization [Li et al., 2006]. In cells where the cAMP degrading PDE4D5 
isoform  is  present  then  a  complex  of  this  isoform  together  with  β-arrestin  can  be 
delivered  to  an  agonist-activated  GPCR,  thus  delivering  an  active  cAMP  degrading 
system to the site of cAMP synthesis at the plasma membrane [Houslay, 2010]. This can 
form an additional part of the desensitization mechanism for cAMP signalling in cells. 
 
Receptor  internalisation  can  lead  to  long-term  desensitisation.  This  works 
through a similar mechanism involving β-arrestin but in this case the binding of β-
arrestin  causes  localisation  of  the  GPCR  to  clatherin  coated  vesicles.  Through 
interaction with clatherin and AP-2 this then leads to endocytosis of the complex. The β-
arrestin-bound  GPCR  can  then  either  become  de-phosphorylated  via  Protein 
Phosphatase 2 (PP2) in the early endosomes, after which it is recycled and returned to 
the cell surface or sent for degradation in lysosomes, with concomitant down-regulation 
of cell surface receptor levels and signalling [Hollmann et al., 2005]. Certain processes 
within the cell can prevent receptor recycling, such as palmitoylation, which involves 
the covalent attachment of palmitic acid to appropriate cysteine residues in the GPCR. 
Other means of regulation involve ubiquitination, which is the attachment of ubiquitin 
peptides to the GPCR, affecting its recycling and facilitating its degradation. 
 
 
1.2 G-Proteins 
 
The  second  step  in  the  cAMP  signalling  pathway  comes  in  the  form  of  G-
Proteins. G-proteins are guanine nucleotide binding proteins [Cabrera-Vera et al, 2003]. 
These  interact  with  the  second  and  third  intracellular  loops  and  the  C-terminal  of 
GPCRs.  There  are  four  major  classes;  Gs,  Gi/o,  Gq/11  and  G12/13.  G-proteins  are 
heterotrimeric and are composed of three subunits; Gα, Gβ and Gγ. In the inactive state 
the Gα unit is bound to GDP, which facilitates binding to a Gβ-Gγ complex that keeps 
the G-protein bound to the plasma membrane [Hollmann et al., 2005]. Activation of the   21 
GPCR leads to a conformational change in its intracellular loops causing activation of 
the guanine exchange factor, which results in GTP being substituted for GDP at the Gα 
subunit.  This  causes  dissociation  of  Gα  from  the  Gβ-Gγ  complex,  which  leads  to 
reduction of agonist binding [Hollmann et al., 2005]. 
 
Each of these classes demonstrates an affinity for particular partner GPCRs. The 
classes of G-proteins can bind GPCRs out with their partners but with a much lower 
affinity.  However  this  low  affinity  can  be  increased  through  phosphorylation  and 
palmitoylation. For example, when the β2-adrenoceptor is phosphorylated by protein 
kinase A (PKA) this reduces its affinity for its partner G-protein Gs but increases its 
affinity for the G-protein Gi/o [Hollmann et al., 2005]. 
 
 
1.3 Adenylyl Cyclases 
 
Following on from G-Proteins in the signalling cascade are the membrane-bound 
adenylyl cyclases. Adenylyl cyclases are a group of membrane-associated glycoprotein 
enzymes that convert ATP to cyclic AMP [Taskén and Aandahl, 2004]. There are 10 
adenylyl  cyclase  isoforms  that  all  exhibit  individual  tissue  specific  patterns  of 
localisation and specific means of regulation. 
 
They  have  two  trans-membrane  helical  domains  which  cause  membrane 
targeting and two cytosolic domains which become the catalytic site when they are in 
the correct conformation. Regulation of these active sites is controlled by the G-proteins 
upstream of them. 
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1.4 cAMP signalling 
 
 
When cyclic AMP was first proposed to be a second messenger eliciting signals 
from within the cell the theory of its role was controversial. It was not understood how 
one small molecule could play a role in so many different, independent, physiological 
roles [Beavo and Brunton, 2002]. However it is now understood that when cAMP is 
produced, by different adenylyl cyclase isoforms, it is diffused throughout the cell into 
distinct compartmentalised pools restricted by effector proteins such as AKAPs, PKA 
and  PDEs  [Baillie,  2009;  Zaccolo  et  al.,  2002;  Houslay,  2010].  cAMP  has  a  basal 
concentration of 1 µM in resting cells but this can rise to 10-20 µM in milliseconds to 
elicit a response. If it was left uncontrolled within the cell this would lead to disruption 
of compartmentalisation and uniform distribution which would result in an inappropriate 
response from the cell.  
 
 
1.4.1  Protein Kinase A 
 
The  first  cAMP  effector  identified,  PKA  is  a  Ser/Thr  protein  kinase  that 
phosphorylates  a  wide  range  of  target  proteins  at  the  consensus  site  Arg-Arg-Xaa-
[Ser/Thr]-Xhydrophobic.  It  is  a  heterotetramer  with  two  regulatory  and  two  catalytic 
domains. These are differentially expressed in different PKA holoenzymes on a cell type 
specific basis.  Four genes encode the regulatory domains; RIα, RIβ, RIIα, RIIβ. RI 
encodes PKA for subcellular cytosolic localisation whereas RII encodes it for targeting 
to AKAPs. The differences in these two forms are in the N-terminal portion of the 
regulatory subunits. The catalytic domain of PKA is encoded by three genes; Cα, Cβ, 
Cγ. PKA activation occurs when cAMP binds to the two regulatory subunits (2 cAMP 
molecules  per  subunit),  causing  dissociation  and  activation  of  the  catalytic  subunits 
allowing for phosphorylation of target proteins [Taskén and Aandahl, 2004]. However   23 
the  catalytic  domains  are  subject  to  interactions  with  the  PKA  inhibitor  PKI  that 
replaces PKA at the active site and abolishes PKA activity. 
1.4.2  EPAC 
 
When cAMP signalling was first being investigated it was initially thought that 
its only effectors were PKA and cAMP-gated ion channels. However now it is widely 
appreciated  the  cAMP  also  targets  an  exchange  protein  known  as  Epac  (exchange 
protein  directly  activated  by  cAMP).  This  protein  was  initially  identified  through 
database screening of an RT-PCR product to explain the PKA-independent activation of 
Rap, a small G protein, through cAMP activation [de Rooij et al., 1998]. Subsequently 
two isoforms of Epac were discovered, Epac 1 and Epac 2 [Kawasaki et al., 1998]. 
Structurally  they  are  multi-domain  proteins  containing  and  N-terminal  regulatory 
domain,  a  C-terminal  exchange  factor  domain  and  linking  these  a  Ras-assocation 
domain [ de Rooij et al., 2000]. Both isoforms are present in most tissues with different 
expression levels. Epac 1 is most abundant in adipose tissue, blood vessels, and the 
ovaries to name but a few, whereas Epac 2 is most abundant in the central nervous 
system and pancreas [Kawasaki et al., 1998].  
 
Functionally Epac proteins act as guanine exchange factors (GEFs) for the Rap 
family of small G-proteins. Their role is to catalyse the exchange of GDP to GTP on 
these G-proteins and therefore activate them [de Rooij et al., 2000]. Various effectors 
proteins downstream of Rap have been identified and it has been shown that Epac plays 
roles in cardiac function, insulin secretion, cerebral function and even immune response 
[Gloerich and Bos, 2010]. 
 
 
1.4.3  AKAPs 
 
AKAPs are A-Kinase (PKA) Anchoring Proteins [Langeberg and Scott, 2005] 
which, despite not being direct cAMP effectors play a very important role in cAMP 
signalling. To date more than 50 members of the AKAP family have been identified   24 
[Wong and Scott. 2004] and these are thought to play a key role in compartmentalisation 
and precision of cAMP signal transduction through binding of PKA into spatial specific 
areas throughout the cell [Carnegie et al., 2009]. Despite a lack of primary sequence 
homology between the AKAP isoforms they have been identified through the presence 
of  three  common  features:  an  anchoring  PKA  domain,  their  ability  to  bind  other 
signalling  enzymes  (such  as  phosphodiesterases)  and  their  ability  to  target  these 
enzymes and kinases to specific sites within the cell [Wong and Scott, 2004]. The first 
of these features, the anchoring site for PKA, has been widely studied. The majority of 
AKAPs bind PKA through its RII regulatory subunit [Carnegie et al., 2009] however 
dual specificity AKAPs which bind both RII and the other regulatory component of 
PKA the RI subunit have also been identified [Huang et al., 1997]. This R subunit 
binding configures PKA to a specific site within the cell, near other cAMP regulating 
components such as PDEs and allows for compartmentalisation of signalling [Baillie. 
2009]. A small 24mer peptide, Ht31, has been developed that binds the PKA binding 
site on AKAPs with nanomolar affinity and this is now being used in disruption studies 
to help identify the cellular and physiological function of AKAPs [Carr et al., 1992]. 
Indeed at a cellular level this has already been used to highlight the role of AKAPs in 
regulation of L-type calcium channels [Johnson et al., 1994] where when Ht31 is used 
cAMP  regulation  of  the  receptor  is  lost,  most  likely  due  to  a  lack  of  cAMP 
compartmentalisation. 
 
Despite these advances in the identification of a large number of AKAPs and the 
elucidation  of  their  ability  to  anchor  PKA,  their  physiological  role  is  not  greatly 
understood. Studies on Drosophila melanogaster have now shown that AKAPs play a 
role in learning and memory [Terman and Kolodkin, 2004]. However the development 
of knockout mice models for AKAPs has been less successful due to high levels of 
embryonic lethality or conversely lack of an obvious phenotype [Carnegie et al., 2009]. 
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1.5 Cyclic Nucleotide Phosphodiesterases 
 
Cyclic Nucleotide Phosphodiesterases (PDEs) play a major role in cell signalling 
by hydrolysing the cyclic nucleotides cAMP and cGMP into their 5’ mononucleotides. 
Due to their diversity they are found in many locations throughout the cell such as the 
cytosol, the plasma membrane, the cytoskeleton and the nucleus [Houslay and Adams, 
2003]. The PDE super-family is represented by 11 gene families (PDE1-11). However 
the occurrence of mRNA splicing and multiple genes within various families leads to 
the potential for a large number of PDE isoforms being expressed. Some PDE families 
specifically hydrolyse cAMP (PDE4, 7, 8) some both cAMP and cGMP (PDE1, 2, 3, 10, 
11) and others which can hydrolyse only cGMP (PDE5, 6, 9) [Conti and Beavo, 2007; 
Lugnier, 2006]. The structure of the catalytic units of various PDEs has been solved 
recently and this has identified the cyclic nucleotide binding pocket and given insight 
into the catalytic mechanism [Zhang et al., 2004]. Structural studies have also given 
insight into the basis of selectivity of active site targeted competitive PDE inhibitors and 
aided in the development of more potent and selective inhibitors [Ke and Wang, 2007; 
Zhang et al., 2004; Card et al., 2005]. Use of these inhibitors has then given an insight 
into the functional role of specific PDEs within the body and led to the development of 
several  therapeutics.  Examples  of  these  are  the  selective  PDE4  inhibitors  in 
development for treating inflammatory diseases [Houslay et al., 2005], PDE3 inhibitors 
that are used to treat intermittent claudication [Thompson et al., 2007] and, of course, 
the most famous PDE inhibitor to date, namely Sildenafil (Viagra), which is a PDE5 
specific inhibitor used to treat erectile dysfunction and infant and, more recently, adult 
pulmonary  hypertension  [Francis  and  Corbin,  2005;  Huddleston  et  al.,  2009;  Singh, 
2010].  Along  with  the  therapeutic  advances  developed  through  research  into  PDE 
isoforms,  research  into  PDE4  enzymes  in  particular  has  helped  to  develop  the 
understanding of compartmentalisation of cAMP signalling and the role of PDEs in 
cross-talk between signalling pathways [Houslay and Adams, 2003; Houslay, 2010].  
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Table 1.1: Classification of PDE enzyme super-family. 
 
Substrates 
PDE  Genes 
cAMP  cGMP 
Regulation 
Regulatory 
Domains 
1  A, B and C  √  √ 
Ca
2+/CaM 
PKA and CaMK 
 
Ca
2+/CaM 
Binding 
2  A  √  √ 
Activated by cGMP 
Phosphorylated by PKC 
 
GAF-A, GAF-
B 
3  A and B  √  x 
Inhibited by cGMP 
Phosphorylated  by  PKA, 
PKB/Akt & PI3-K 
 
4 
A,  B,  C  and 
D 
√  x 
Phosphorylated  by  PKA 
and ERK1/2 
 
UCR1, UCR2 
5  A  x  √ 
Binds cGMP 
Phosphorylated  by  PKA 
and PKG 
GAF-A, GAF-
B 
6  A, B and C  x  √ 
Activated  by  Rhodopsin 
and Transducin (Gt) 
 
GAF-A, GAF-
B 
7  A and B  √  x   
 
 
 
8  A  √  x 
 
 
 
PAS 
9  A  √  √ 
 
 
 
REC   27 
10  A  √  √ 
Inhibited by cAMP 
 
 
GAF-A, GAF-
B 
11  A  √  √ 
 
 
 
GAF-A, GAF-
B 
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1.5.1  Phosphodiesterase 1 
 
Phosphodiesterase 1 (PDE1) enzymes are encoded by 3 genes (A-C), expressed 
as multiple splice variants [Wang et al., 1990]. They can hydrolyse both cAMP and 
cGMP but have a lower Km value for cGMP and therefore shows higher affinity for it 
than for cAMP (Km values = 1-100 µM for cAMP and 1-5 µM for cGMP) [Francis et 
al., 2001]. Structurally PDE1 enzymes consist of two paired Ca
2+ calmodulin domains 
(CaM)  which,  with  the  binding  of  four  calcium  ions,  cause  activation  of  enzymatic 
activity [Huang et al., 1981].  This means that increased intracellular calcium levels 
generate a fall in cAMP/cGMP levels by activating PDE1, thus providing a point of 
cross talk. Regulation of PDE1 enzymes is thought to occur through phosphorylation by 
PKA and CaM kinase II which down-regulate its action by attenuating CaM binding 
[Sharma, 1991; Sharma & Wang, 1986].  
 
PDE1 isoforms are differentially expressed in cells; with particularly high levels 
found in the central nervous and cardiac systems [Yan et al., 1994; Miller et al., 2009]. 
In the central nervous system the enzymes exists in an auto-inhibited state but can also 
be inhibited by vinpocetine and nicardipine [Yan et al., 1996; Lefievre et al., 2002]. In 
recent  years  specific  PDE1  inhibitors  have  been  developed  with  the  hope  of 
development of a potential therapeutic for Parkinsons disease however the results of this 
work are as yet inconclusive [Laddha and Bhatnagar, 2009]. In the cardiac system a role 
for  the  PDE1A  isoform  has  been  implied  to  regulate  pathological  cardiomyocyte 
hypertrophy through a cGMP/PKG dependent mechanism. This demonstrates cross-talk 
between cGMP and Ca
2+ signalling pathways during cardiac hypertrophy [Miller et al., 
2009]. 
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1.5.2  Phosphodiesterase 2 
 
Phosphodiesterase 2 (PDE2) enzymes are encoded by one gene and have 3 splice 
variants  [Francis  et  al.,  2001].  They  can  hydrolyse  both  cAMP  and  cGMP  and  are 
unique in that they are activated by a decrease in Km rather than an increase in Vmax as 
is usually observed in the other members of the PDE family [Erneux et al., 1981]. The 
Km value is 15-30 µM for both cAMP and cGMP [Erneux et al., 1981]. 
 
Structurally PDE2 enzymes have paired cGMP-binding GAF domains [Ho et al., 
2000]. The GAF acronym is derived from the names of the first 3 classes of proteins 
recognized to contain this domain, namely cGMP-binding PDEs, Anabaena adenylyl 
cyclases and Escherichia coli (FhlA) [Aravind and Ponting, 1997]. There are now more 
than 1400 proteins in the non-redundant database that are predicted to contain a GAF 
domain [Zoraghi et al., 2004]. These GAF domains promote hydrolysis of cAMP in a 
positively homotrophic/ cooperative fashion with a hill coefficient of >1 [Erneux et al., 
1981]. This means, therefore, that small increases in intracellular cGMP concentration 
can lead to a decrease in intracellular cAMP concentration in cells or compartments 
where PDE2 is located [Martinez et al., 2002; Mongillo et al., 2006]. However, higher 
levels of cGMP will then compete out cAMP for binding to the PDE2 active site and 
thus inhibit cAMP hydrolysis by this enzyme.  
 
PDE2 is expressed in many different parts of the body with the main sites of 
expression  being  the  adrenal  medulla,  heart,  liver  and  brain  [Yanaka  et  al.,  2003; 
Coudray et al., 1999]. It is essentially a soluble, cytosolic enzyme. However, alternative 
mRNA  splicing  yields  isoforms  with  N-terminal  regions  that  confer  membrane 
association.  
 
PDE2  is  thought  to  play  a  major  feedback  role  for  cyclic  nucleotides  under 
hormonal regulation and plays an important role in feedback between cAMP and cGMP. 
Two PDE2 selective inhibitors are EHNA (erythro-9-(hyroxy-3-nonyl) adenite) and Bay   30 
60-7550. EHNA binds to both the catalytic and the regulatory sites of PDE2 [Michie et 
al., 1996]. However, EHNA also acts as an adenosine deaminase inhibitor. Recently it 
has  been  discovered  that  PDE2  may  play  an  important  role  in  cardiac  inotrophy 
[Mongillo et al., 2006] and mediating angiogenesis through Rac1 and NADPH oxidase, 
providing a potential new therapeutic target for endothelial dysfunction, oxidative stress, 
vascular proliferation and angiogenesis [Diebold et al., 2009]. 
 
 
1.5.3  Phosphodiesterase 3 
 
Phosphodiesterase 3 (PDE3) enzymes are encoded by 2 different genes [He et 
al., 1998]. They specifically hydrolyse cAMP but this hydrolysis can be competitively 
inhibited by cGMP [Lugnier, 2006]. The Km value of hydrolysis of both cAMP and 
cGMP is 0.1-0.8 µM however cAMP has a higher Vmax value for hydrolysis [Francis, 
2001]. This therefore means that PDE3 enzymes provide a means by which increased 
intracellular cGMP can lead to increased intracellular cAMP by selective inhibition of 
PDE3. 
 
PDE3 enzymes play a key role in metabolic signalling, specifically in adipocytes 
and  hepatocytes  [Meacci  et  al.,  1992;  Wechsler  et  al.,  2002].  Here  it  mediates  the 
functional consequences of insulin on cAMP concentration [Zhao et al., 2002]. Insulin 
triggers  Protein  Kinase  B  (PKB/Akt)  to  phosphorylate  and  activate  PDE3,  thereby 
decreasing  cAMP  concentration  and  inhibiting  lipolysis,  gluconeogenesis,  and 
glycogenolysis [Geoffroy et al., 2001] where it is critical in underpinning insulin action 
adipocytes, counteracting action of adrenaline. 
 
Another important role for PDE3 has been found in the cardiac system. Here 
PDE3 has been shown to play several roles including control of myocyte contraction 
and  relaxation  through  regulation  of  cAMP  at  L-type  Ca
2+  channels  and  through 
modulating calcium current by facilitating the constitutive association of SERCA2 with 
PI3 Kinase [Kakkar et al., 1999].   31 
Selective inhibitors of PDE3 have been generated and these have been shown to 
exert a marked effect on cardiac function [Moos et al., 1987]. These inhibitors were 
originally developed as positive ionotropic agents for treating congestive heart failure 
[Bristol et al., 1984]. The compound milrinone in particular is a moderately selective, 
first  generation  PDE3  inhibitor  with  a  Ki  value  of  0.5  µM  [Mongillo  et  al.,  2004]. 
Milrinone,  however,  was  withdrawn  from  clinical  use  due  to  side  effects,  namely 
arrhythmias,  probably  because  it  also  could  exert  effects  on  other  PDEs,  including 
PDE4.  However, the pure PDE3 selective inhibitor cilostazol is now considered safe 
and used clinically to treat intermittent claudication by inhibiting platelet aggregation 
[Liu et al., 2001]. 
 
 
1.5.4  Phosphodiesterase 4 
 
This family of cAMP specific enzymes is discussed in detail below (see Section 
1.6). 
 
 
1.5.5  Phosphodiesterase 5 
 
Phosphodiesterase  5  (PDE5)  enzymes  are  encoded  by  one  gene  which  has  5 
splice  variants  [Lin  et  al.,  2002].  They  specifically  hydrolyses  cGMP  and  are  most 
commonly known as the target for Viagra (Sildenafil) used to treat Erectile Dysfunction 
[Coquil  et  al.,  1980;  Boolell  et  al.,  1996].  Structurally  they  have  two  paired  GAF 
domains that are a site for cGMP binding with a Km of 5-20 µM [Francis et al., 2001]. 
This binding initially alters activation and conformation of PDE5 and is also thought to 
influence phosphorylation by PKA and Protein Kinase G [Francis et al., 2002].  
 
PDE5 is expressed throughout the body with highest expression levels seen in 
the  lungs,  heart,  blood  vessels  and  brain  [Giordano  et  al.,  2001].  The  most  famous 
inhibitor of PDE5, Viagra, promotes smooth muscle relaxation and increases the blood   32 
flow to the corpus cavernosum by preventing the PDE5 hydrolysis of cGMP [Lin et al., 
2003]. More recently it has also been used to treat infantile and severe adult pulmonary 
hypertension [Huddleston et al., 2009; Singh, 2010]. 
 
 
1.5.6  Phosphodiesterase 6 
 
Phosphodiesterase 6 (PDE6) enzymes are encoded by three genes with multiple 
splice variants [Gillespie & Beavo, 1989]. PDE6 specifically hydrolyses cGMP with a 
Km value of 5-20 µM [Miki et al., 1975]. Structurally they contain two paired GAF 
domains and appear to be a tetramer with one alpha catalytic subunit, one beta catalytic 
subunit and two gamma regulatory (inhibitory) subunits [Gillespie & Beavo, 1989].  
 
PDE6 is membrane bound and found exclusively in the rods and cones of the 
eyes [Francis et al., 2001 and Houslay, 2001]. PDE6 is light activated via rhodopsin, 
which couples to the G-protein, transducin [Chabre et al., 1988]. Rod PDE6 enzymes 
consist of one α, one β, two γ subunits whereas cone PDE6 enzymes consist of two α 
and two γ subunits [Artemyev et al., 1996]. Rhodopsin absorbs a photon of light, which 
then physically interacts with transducin causing an exchange of GDP for GTP. The 
GTP-bound transducin undergoes a conformational change such that it interacts with 
and activates, membrane bound PDE6 by triggering the release of the inhibitory gamma 
subunits from this enzyme [Morin et al., 2001; Pugh & Lamb, 1990]. The consequential 
increase  hydrolyses  cGMP  to  GMP  allowing  the  closure  of  cGMP-gated  channels 
located in the plasma membrane of photoreceptors [Beavo, 1995]. 
 
Recently  a  potential  role  for  PDE6  in  retinal  malignant  melanoma  has  been 
identified. In these melanoma cells activation of PDE6 through the Wnt5a–Frizzled-2-
transducin cascade leads to a decrease in cGMP allowing for a build-up of calcium 
which in turn can regulate the metabolism of the melanoma cells [Bazhin et al., 2010]. If 
this  pathway  occurs  in  cells  out  with  the  eyes  inhibition  of  PDE6  may  provide  a 
potential non-invasive therapeutic for malignant melanoma.   33 
1.5.7  Phosphodiesterase 7 
 
Phosphodiesterase 7 (PDE7) enzymes are encoded by two genes, one of which 
has splice variants [Beavo, 1995]. They are specific for cAMP for which they have been 
shown to have an extremely low Km value of 0.01-0.05 µM [Michaeli et al., 1993]. 
PDE7A is ubiquitously expressed throughout the body but is particularly well expressed 
in the pro-inflammatory and immune system [Smith et al., 2003] whereas PDE7B is 
expressed throughout the heart, skeletal and brain tissues but its expression is lower than 
PDE7A in the immune system [Hetman et al., 2000].  
 
The majority of PDE7 research has focussed on the role of PDE7A. In T-cells in 
particular a functional role for PDE7A has been proposed where it is envisaged that 
PDE7  may  regulate  T-cell  proliferation  and  activation.  In  T-cells  the  main  PDE 
isoforms present in resting cells are PDE3 and PDE4, however it was shown that upon 
T-cell activation PDE7A is up-regulated and if this is up-regulation of PDE7 is inhibited 
there is a loss of T cell proliferation [Li et al., 1999; Smith et al., 2003]. As a result of 
this  discovery  several  PDE7  inhibitors  have  been  developed.  These  include  several 
unnamed pyrimidine inhibitors shown that selectively inhibit PDE7A and have been 
shown  to  have  some  effect  in  vitro  on  T  cell  proliferation  [Guo  et  al.,  2009]  and 
ASB16165,  a  novel  inhibitor  for  PDE7A,  that  suppresses  IL-12-induced  IFN-γ 
production  by  mouse  activated  T  lymphocytes  in  vitro  [Kadoshima-Yamaoka  et  al., 
2009].  However  it  should  be  noted  that  studies  using  knock-out  animals  have  not 
supported the notion of any particular role of PDE7 inhibitors as regulators of T-cell 
functional and potential as anti-inflammatory agents and PDE7 selective inhibitors have 
no shown any particular promise as anti-inflammatory agents [Guo et al., 2009; Yang et 
al., 2003].  
 
Despite  PDE7B  only  having  low  level  expression  in  the  immune  system  in 
normal circumstances its expression has been found to be up-regulated in B cells and 
peripheral  blood  mononuclear  cells  in  chronic  lymphocytic  leukaemia,  the  most 
common form of adult leukaemia. It has also been shown that inhibition of PDE7 in   34 
these leukaemia cells leads to apoptosis in vitro, providing a potential therapeutic target 
for treatment of this form of leukaemia [Zhang et al., 2008]. 
 
 
1.5.8  Phosphodiesterase 8 
 
Phosphodiesterase  8  enzymes  are  encoded  by  two  genes  and  many  splice 
variants [Fisher et al., 1998; Hayashi et al., 1998]. They are specific for cAMP with a 
very low Km value of 0.06 µM [Francis et al., 2001]. They are one of the only known 
PDE  subfamily  members  that  are  insensitive  to  inhibition  by  IBMX 
(isobutylmethylxanthine) [Hayashi et al., 1998; Lavan et al., 1989]. Structurally they 
contain a single Per-ARNT-Sim (PAS) domain that has been shown in other proteins to 
mediate  protein-protein  interaction  so  may  regulate  PDE8’s  intracellular  distribution 
[Wang et al., 2001]. Expression of PDE8 is highest in the testis [Soderling et al., 1998] 
but  it  has  also  been  shown  to  be  involved  in  regulation  of  T-cell  activation  and 
chemotaxis of activated lymphocytes [Glavas et al., 2001; Dong et al., 2006].  
 
Unfortunately until recently purification of PDE8 was not possible therefore its 
crystal structure could not be solved and in turn selective PDE8 inhibitors have not been 
developed. However recent structural studies may help solve this problem and lead to 
the  development  of  inhibitors  [Wang  et  al.,  2008].  This  may  be  of  major  potential 
therapeutic benefit as a recent clinical study has shown that PDE8 is up-regulated in the 
hippocampus of end stage patients with Alzheimers Disease [Perez-Torres et al., 2003]. 
 
 
1.5.9  Phosphodiesterase 9 
 
Phosphodiesterase 9 (PDE9) enzymes are encoded by one gene but it is thought 
to  be  a  rather  complicated  isoform  as  up  to  20  splice  variants  have  been  identified 
[Rentero and Puigdomenech, 2006]. They are cGMP specific and have the lowest Km 
value for cGMP known to date at 0.07 µM [Fisher et al., 1998]. Structurally they are not   35 
thought  to  contain  GAF  domains  but  may  contain  REC  domains  instead  [Lugnier, 
2006]. CheY-like phosphoacceptor (or receiver (REC)) domain is a common
 module in 
a  variety  of  response  regulators  of  the  bacterial
  signal  transduction  systems.  REC 
domains  have  a  propensity  to  regulate  dimerisation  and  protein-protein  interactions 
[Galperin, 2006]. Thus they may be involved in either targeting of PDE9 or regulation 
by dimerisation.  
 
PDE9A isoforms are expressed in several regions of the brain where it has been 
implied  to  play  a  role  in  cognition  [Reyes-Irisarri  et  al.,  2007]  and  has  also  been 
proposed to play a role in diabetes as PDE9 knockout mice developed an diabetes like 
phenotype when placed on a high fat diet [DeNinno et al., 2009]. PDE9 isoforms are 
insensitive  to  IBMX  but  their  actions  are  attenuated  by  zaprinast  and  SCH  51866 
[Soderling et al., 1998]. Few selective PDE9 inhibitors have been developed. However 
of those that have the novel selective PDE9 inhibitor BAY 73-6691 has been shown to 
improve learning and memory in rodents [van der Staay et al., 2008]. 
  
 
1.5.10  Phosphodiesterase 10 
 
PDE10 enzymes are encoded by one gene and have been indicated to have many 
splice variants [Kotera et al., 1999; O’Connor et al., 2004]. They can hydrolyse both 
cAMP and cGMP with Km values of 0.05-0.26 µM and 3-7.2 µM respectively and a 
Vmax value 5 times higher for cAMP than cGMP [Lugnier, 2006]. Structurally they 
have two paired GAF domains but so far there is no evidence that these can bind cGMP 
[Lugnier, 2006]. IBMX, dipyridamole and zaprinast all inhibit PDE10.   
 
It is ubiquitously expressed throughout all human tissues [Soderling et al., 1999] 
but  its  unique  distribution  of  expression  in  the  brain  has  lead  to a  great  amount  of 
research. In the brain PDE10 expression is very high in the caudate putamen, nucleus 
accumbens,  and  the  olfactory  tubercle,  however  expression  is  minimal  in  cortex, 
hippocampus, and cerebellum [Kelly and Brandon, 2009]. This distribution has lead to a   36 
great  deal  of  interest  in  the  potential  role  of  PDE10  in  schizophrenia.  In  PDE10A 
knockout  mice  a  decrease  in  basal  locomotor  activity  and  impaired  learning  of  a 
conditioned  avoidance  task  was  observed  which  is  consistent  with  a  model  of 
schizophrenia  [Siuciak  et  al.,  2008].  These  mice  also  show  increased  sensitivity  to 
indirect dopaminergic agonists [Siuciak et al., 2008]. Indeed it has also been shown that 
selective  PDE10  inhibitors  developed  by  Wyeth  modulate  the  dopamine  striatal 
pathways and can improve both the positive and negative symptoms of schizophrenia 
[Grauer et al., 2009]. 
 
 
1.5.11  Phosphodiesterase 11 
 
PDE11  enzymes  are  encoded  by  just  one  gene  and  have  4  splice  variants 
[Hetman et al., 2000]. It exhibits dual specificity in a similar way to PDE10 but has a 
Km value of about 0.75 µM for both cAMP and cGMP [Francis et al., 2001]. Only some 
of  its  isoforms  express  two  paired  GAF  domains  in  a  way  that  is  similar  to  the 
expression of UCR domains in PDE4. The presence of these GAF domains may allow 
for regulation by PKA and PKG phosphorylation [Yuasa et al., 2000].  
 
The  range  of  tissues  that  express  this  enzyme  is  controversial  and  little  is 
understood about its function. Studies into its expression in the brain have shown that 
expression is limited but through knockout mice models it has been shown to play a 
vital role in brain function with lack of this enzyme leading to hyperactivity and loss of 
social function [Kelly et al., 2010]. Other research using PDE11 knockout mice has 
shown that these mice exhibit reduced sperm concentration and live spermatozoa after 
ejaculation implying that this isoform plays an important role in reproduction [Wayman 
et al., 2005].   37 
 
Figure 1.2 - Modular structure of PDE enzyme super-family.    38 
1.6 Phosphodiesterase 4 
 
 
PDE4 enzymes specifically hydrolyse cAMP.  They are encoded by four genes 
(PDE4A, PDE4B, PDE4C and PDE4D), which are located on three chromosomes in 
humans [Houslay et al., 1998; Houslay and Adams, 2003; Houslay, 2010].  The genes 
for  both  PDE4A  and  PDE4C,  are  located  at  19p13.2  and  19p13.1,  respectively,  on 
chromosome 19 [Milatovich et al., 1994 and Sullivan et al., 1999].  The PDE4B and 
PDE4D genes are located on chromosomes 1p31 and 5q12 respectively [Milatovich et 
al., 1994 and Szpirer et al., 1995]. These four PDE4 genes in turn encode upwards of 20 
different  isoforms  each  of  which  is  characterised  by  a  unique  N-terminal  region 
[Houslay and Adams, 2003].  The N-terminal region of each isoform is encoded by 
unique 5’ exons. As well as this unique N-terminal region, PDE4 isoforms exhibit two 
Upstream Conserved Regions (UCR1 and UCR2), a conserved catalytic unit and a C-
terminal region that is unique to each of the four PDE4 subtypes. The two UCR regions 
are joined together by regions known as Linker Region 1 (LR1) and Linker Region 2 
(LR2). Figure 1.3 details the encoding of these exons. 
 
 
 
 
Figure 1.3: Structure and encoding of PDE4 Isoforms (Houslay and Adams, 2003).   39 
1.6.1  N-Terminal 
 
One of the most important roles of the unique N-terminal region in PDE4 is to 
confer intracellular targeting of the isoforms leading to compartmentalisation within the 
cell. It invariably confers the ability of the PDE4 isoform to interact specifically with 
other signalling complexes [Houslay, 2010]. One example of this is the interaction of 
PDE4A4/5  with  the  Src  tyrosyl  kinase  Lyn  [McPhee  et  al.,  1999],  which  will  be 
discussed  in  detail  later  and  another  is  the  binding  of  PDE4D5  to  the  signalling 
scaffolds, RACK1 and β-arrestin [Bolger et al., 2006]. 
 
 
1.6.2  UCR1 and UCR2 
 
As  seen  in  Figure  1.3,  PDE4  isoforms  can  be  sub-grouped  into  long,  short, 
super-short and dead-short forms depending on the presence of the regulatory UCR1 and 
UCR2 regions and, in the case of dead-short variants, a severe C-terminal truncation 
[Houslay, 2001; Houslay and Adams, 2003; Houslay et al., 2007]. Long forms have 
both UCR1 and UCR2 present as well as linker regions LR1 and LR2 that, respectively, 
connect UCR1 to UCR2 and UCR2 to the catalytic unit whereas short forms possesses 
an intact UCR2 but lack UCR1 and LR1. Super-short forms also lack UCR1 and LR1 
but possess a truncated version of UCR2.  The dead short forms lack both regulatory and 
linker regions and are both N and C-terminally truncated into the catalytic units such 
that  they  are  uniquely  enzymatically  inactive  and,  as  such  may  have  a  scaffolding 
function [Johnston et al., 2004]. 
  
UCR1 and UCR2 can interact with each other to form a regulatory module that 
interacts with and regulates the catalytic domain [Beard et al, 2000]. As recent structural 
data shows, this is achieved by the binding of UCR2 alongside and across the active site 
of the catalytic unit [Houslay and Adams, 2010; Burgin et al., 2010]. 
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1.6.3  Catalytic Domain 
 
The catalytic unit of all PDE4 isoforms consists of 17 α-helices, which form 3 
distinct  sub-domains.  These  sub-domains  comprise  of  eight,  four  and  six  helices 
respectively and a short β-hairpin [Houslay and Adams, 2003 and Xu et al., 2000]. 
UCR2  is  known  to  exhibit  an  auto-inhibitory  effect  on  the  core  catalytic  domain 
although the structural reason for this remained unclear until recently. Thus the recent 
elucidation of the UCR2-bound catalytic region greater insight into the function of this 
region has been discovered [Burgin et al., 2010]. In this structure an α-helical sequence 
within UCR2 was shown to bind across the catalytic pocket, thereby forming a gate 
controlling substrate and inhibitor access to it [Burgin et al., 2010]. Uncapping of this 
UCR2 ‘gate’ allows cAMP to bind to the PDE.  
 
Hydrophobic residues and residues with negatively charged side chains form a 
cAMP-binding  pocket  between  the  three  sub-domains  [Houslay,  2001].  This  pocket 
contains two divalent cation binding sites. The first binding site tightly binds a Zn
2+, 
which is co-ordinated by four amino acids (His-238, His-274, Asp-275 and Asp-392) 
The second site usually binds Mg
2+ but may also bind either Zn
2+ or Mn
2+ [Houslay and 
Adams, 2003]. This binding is co-ordinated by five amino acids (His-274, Glu-304, His-
307, Thr-345 and Asp-392). The nine amino acids involved in the binding of these metal 
ions are highly conserved across all 11 members of the PDE family. The metal ions are 
essential for cAMP hydrolysis [Laliberté et al., 2002].  Interestingly, it is changes in the 
side-chain orientation of a single amino acid within the active site of different PDE 
families that confers selectivity between cAMP and cGMP [Wang et al., 2007].  
 
Recent structure studies have helped give greater insight into how inhibitors of 
PDE4 bind and help to explain their somewhat complicated inhibitor kinetics. Certain 
inhibitors  such  as  RS25344  interact  favourably  with  the  gating  sequence  of  UCR2, 
stabilizing the UCR2 into the capped state whereas inhibitors like Roflumilast, which 
has recently gained approval in Europe for treating COPD, interact less favourably with 
the capped UCR2 and instead preferentially occupies the uncapped catalytic pocket.   41 
Interestingly the more complicated PDE4 inhibitors, in terms of the range of affinities 
shown  for  enzyme  preparations  from  different  tissues,  such  as  Rolipram  are  now 
understood  to  have  affinity  for  the  catalytic  pocket  in  both  the  UCR2  capped  and 
uncapped states. This may explain why the action of inhibitors like rolipram can be 
altered  by  PKA  phosphorylation  of  long  forms  and  by  protein-protein  interactions 
involving PDE4 [Burgin et al., 2010; Houslay and Adams, 2010]. 
 
 
1.6.4  C-terminal 
 
The C-Terminal domain of PDE4 isoforms is differs somewhat between each of 
the four sub-families. The functional significance of this is unknown, although recent 
structural  studies  suggest  that  the  C-terminal  portion  of  the  catalytic  unit  can,  like, 
UCR2,  cap  the  active  site.  This  may  point  to  a  potential  regulatory  role  for  the  C-
terminal [Burgin, 2010].  Interestingly the C-Terminal domain of PDE4B, C and D, but 
not PDE4A, shows conservation between mammalian species and the significance of 
this divergence for PDE4A remains to be elucidated [Hoffmann et al., 1998].  
 
 
 
1.7 Phosphodiesterase 4 Isoforms 
 
 
1.7.1  Phosphodiesterase 4A 
 
PDE4A has several different isoforms some of the most notable being PDE4A4 
[Huston et al., 1996], 4A5 [McPhee et al., 1995], 4A8 [Huston et al., 2000; MacKenzie 
et al., 2008], 4A10 [Rena et al., 2001] and 4A11 [Wallace et al., 2005]. The function of 
this  group  of  enzymes  is  only  recently  being  uncovered  as  they  are  present  at 
notoriously low levels endogenously, there are no selective inhibitors and genetically 
modified  (KO)  animals  have  not  been  generated.  The  PDE4A  isoforms  are  unusual   42 
amongst the PDE4 gene families because their C-terminal regions are not conserved 
across humans and rats [Houslay and Adams, 2003]. A good example of this is that 
PDE4A4 is expressed in humans and is the homologue of the rat enzyme PDE4A5 
[Terry et al., 2003].  Both of these isoforms are long form phosphodiesterases with 
similar  molecular  weights  (99kDa  and  94kDa  respectively  [Huston  et  al.,  1996  and 
McPhee et al., 1995]), however the rat homologue has a significantly lower cytosolic 
Vmax value than the human homologue [Houslay and Adams, 2003]. 
 
PDE4A8  is  expressed  in  rats  and  humans  and  is  a  long  isoform  of  88kDa 
[MacKenzie  et  al.,  2008;  Bolger  et  al.,  1996].  PDE4A10  and  4A11  are  also  long 
isoforms, with a molecular weight of 93kDa but these are expressed in both humans and 
rats [Wallace et al., 2005]. 
 
 
1.7.1.1 PDE4A Brain Distribution Patterns 
 
PDE4A  isoform  brain  expression  has  been  studied  [McPhee  et  al.,  2001]  in 
relation  to  the  two  long  form  isoforms,  PDE4A5  and  PDE4A10  and  the  short  for 
PDE4A1. PDE4A5 and PDE4A10 expression was shown to be highest in the olfactory 
bulb and both displayed a very similar distribution pattern throughout the brain except 
for in the major island of Calleja where only PDE4A10 is present. This suggests that the 
two  long  forms  may  have  similar  promoter  regions  but  are  likely  to  have  distinct 
functional  roles  within  the  cells.  The  short  PDE4A1  isoform  was  shown  to  be 
distributed highest in the olfactory bulb, the cerebellum and the paraflocculus [McPhee 
et al., 2001]. More recent work has also shown that the long PDE4A8 isoform is also 
distributed throughout the brain, in particular in the cortex, spinal cord and cerebellum 
[MacKenzie et al., 2008]. 
 
Several partner proteins have been identified for the different PDE4A isoforms. 
These are described in detail below. 
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1.7.1.2 PDE4A aggregation and p62 (sequestosome1, SQSTM1) 
 
 
Chronic  challenge  of  PDE4A4  with  rolipram  causes  it  to  form  reversible 
intracellular  aggregates.  These  aggregates  are  not  stress  processing  bodies  or  stress 
granules  as  they  do  not  contain  the  regulating  proteins  necessary  to  make  these 
complexes. PDE4A4 aggregates have also been shown to not be autophagosomes or 
aggresomes. However microtubule disruptors do prevent the aggregates from forming. 
Instead  it  has  been  shown  that  PDE4A4  interacts  with  p62  protein  (sequestosome1, 
SQSTM1)  in  these  aggregates,  and  loss  of  p62  from  this  complex,  via  the  mTor 
inhibitor  rapamycin,  prevents  aggregation  from  occurring.  The  purpose  for  this  is 
proposed to be a novel regulatory mechanism where a sub-population of p62-interacting 
PDE4A4 aggregates form in a rapid, reversible manner which is thought to be used to 
sequester the PDE4A4 away from its important functional site within the cell [Christian 
et al., 2010]. 
 
 
1.7.1.3 PDE4A and Src Homology 3 binding domains  
 
The Src Homology 3 (SH3) binding domain is a distinct small protein domain of 
roughly 60 amino acids which are self-folding. It allows protein-protein interaction by 
binding to proline rich motifs on acceptor proteins. It is found in a variety of families of 
proteins  such  as  the  Src  tyrosyl  family  kinases  [Pawson,  1995].  Certain  PDE4A 
isoforms  (PDE4A4B  and  PDE4A5)  contain  proline-  and  arginine-rich  sites  for 
interaction with SH3 domains. The Src family tyrosyl kinases interact with PDE4A5 
through SH3 domain binding in PDE4A5s N-terminal region [O’Connell et al., 1996]. 
The SH3 domain of the Src tyrosyl kinase Lyn has also been shown to interact with the 
human homologue of PDE4A5 which is PDE4A4B. This interaction occurs at a proline 
and arginine rich motif (RPRPSQP) within the LR2 region of the enzyme [McPhee et 
al.,  1999].  PDE4A4B  can  exhibit  two  different  sensitivities  for  the  PDE4  specific 
inhibitor rolipram dependent on where it is located in the cell. When it is located in the   44 
cytoplasm it exists in a low affinity rolipram binding state (LARBS) whereas if it is 
membrane bound it exists in a high affinity rolipram binding state (HARBS) which is 
approximately 60 times more sensitive to rolipram [Huston et al., 1996]. Interestingly 
interaction of the SH3 domain of Lyn with PDE4A4B mimics HARBS throughout the 
cell [McPhee et al., 1999]. This is now thought that this may be because Lyn can still 
interact with, and elicit its effect on PDE4A4B even when the inhibitor rolipram is 
bound to the catalytic site of the enzyme [Burgin et al., 2010; Houslay and Adams, 
2010].  
 
 
1.7.1.4   PDE4A and the immunophilin XAP2 
 
XAP2/Ara9 is an immunophilin that was first identified as a protein that interacts 
with the X protein of the hepatitis B virus [Kuzhandaivelu et al., 1996]. It is 38kDa long 
and  contains  an  N-terminal  immunophilin  homology  domain  and  a  C-terminal 
tetratricopeptide repeat (TPR) domain. It has been shown to interact with heat shock 
protein  90  (Hsp90),  the  aryl  hydrocarbon  receptor  and  certain  phosphodiesterases, 
specifically PDE4A5 [Bolger et al., 2003].   
 
PDE4A5 has a highly conserved TPR domain in its UCR2 region which allows 
for binding to XAP2 along with another binding region in its unique N-terminal domain 
[Bolger et al., 2003]. This is the only PDE isoform that XAP2 can interact with in this 
way except for its human orthologue, PDE4A4, which has the same binding residues 
conserved within its sequence. Although XAP2 doesn’t bind directly to the catalytic site 
of PDE4A5 it inhibits its enzymatic activity. It therefore must be working as a non-
competitive inhibitor. XAP2 association also results in a marked increase in sensitivity 
to inhibition which indicates that its presence, although not directly on the catalytic 
domain, is causing altered conformation of the catalytic unit [Bolger et al., 2003].  
 
Interestingly although XAP2 has only been found to associate with these two 
closely  related  isoforms  of  PDE4  it  has  very  recently  been  found  to  associate  with   45 
PDE2A [de Oliveira et al., 2007]. In this enzyme it binds to a site located within the 
GAF-B regulatory domain although this site appears to show no similarity to the site of 
binding in UCR2, which suggests a different mode of binding. The association of XAP2 
with PDE2A also differed from its association with PDE4A5 in that it does not altered 
the  enzymatic  activity  of  PDE2A  but  does  appear  to  guide  it  towards  the  aryl 
hydrocarbon receptor complex [de Oliveira et al., 2007]. 
 
 
1.7.2  Phosphodiesterase 4B 
 
There are four known phosphodiesterase 4B isoforms, PDE4B1, 4B2, 4B3 and 
4B4. Unlike the PDE4A enzymes their endogenous expression in cells is higher so they 
can be detected more easily. Phosphodiesterase 4B1 and 4B3 are both long isoforms 
with a molecular weight of 83kDa [Huston et al., 1997] whereas PDE4B2 is a short 
isoform with a molecular weight of only 64 kDa [Bolger et al., 1994]. PDE4B4 is the 
most recently cloned and characterised member of this family, it is found in the rat and 
has a molecular weight of 73kDa [Shepherd et al., 2003]. 
 
 
1.7.2.1 PDE4B knockout mice 
 
The development of PDE4B knockout mice has given a huge insight into the 
functional  purpose  of  this  PDE4  sub-family.  It  has  in  particular  highlighted  the 
importance  role  of  PDE4B  isoforms  in  the  immune  response.  In  mouse  peritoneal 
macrophages from PDE4B knockout mice it has been shown that loss of this PDE4 
isoform  impacted  LPS  TLR  signalling  and  TNFα  production  [Jin  et  al.,  2005].  In 
neutrophil studies it has also been shown that knockout of PDE4B leads to an inhibition 
of  neutrophil  migration  [Ariga  et  al.,  2004].  In  addition  to  the  role  in  the  immune 
system, knockout mice studies have also highlighted behavioural and neurochemical 
phenotypes  that  appear  to  be  PDE4B  dependent.  In  PDE4B  knockout  mice  it  was 
observed that spontaneous locomotive activity was decreased when compared to wild   46 
type [Siuciak et al., 2008], and that these knockout mice also exhibited depression and 
anxiety like behaviour [Zhang et al., 2008]. 
 
 
1.7.2.2 PDE4B and DISC1 
 
Perhaps one of the most important discoveries made in relation to PDE4B is its 
potential role in schizophrenia. The disrupted in schizophrenia 1 (DISC1) gene locus 
was  first  identified  as  a  disrupted  gene  in  a  large  Scottish  family  presenting  with 
schizophrenia and bipolar disorder [Blackwood et al., 2001]. It has subsequently been 
shown that DISC1, the scaffold protein encoded by the DISC1 gene, can interact with 
the UCR2 domain of the PDE4B isoform PDE4B2 [Millar et al., 2005]. It was then 
proposed that this interaction lead to DISC1 sequestering PDE4B2 in resting cells and 
releases it in an activated state to deal with elevated cAMP levels [Millar et al., 2005]. It 
is  proposed  that  disruption  of  this  DISC1-PDE4B  complex  may  be  involved  in  the 
molecular mechanism of schizophrenia and therefore could provide a therapeutic target 
for  treatment  of  schizophrenia  [Millar  et  al.,  2007].  In  addition  to  this  work  it  has 
subsequently been shown that other PDE4 isoforms can bind to DISC1 [Murdoch et al., 
2007]. 
 
 
1.7.3  Phosphodiesterase 4C 
 
Like the PDE4A gene family PDE4C isoforms exist at very low endogenous 
expression  levels  in  the  cell.  Due  to  this  there  has  not  been  much  work  done  on 
members of this gene family. However, three long isoforms of this enzyme, PDE4C1, 
4C2 and 4C3 have been identified [Bolger et al., 1993; Swinnen et al., 1989].  
Distribution in the human brain of PDE4C is restricted to the cortex, thalamic 
nuclei and cerebellum whereas in monkeys distribution is seen in the olfactory bulb 
[Perez-Torres et al., 2000]. 
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1.7.4  Phosphodiesterase 4D 
 
The PDE4D gene family is probably the best studied out of all of the PDE4 
enzymes. There are thought to be 11 isoforms PDE4D1 to 4D11. The most notable of 
these are PDE4D3, 4D4 and 4D5 which are all long isoforms with molecular weights 
between  77kDa  and  91kDa  [Bolger  et  al.,  1997].  PDE4D3  and  PDE4D5  are  both 
expressed at relatively high levels endogenously. The short form PDE4Ds, PDE4D1 and 
PDE4D2  have  a  more  limited  expression  pattern  [Vicini  and  Conti,  1997].  Little, 
however, is known about the more recently discovered PDE4D6-11 species, although 
the PDE4D7 gene locus has been linked to stroke [Houslay, 2005].  
 
 
1.7.4.1 PDE4D knockout mice 
 
In a similar way to PDE4B, a great deal of the functional role of PDE4D has 
been elucidated through the generation of PDE4D knockout mice. Neurological studies 
have shown that PDE4D knockout mice presented an anti-depressant like phenotype 
(measured through mobility in response to stress tests) and this is thought to imply that 
PDE4D is the essential mediator of the antidepressant-like effects of rolipram [Zhang et 
al., 2002]. In further neurological studies it has also been shown that there may be a role 
for PDE4D in long term memory formation [Rutten et al., 2008]. However PDE4D 
knockout models have shown far wider ranging effects than just within the neurological 
system, for example within the airway smooth muscle it has been shown that PDE4D 
plays a key role in balancing relaxation of contraction of smooth muscle, playing a role 
in controlling airway tone [Mehats et al., 2003]. In addition to this PDE4D knockout has 
been shown to have a small but still significant effect on neutrophil migration within the 
immune system while also reducing chemotaxis in response to the cytokines KC and 
MIP2 [Ariga et al., 2004]. 
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1.7.4.2 PDE4D and β-arrestin 
 
G-protein coupled receptors (GPCRs) couple to Gs, upon activation, and activate 
adenylyl  cyclase  to  produce  cAMP.  Desensitisation  of  these  GPCRs  involves 
phosphorylation  by  G-protein  coupled  receptor  kinases  (GRKs)  and  subsequent 
recruitment of cytosolic signalling scaffold proteins, β-arrestins [Lefkowitz and Shenoy, 
2005]. The presence of β-arrestin then blocks further GPCR coupling to Gs. β-arrestin 
has been shown to interact with all isoforms of PDE4 regardless of whether they are 
long, short or super-short through a region in their catalytic domain [Perry et al., 2002]. 
Binding occurs through the N-terminal and C-terminal regions of β-arrestin [Baillie et 
al., 2007]. Interaction of β-arrestin with PDE4 seems to recruit the enzymes to the site of 
agonist  occupied,  GRK  phosphorylated  GPCRs  where  they  regulate  PKA 
phosphorylation of the receptor by lowering the local level of cAMP. 
 
However the PDE4 isoform PDE4D5 shows greater affinity for β-arrestin than 
all other PDE4 isoforms [Bolger et al., 2006; Bolger et al., 2003; Lynch et al., 2005; Li 
et al., 2006]. This is due to two separate factors: the presence of an extra β-arrestin 
binding domain located at amino acids 70-88 within its unique N-terminal region [Perry 
et al., 2002; Baillie et al., 2007] and ubiquitination of PDE4D5 by Mdm2 guiding it to 
bind more β-arrestin [Li et al., 2009]. These interactions do not affect the enzymatic 
activity of PDE4D5.  
 
Recently  it  has  also  been  discovered  that  the  binding  site  on  the  N-terminal 
overlaps with the binding site of RACK1 for PDE4D5 [Bolger et al., 2006]. 
 
 
 
1.7.4.3 PDE4D and RACK1 
 
Receptor for activated C-Kinase 1 (RACK1) is a 36 kDa protein which has a 
high affinity for partner protein binding. It has a seven bladed propeller like structure   49 
composed of β-sheets which allow it to scaffold Protein Kinase C (PKC) [McCahill et 
al., 2002]. RACK1 can interact with proteins in two different ways: constitutively or 
stimulus dependent. The individual blades of its propeller structure have multiple sites 
for protein interactions which would indicate that it has the ability to associate with 
many different proteins classes. 
 
RACK1 specifically interacts with the PDE4 isoform PDE4D5 through two sites. 
This first site is a RACK1 interaction domain (RAID1) in the unique N-terminal of 4D5 
[Yarwood et al., 1999, Bolger et al., 2006]. The functional reason for this association is 
yet  unknown  but  it  is  thought  that  it  may  be  to  alter  the  sensitivity  of  RACK1 
surrounding  proteins  to  PKA  phosphorylation  [McCahill  et  al.,  2002].  The  second 
interaction site is found in the third sub-domain of the catalytic region of PDE4D. While 
this site is essential for PDE4D5 binding it is not a strong enough binding site itself to 
elicit binding of RACK1 without the N-terminal. This is why, despite the presence of 
this  catalytic  site  across  the  other  PDE4  isoforms  no  RACK1  binding  is  observed 
[Bolger  et  al.,  2006].  It  has  also  been  proposed  that  RACK1  and  β-arrestin  partner 
PDE4D5 in a mutually exclusive fashion therefore if one of these scaffolding proteins is 
knocked  out  of  the  cell  it  allows  for  the  other  to  bind  [Bolger  et  al.,  2006].  The 
functional reason for the interaction of PDE4D5 and RACK1 has been proposed in the 
past few months where it has been shown that RACK1 may serve as the molecular 
bridge  linking  FAK  to  the  recruitment  of  PDE4D5.  The  FAK/RACK1/PDE4D5 
complex then acts as a novel 'direction-sensing' complex that acts to recruit specific 
components of the cAMP second-messenger system to the leading edge of polarizing 
cells [Serrels et al., 2010]. 
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1.7.4.4 PDE4D and its genetic link to disease states 
 
Two major gene studies have been carried out in relation to the PDE4D gene and 
disease states. The first of these studies looked at the role of the PDE4D gene in bone 
mineral density [Reneland et al., 2005]. In this study it was show that variants in the 
gene that encodes PDE4D accounts for some of the genetic contribution to bone mineral 
density variations observed in humans. This work corresponds well with the fact that 
PDE4 inhibitors have been shown to increase bone mass in mouse studies [Reneland et 
al., 2005]. The second of these studies was carried out across a wide-ranging population 
and uncovered the role of the PDE4D gene in asthma-susceptibility through a series of 
different mutations and SNPs [Himes et al., 2009].  
 
 
 
1.8 PDE4 Phosphorylation 
 
 
One  of  the  main  modes  of  control  of  PDE4  activity  is  through  its 
phosphorylation. The main kinases that can phosphorylate PDE4 are PKA and ERK and 
both of these kinases have different resultant effects.  
 
 
1.8.1  Protein Kinase A 
 
Long  isoforms  of  PDE4  can  all  be  phosphorylated  by  PKA,  which  leads  to 
activation [Sette and Conti, 1996; Hoffmann et al., 1998; MacKenzie et al., 2002]. This 
phosphorylation occurs at a single conserved serine residue in UCR1 which is contained 
in  the  PKA  consensus  RRES*F  [MacKenzie  et  al.,  2002].    This  phosphorylation 
increases PDE4 activity in cells by around 60% but it appears that PDE4A4 and 4D3 
show the greatest increase in activation [Laliberte et al., 2002; Sette and Conti, 1996; 
MacKenzie et al., 2002], although the reason for this is unknown.   51 
In PDE4D3 two sites for PKA phosphorylation, the conserved one at Ser54 in 
UCR1 together with another one at Ser13, that is located within its unique N-terminal 
region [Hoffmann et al., 1998; Sette and Conti, 1996]. The N-terminal site has no effect 
on activity, but is involved in targeting, increasing the association of PDE4D3 with 
mAKAP [Carlisle Michel et al., 2004] and reducing its interaction with the scaffold 
protein, Ndel1 [Collins et al., 2008]. 
 
Interestingly  PKA-phosphorylated  forms  of  both  PDE4A4  and  4D3  show 
enhanced sensitivity to stimulation by Mg
2+, a cation found in the catalytic site which is 
necessary for PDE activity [Oki et al., 2000; Perry et al., 2002]. It has recently been 
shown [Burgin et al., 2010] that in the absence of UCR1 phosphorylation of PDE4 by 
PKA the UCR2 domain adopts a ‘closed’ conformation over catalytic pocket. However 
when  PKA  phosphorylation  occurs  the  interactions  between  UCR1  and  UCR2  are 
altered causing the UCR2 helix to move into an ‘open’ active conformation, activating 
the enzyme and increasing its Vmax without affecting Km.  
 
 
1.8.2  Extra-cellular Signal Regulated Kinase (ERK) 
 
The Mitogen-Activated Protein (MAP) Kinase signalling cascade is a pivotal 
signalling pathway where growth factors, cytokines and hormones [Pearson et al., 2001] 
exert crucial effects on cell survival and growth. ERK1 and ERK 2 are members of the 
MAPK family. All PDE4 enzymes, except for PDE4A species, contain a consensus 
motif for ERK binding (Pro-Xaa-Ser-Pro) in their catalytic unit within which a serine 
can be phosphorylated [MacKenzie et al., 2000]. However for ERK binding to occur 
there must be the presence of ERK docking sites at either side of the consensus motif. 
These consist of a kinase interaction motif (KIM) which is found approximately 135 
amino acids N-terminal of the consensus site and a Phe-Xaa-Phe (FQF) motif found 
approximately 16 amino acids C-terminal of the consensus site. The presence of these 
two docking sites allows for specificity of ERK1/2 phosphorylation over other kinase 
phosphorylations  that  can  occur  here,  such  as  c-Jun  N-terminal  kinase  (JNK)   52 
phosphorylation  [Sharrocks  et  al.,  2000].  These  recognition/binding  sites  have  been 
identified in PDE4 and shown to be functional as regards being essential for PDE4 to be 
phosphorylated by ERK in cells [MacKenzie et al., 2000]. 
 
ERK  phosphorylation  exerts  different  effects  on  PDE4  enzymes  which  are 
dependent on whether the enzyme is long or short form. In short form PDE4s it leads to 
activation  of  the  PDE4  enzymes  with  an  increase  in  intracellular  activity  of  40% 
[MacKenzie et al., 2000 and Baillie et al., 2000]. In contrast to this, in long form PDE4s 
then phosphorylation by ERK causes inhibition of enzymatic activity by around 40%. 
However, this is a transitory effect that can be overcome if ERK inhibition of PDE4 
long  forms  cause  cAMP  levels  to  rise  enough  to  activate  PKA,  which  can  then 
phosphorylate the long form and overcome the ERK inhibitory effect, leading to a net 
activation [Houslay and Kolch, 2000 and Baillie at al., 2000]. This inhibition is now 
understood to be caused by the ERK phosphorylated serine on the C-terminus of the 
enzyme  interacting  directly  with  the  UCR2  region  stabilising  it  in  a  ‘closed’ 
conformation over the catalytic pocket [Burgin et al., 2010]. 
 
 
 
 
1.9 New partner proteins for PDE4A 
 
 
The work detailed in this thesis will introduce two new partner proteins for the 
long form PDE4A isoform PDE4A5 and will highlight the presence of a potential multi-
functional docking domain on this, and other long form PDE4 isoforms.  
 
 
1.9.1  MAPKAPK2 
 
The p38 MAPK pathway is a key signal transduction pathway involved in the 
control of cellular immune, inflammatory and stress responses [Hommes et al., 2003].   53 
One of its downstream effectors is the kinase mitogen-activated protein kinase-activated 
protein kinase 2 (MAPKAPK2). In chapter 3 is it described how MAPKAPK2 interacts 
with PDE4A5.  
 
 
1.9.2  p75NTR 
 
Another important protein shown to interact with PDE4A5 in chapter 4 of this 
thesis  is  the  low  affinity  neurotrophin  receptor  p75NTR.  This  75  kDa  neurotrophin 
receptor is pivotal in neuronal signalling and inflammatory responses. It gets its name 
from its ability to bind several different neurotrophins at a low affinity [Barker, 2009]. 
This protein will be discussed in more detail in Chapter 4.    54 
Chapter 2              Materials and Methods 
 
 
2.1   Materials 
 
  All  materials,  chemicals  and  equipment  were  supplied  by  Sigma-Aldrich® 
unless otherwise stated. 
 
2.2  Plasmid Preparation 
 
  All plasmid work was carried out in a sterile environment and all buffers used 
were molecular biology grade. Buffers were sterilised by sterile filtration or autoclaving.  
 
 
2.2.1  Transformation of Competent Cells 
 
  Competent cells are bacterial cells that can incorporate foreign DNA plasmids. 
Not  all  cells  have  this  ability  but  can  often  be  manipulated  to  be  electrically o r 
chemically competent. Most competent cells have an optimal transformation protocol, 
often  provided  by  the  manufacturers,  but  these  protocols  all  follow  same  general 
principle. Competent cells were stored at -80
oC and thawed on ice. 1-10ng of DNA was 
added to 50µL of competent cells and incubated on ice for 15 mins, although longer 
incubation periods generally have no effect on transfection efficiency. The cells were 
then heat shocked at 42
oC for 45-90s before being returned to ice for 2 mins.  450µL of 
pre-warmed L-Broth media (1% (w/v) bacto-tryptone, 0.5% (w/v) bacto-yeast extract 
and 170mM NaCl) was then added to the cells and incubated shaking at 37
oC for one 
hour.  Agar  plates  were  produced  using  L-Broth  media  and  1.5%  (w/v)  agar.  This 
solution was autoclaved and cooled to less then 50
oC then the appropriate antibiotic for 
the plasmid was added (commonly used antibiotics and their concentrations are shown 
in  Table  2.1)  before  being  poured  out  and  set  in  90mm  plates.  50-250µL  of 
transformation mix was then spread on the agar plates and incubated at 37
oC for 14-18   55 
hours. Colony growth indicated successful cell transformation. Plates were stored at 4
oC 
for up to one month before being discarded.  
 
Antibiotic  Stock Concentration  Storage  Working Concentration 
Ampicillin  100mg/ml in H2O  -20
oC  100 µg/ml 
Kanamycin  10mg/ml in H20  -20
oC  50 µg/ml 
Zeocin (Invitrogen)  100mg/ml in HEPES  -20
oC  25 µg/ml 
 
Table 2.1 – Concentrations of commonly used antibiotics. 
 
2.2.2  Isolation of Plasmid DNAs 
 
  From agar plates single colonies were picked and grown overnight in 5mL L 
Broth media containing the appropriate antibiotic in an orbital shaker at 37
oC. 1ml of the 
bacterial culture was saved for production of a glycerol stock (see section 2.2.3). The 
remaining  bacterial  stock  was  used  for  plasmid  isolation  using  the  QIAGEN® 
QIAprep® Miniprep Kit.  Alternatively, the 5 ml overnight bacterial culture was used to 
inoculate a larger L Broth media culture of 500 ml, supplemented with the appropriate 
antibiotic,  for  overnight  growth  and  isolation  of  significantly  greater  plasmid  DNA 
concentrations and volumes using the QIAGEN® QIAprep® Maxiprep Kit.  For in-
depth details of the plasmid DNA isolation protocols please refer to the manufacturers 
instructions. Purified plasmid DNA was stored at 4
oC, if eluted in 10mM Tris-Cl; pH 
8.5, and –20
oC, if eluted in sterile water. 
 
2.2.3  Storage of Plasmid DNAs 
 
  To produce a glycerol stock 1ml of overnight culture (see section 2.2.2 above) 
was removed and mixed with 500µl sterile filtered glycerol in a sterile cryo-vial. This 
was then snap-frozen on dry ice and stored at -80
oC until required. Generally the E.Coli 
bacterial strain JM109 was used for storage as long-term glycerol stocks.   
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Glycerol stocks were used to inoculate culture media (L Broth) by scrapping the 
frozen stock with a sterile pipette tip, which is then transferred into 5ml of sterile L 
Broth media containing the appropriate antibiotic for the plasmid in which they were 
cultured or the bacterial host strain. This culture was then incubated in an orbital shaker 
overnight at 37
oC. The plasmid isolation can then be carried out as described in Section 
2.2.2 and 2.3.  
 
2.2.4  Analysis of Plasmid DNA 
 
2.2.4.1     Agarose Gel Electrophoresis 
 
  Agarose gel electrophoresis is a method used to analyse DNA molecules by size. 
This is achieved by moving negatively charged nucleotides through an agarose matrix 
with an electric field. Shorter molecules migrate faster than larger molecules and DNA 
is resolved into fragments between 0.5-10 kilobases with 20-500ng of DNA per band. 
1% agarose was dissolved in 40mM Tris-Cl; pH 8.5, 0.114% (v/v) glacial acetic acid 
and 2mM EDTA (TAE) by heating in a microwave oven until the agarose dissolved. 
The  1%  agarose  solution  was  cooled  to  55
oC  and  0.5µg/ml  ethidium  bromide  was 
added. The solution was then poured into the Bio-Rad® Sub-Cell GT gel apparatus, 
with the well comb in place, and allowed to set.  For more details about the Bio-Rad® 
Sub-Cell GT gel apparatus please consult the manufacturers instructions. Once set for 
30-40 min the comb was removed and the gel was placed in a gel tank with 1x TAE 
buffer (40mM Tris, 20mM Acetic Acid, 1mM EDTA) to a level of 1mm above the gel. 
1kb DNA ladder was also loaded to an appropriate well of the gel to allow the size of 
the DNA plasmid or fragment within the sample to be determined. For DNA samples 6x 
loading buffer (0.25% (w/v) bromophenol blue, 0.25% (w/v) xylene cyanol FF and 40% 
(w/v) sucrose) was diluted 1:6 into the DNA solution and mixed gently. The gels were 
then run at 100V for approximately one hour and were then removed from the tank and 
analysed  under  ultra  violet  light  where  ethidium  bromide  stained  DNA  can  be 
visualised. Images of the gels were then captured using an ultra violet light box. 
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2.2.4.2   Quantification of DNA Concentration  
 
  The concentration of purified DNA was determined using the Nanodrop 2000 
spectrophotometer  from  Thermo  Scientific  which  measures  DNA  concentration  at 
absorbance of 260 nm. 
 
2.2.4.3   DNA Sequencing 
   
DNA samples for sequencing were sent to the University of Dundee Sequencing 
Service (www.dnaseq.co.uk) where sequencing of 500bp lengths of DNA was carried 
out using standard or custom primers. Analysis of DNA sequencing was carried out 
using Gene Jockey Version 2.2 or Geneious computer software programs.  
 
2.2.5  Site-Directed Mutagenesis of Plasmid DNA 
 
  Site-directed  mutagenesis  of  plasmid  DNA  was  carried  out  using  the 
QuikChange®  Site-Directed  Mutagenesis  Kit.  In  short,  Polymerase  Chain  Reaction 
(PCRs) samples were set up in 10x reaction buffer containing various concentrations of 
purified, template DNA (5-50ng). Primer pairs used for site directed mutagenesis were 
designed  using  Gene  Jockey  or  Genious  computer  software  and  manufactured  by 
Thermo Bioscience. 125ng of each primer and 1µl of deoxynucleotide tri-phosphate 
(dNTP) mix were added to the PCR reaction and it was made up to a total volume of 
50µl with RNAase, DNAase free water. 1µl of Pfu Turbo polymerase was added to each 
reaction. PCR was then carried out using the MJ Research Peltier Thermal Cycler 200 
with conditions set as 95
oC for 30s, and 18 cycles of 95
oC for 30s, 55
oC for 1min, and 
68
oC for 1min per kb of the plasmid length. Once this reaction is complete 1-4µl of the 
Dpn I restriction enzyme was added to each reaction and incubated at 37
oC for 1h. 1µl 
of the Dpn I-treated DNA was used to transform 50µl of XL-Blue super-competent cells 
as described above and plasmid DNA was then isolated from single colonies on agar 
plates,  cultured,  purified  and  sequenced  as  described  above  to  assess  whether  site   58 
directed mutagenesis was successful. I wish here to thank Mrs Irene Gall, who carried 
out all the site-directed mutagenesis for this project. 
 
2.3  Expression and Purification of Recombinant Fusion Proteins 
 
 
2.3.1  Maltose Binding Protein (MBP) Fusion Proteins 
 
  Competent E.coli BL21 cells were transformed, as described in Section 2.2.1, 
with the appropriate pMAL plasmid, as described in Table 2.2, and grown in 30ml or 
sterile L-Broth media, supplemented with 100µg/ml ampicillan, overnight in an orbital 
shaker  at  37
oC.  450ml  of  L-Broth  media,  containing  100µg/ml  ampicillan  was  then 
inoculated with the 30ml overnight culture and grown in the orbital shaker at 37
oC for a 
further 1-2 hours. A 1ml sample of the culture was taken at regular intervals, placed in a 
plastic  cuvette  and  its  optical  density  was  measured  at  600nm  (OD600)  against  an 
uncultured L-Broth media control. Once this density reached a value of between 0.6 and 
1  expression  of  the  fusion  protein  was  induced  with  0.2mM  isopropyl-β-D-
thiogalactopyranoside (IPTG). An OD600 at this level ensured that the culture was in 
the logarithmic phase, where bacteria will grow exponentially. The culture was then 
grown for a further 4 hours in an orbital shaker set at 30
oC. Hourly 1ml samples were 
removed to monitor protein expression. These samples (including the samples used for 
OD600 measurement) were centrifuged at 13000rpm, the supernatant was discarded and 
the pellet was re-suspended in 100µl SDS sample buffer for analysis by SDS-PAGE and 
Coomassie staining as described in Section 2.7. The cells from the 450ml culture were 
then harvested by centrifugation at 4000rpm for 10 min. The cells were re-suspended in 
12ml of 50mM Tris-HCl; pH 8.0, 10mM NaCl and 10mM β-mercaptoethanol containing 
a 1x solution of Roche Diagnostics protease inhibitor cocktail tablets. The re-suspended 
cells were then frozen at -80
oC overnight. Cells were thawed on ice and lysozyme was 
added at a final concentration of 1mg/ml and the cell suspension subjected to sonication 
to ensure sufficient cell lysis occurred. A final concentration of 0.05% NP-40 was added 
to aid cell lysis and the cells were centrifuged at 13000rpm for 15 min to remove cell   59 
debris.  1ml  of  amylose  resin  (New  England  BioLabs)  was  pre-equilibrated  with  re-
suspension buffer containing 0.05% NP-40. The cell supernatant was applied to the pre-
equilibrated resin and incubated end-over-end at 4
oC for 1h to bind the expressed fusion 
protein. The resin was the collected by centrifugation at 2000rpm for 2min and washed 
three times with 1ml of re-suspension containing 0.05% NP-40. The fusion protein was 
eluted from the amylose resin with 500µl of 10mM maltose, 50mM Tris-HCL; pH8.0 by 
incubation end over end for 20 min at 4
oC. This was repeated up to three times, if 
necessary.  The  eluted  fractions  were  pooled  and  dialysed  using  Pierce®    Slide-A-
Lyser® dialysis cassettes against three 750ml volumes of 100mM NaCl, 50mM Tris-
HCL; pH 8.0 and 5% glycerol for 1h each at 4
oC. The purified fusion protein was frozen 
on dry ice, and stored as aliquots of 25µl at -80
oC. The expression time-course and final 
purification products were analysed by SDS-PAGE and Coomassie® staining, described 
in Section 2.7. 
 
2.3.2  Glutathione-S-Transferase (GST) Fusion Proteins 
 
  The E.coli expression and purification of recombinant GST fusion proteins is 
extremely similar to the purification of MBP protein described above in Section 2.3.1. 
Competent E.coli BL21 cells were transformed, as described in Section 2.2.1, with the 
appropriate pGEX plasmid, as described in Table 2.2.  Cultures were grown, induced, 
harvested and lysed as described above however for the purification of GST fusion 
proteins  glutathione  sepharose  resin  (Amersham  Biosciences)  was  used  and  elution 
required an elution buffer composed of 10mmM glutathione, 50mM Tris-HCl; pH 8.0. 
The  expression  time-course  and  final  purification  products  were  analysed  by  SDS-
PAGE and Coomassie® staining, described in Section 2.7. 
 
2.3.3  Histidine (His) Fusion Proteins 
 
  The  E.coli  expression  and  purification  of  recombinant  His  fusion  proteins  is 
extremely  similar  to  the  purification  of  MBP  and  GST  protein  described  above  in 
Section  2.3.1  and  Section  2.3.2.  Competent  E.coli  BL21  cells  were  transformed,  as   60 
described  in  Section  2.2.1,  with  the  appropriate  (pEX-His)  plasmid,  as  described  in 
Table  2.2.    Cultures  were  grown,  induced,  harvested  and  lysed  as  described  above 
however for the purification of His fusion proteins nickel resin (Qiagen) was used and 
elution required an elution buffer composed of (6M Urea, 20mM Tris pH 7.5, 100mM 
NaCl);  pH  8.0.  The  expression  time-course  and  final  purification  products  were 
analysed by SDS-PAGE and Coomassie® staining, described in Section 2.7. 
 
2.4  Mammalian Cell Culture 
 
  All cell culture techniques were carried out in a class two hood using aseptic 
techniques and reagents had been filter sterilised or autoclaved to ensure sterilisation.  
 
2.4.1  Maintenance of Cell Lines 
 
  Cells of a low passage number were stored at -200
oC, in cryovials containing 
freezing cell media (70% serum, 10% DMSO), to ensure their long-term integrity.  To 
revive  cells  from  the  temperature  individual  vials  were  quickly  thawed  and  added 
directly to 10ml of growth media pre-warmed to 37
oC, under sterile conditions. Once 
the cell line is established and confluent, further aliquots of cells were re-suspended in 
freezing cell media and initially frozen at -80
oC before being transferred to -200
oC for 
long-term storage.  
 
2.4.1.1   COS1 Cells 
   
COS1 cell lines are derived from African green monkey kidney cells and have 
been  transformed  with  the  SV40  virus.  The  cells  were  propagated  in  growth  media 
containing  Dulbecco’s  modified  Eagle’s  medium  (DMEM)  supplemented  with  0.1% 
penicillin/streptomycin  (10000U/ml),  2mM  glutamine  and  10%  foetal  bovine  serum 
(FBS). The cell line was maintained at 37
oC in an atmosphere of 95% air and 5% CO2. 
The  cells  were  passaged  when  approximately  70-90%  confluence  was  reached.  To 
passage  the  cells  the  growth  media  was  removed  and  5ml  of  sterile  pre-warmed   61 
phosphate  buffer  saline  (PBS)  was  added  to  gently  wash  the  cells.  The  PBS  was 
removed and 5ml of trypsin-EDTA solution was added and cells were incubated for 5 
min at 37
oC. The cells were vigorously agitated and then analysed under the microscope 
to ensure complete cell detachment. 5ml of growth media was then added to inactivate 
the trypsin-EDTA solution. The cells were collected by centrifugation at 10,000rpm for 
3 min at room temperature. The growth media and trypsin-EDTA solution was removed 
and  the  cell  pellet  was  re-suspended  in  5ml  of  fresh  growth  media.  Once  fully  re-
suspended 1ml of cells were added to fresh growth media in sterile flasks, 100mm or six 
well plates. The cells were incubated at 37
oC in an atmosphere of 95% air and 5% CO2 
until required or confluent.  
 
2.4.1.2   HEK293 Cells 
 
  The  human  embryonic  kidney  293,  (HEK293)  cell  line  has  epithelial 
morphology.  These  cells  were  maintained  as  described  in Section  2.4.1.1  for  COS1 
cells. 
 
2.4.1.3   NIH3T3 Cells 
 
  NIH3T3 cells are fibroblasts from Swiss mouse embryo tissue with the ‘3T3’ 
designation referring to the abbreviation of “3-day transfer, inoculum 3 x 10
5 cells”. 
These  cells  were  grown  in  Dulbecco’s  modified  Eagle’s  medium  (DMEM) 
supplemented  with  0.1%  penicillin/streptomycin  (10000U/ml),  2mM  glutamine  and 
10% newborn calf serum (NCS) and maintained as described in Section 2.4.1.1. A stable 
NIH3T3  cell  line  expressing  p75NTR-GFP  was  provided  by  the  laboratory  of  Dr 
Katerina Akassoglou (Gladstone Research Institute, San Francisco, USA). These cells 
were maintained in the same manner as above with the growth media supplemented with 
100µg/ml Hygromycin B. These cells were maintained as described in Section 2.4.1.1 
for COS1 cells. 
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2.4.1.4   Mouse Embryonic Fibroblasts (MEFs) 
 
  Mouse  Embryonic  Fibroblasts  (MEFs)  are  fibroblast  cells  isolated  from  the 
bodies  of  c57  black  mouse  embryos.  The  cells  were  propagated  in  growth  media 
containing  Dulbecco’s  modified  Eagle’s  medium  (DMEM)  supplemented  with  0.1% 
penicillin/streptomycin  (10000U/ml),  2mM  glutamine  and  10%  foetal  bovine  serum 
(FBS). The cell line was maintained at 37
oC in an atmosphere of 95% air and 5% CO2.  
These cells were maintained as described in Section 2.4.1.1 for COS1 cells. PDE4A (-/-) 
and PDE4B (-/-) MEFs were a generous gift from Dr Marco Conti (UC San Francisco, 
USA).  
 
2.5  Mammalian Cell Transfection of Plasmid DNA 
 
  A list of DNA plasmids used for the transfection of the mammalian cell lines are 
described in Table 2.2. 
 
2.5.1  PolyFect® Transient Transfection 
 
  The PolyFect® the method of mammalian cell transfection, from QIAGEN®, 
was used for transfection of COS1, HEK293 and NIH3T3 cell lines. Flasks of confluent 
cells  were  passaged  the  day  prior  to  transfection  and  plated  to  ensure  40-80% 
confluency on the day of transfection. These plates were incubated overnight at 37
oC in 
an atmosphere of 95% air and 5% CO2. The amount of DNA required for each plate 
was dependent on the cell line and number of cells to be transfected and should be 
scaled accordingly. The protocol described is accurate for 100mm plates of 40-80% 
confluent cells in 6ml growth media. See manufacturers instructions for the amount of 
DNA  required  for  different  plate  sizes.  4µg  of  the  desired  DNA  plasmid  for  the 
transfection of COS1 or NIH3T3 cells was diluted in antibiotic and serum free DMEM 
to a final volume of 300µl. 8µg of the desired DNA plasmid for the transfection of 
HEK293 cells was diluted in antibiotic and serum free DMEM to a final volume of 
300µl. 25µl of PolyFect® Transfection Reagent was added to the DNA solution for   63 
COS1  and  NIH3T3  cell  transfections  whereas  80µl  was  required  for  efficient 
transfection  of  HEK293  cells.    The  transfection  reagents  were  incubated  at  room 
temperature for 5-10min to allow complex formation.  Where co-transfection of two 
DNA plasmids was required the amount indicated above of each plasmid was diluted in 
300µl of antibiotic and serum free DMEM before the addition of the specific volume of 
PolyFect® Transfection Reagent indicated above for the cell type. During the incubation 
period  the  growth  media  was  removed  and  replaced  with  6ml  of  fresh  DMEM 
supplemented with 0.1% penicillin/streptomycin (10000U/ml), 2mM glutamine and the 
relevant serum for the cell line. Following incubation, 1ml of supplemented DMEM 
containing  the  antibiotics  and  serum  was  added  to  the  DNA-DMEM-  PolyFect® 
complex. This was mixed gently and added directly to the appropriate transfection plate. 
The plates were then incubated for 24-72 hrs at 37
oC in an atmosphere of 95% air and 
5% CO2 prior to any cell treatments and harvesting. Details of ligands and inhibitors 
used for cell treatments post-transfection are described in Table 2.3. 
 
2.5.2  Nucleofector Transfection 
 
  Transfection  of  MEF  cells  cannot  be  successfully  carried  out  using  Polyfect 
transient  transfection  therefore  Amaxa  Nucleofector  nucleoporation  transfection  was 
instead  carried  out  using  their  MEF  transfection  kit  according  to  manufacturers 
instructions. 
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Vector  Construct 
pcDNA  PDE4A5 – Wild Type 
pcDNA  PDE4A5 – Ser147Ala 
pcDNA  PDE4A5 – Ser147Asp 
pcDNA  PDE4A5 – Ser161Ala 
pcDNA  p75NTR – Wild Type 
pcDNA  PDE4D3 – Wild Type 
pcDNA  PDE4D3 – Ser61Ala 
pcDNA  PDE4D3 – Ser61Asp 
pcDNA  PDE4A4 – Wild Type 
pcDNA  PDE4A1 – Wild Type 
pcDNA  PDE4A10 – Wild Type 
pcDNA  PDE4A11 – Wild Type 
pMAL  PDE4A5 MBP 
pMAL  PDE4A4 MBP 
pMAL  PDE4A1 MBP 
pMAL  PDE4A10 MBP 
pMAL  PDE4A11 MBP 
pGEX  p75NTR GST 
pGEX  MAPKAPK2 GST 
pGEX  Lyn GST 
pGEX  UBC9 GST 
pGEX  GST alone 
pGEX  β-Arrestin GST 
pGEX  ERK GST 
pEX-His  p75NTR 
 
Table 2.2  List of Plasmids 
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Agonists/ 
Inhibitors 
Role  Concentration  Reference   
Anisomycin  p38 MAPK activator  10 µg/ml  Cuenda  et  al., 
1995 
TNFα  TNFα  signalling 
cascade activator 
p38 MAPK activator 
10 µM  Winston  et  al., 
1997 
SB203580  p38  MAPK  cascade 
inhibitor 
25 µM  Cuenda  et  al., 
1995 
Forskolin  Adenylate  cyclase 
activator 
100 µM  Seamon  et  al., 
1981 
IBMX  Broad  spectrum  PDE 
inhibitor 
100 µM  Essayan, 2001 
Rolipram  PDE4 inhibitor  10 µM  Watchel, 1982 
 
Table 2.3 – Agonists and Inhibitors. 
 
 
2.6 Preparation of Cell Lysates 
 
2.6.1  Whole Cell Lysate 
 
  Confluent cells were harvested at 4
oC using buffers that had been previously 
chilled to minimise protein degradation. The culture media was aspirated and the cells 
were  washed  three  times  with  ice  cold  sterile  PBS.  The  cell  plates  were  drained 
thoroughly and an appropriate volume of cell lysis buffer was added. For a 100mm plate 
500µl of lysis buffer was used whereas for a 6 well plate 300µl was added to each well. 
For the production of whole cell lysate 3T3 lysis buffer was used. This composed of 
25mM HEPES-OH: pH 7.5, 50mM NaCl, 10% glycerol, 1% Triton, 50mM NaF, 30mM 
Na  pyrophosphate,  5mM  EDTA  and  1x  solution  of  Roche  Diagnostics  (Mannheim,   66 
Germany) protease inhibitor cocktail tablets. The cells were incubated for 5 min on ice 
then  scraped  using  a  disposal  scraper.  The  lysate  was  then  collected  into  a  1.5ml 
Eppendorf  tube.  The  cell  lysates  were  centrifuged  in  a  refrigerated,  bench-top  at 
13.000rpm at 4
oC and the supernatant was retained. The cell lysates were then snap 
frozen in dry ice and stored at -80
oC until required. 
 
2.6.2  Sub-cellular Fractionation 
 
  Confluent cells were harvested at 4
oC using buffers that had been previously 
chilled to minimise protein degradation. The culture media was aspirated and the cells 
were washed three times in ice cold PBS. The cell plates were drained thoroughly and 
an appropriate volume of cell lysis buffer was added. For a 100mm plate 500µl of lysis 
buffer was used whereas for a 6 well plate 300µl was added to each well. For the 
production of sub-cellular fractions, 500µl sterile 50mM KCl, 50mM HEPES; pH 7.2, 
10mM EGTA, 1.92mM MgCl2, 1mM dithiolthreitol  (DTT) and 1x solution of Roche® 
Diagnostics  (Mannheim,  Germany)  protease  inhibitor  cocktail  tablets    (KHEM)  was 
added to the cells and incubated at 4
oC for 5 min. The lysate was then collected into a 
1.5ml Eppendorf tube. The cells were homogenised on ice by drawing through a 26G 
needle and 1 ml syringe, approximately 20 times, and centrifuged at 2,000rpm in a 
refrigerated,  bench-top  centrifuge  at  4
oC  for  10  min.  The  pellet  formed  was  the  P1 
fraction (unbroken cells and nuclei). The supernatant was transferred to a plastic ultra-
centrifuge tube and centrifuged at 75,000rpm in a Beckman TLA-100 ultra-centrifuge 
for  30  min  at  4
oC.  The  pellet  formed  at  this  stage  was  the  P2  fraction  (plasma 
membrane,  Golgi  vesicles,  endoplasmic  reticulum,  endosomes  and  lysosomes).  The 
supernatant from this fraction was retained as the S fraction (enriched cytosolic proteins) 
and the volume noted. P1 and P2 fractions were both washed twice in 500µl if KHEM.  
The P1 fraction was washed at 2,000rpm for 10 min and the P2 fraction at 75,000rpm 
for 30 min. The pellets were then re-suspended in an appropriate volume of KHEM 
buffer. To asses sub-cellular distribution of a given protein in each fraction they were 
subjected to SDS-PAGE and Western-immuno-blotting as described in section 2.7. 
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2.6.3  Determination of Protein Concentration 
 
  The protein concentration of cell lysates and purified recombinant proteins was 
determined  using  bovine  serum  albumin  (BSA)  in  a  standard  spectrophotometric, 
Bradford assay [Bradford, 1976]. The assays were undertaken in 96-welll micro-titre 
plates.  As  standard  curve  of  know  BSA  concentrations  between  zero  and  5µg  was 
generated diluted in sterile water to a final volume of 50µl in triplicate. The protein 
sample of interest was assayed at various dilutions (1:100, 1:50, 1:25) in a final volume 
of 50µl to ensure it was within the range of the standard curve. Bradford reagent from 
Bio-Rad (Hemel Hempstead, U.K.) was diluted 1:5 with sterile water and 200µl was 
added  to  each  well  of  the  micro-titre  plate.  The  96-well  plate  was  analysed  with  a 
590nm test filter using a Dynex MRX micro-titre plate reader controlled through Dynex 
Revelation, Version 3.04 computer software. The intensity of the colour change (brown 
to blue) is directly proportional to protein concentration and this was determined by 
plotting the standard curve and using least squared regression analysis to obtain the line 
of best fit. The equation of the line was used to determine the concentration of the 
protein samples. This concentration was then adjusted to account for any dilution factor. 
 
 
2.7  Protein Analysis 
 
2.7.1  SDS-PAGE 
 
  Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) is a 
method used to separate proteins by virtue of their molecular weight. Protein samples of 
1-100µg were denatured and reduced by dilution in 10% SDS, 300mM Tris-Cl; pH6.8, 
0.05% bromophenol blue, 50% glycerol and 10% B-mercaptoethanol (5x SDS Hannah 
sample  buffer).  The  samples  were  boiled  for  3  min  and  then  loaded  directly  to  an 
Invitrogen (Paisley, U.K.) NuPAGE 4-12% Bis-Tris polyacrylamide gel immersed in 
Invitrogen NuPAGE MES or MOPS SDS running buffer. 5µl of Bio-Rad pre-stained   68 
molecular weight protein marker was loaded to the first well of the gel, to assess the 
molecular weight of proteins being analysed, and protein sample were loaded to the 
subsequent wells. The gel was then run at 200V for 1.5 hours. For more details of the 
Invitrogen Nu-PAGE pre-cast gels and associated X-Cell II apparatus please consult the 
manufacturer’s  instructions ( http://www.invitrogen.com/site/us/en/home/Products-and-
Services/Applications/Protein-Expression-and-Analysis/Protein-Gel-
Electrophoresis.html). 
 
2.7.2  Coomassie Staining 
 
  Proteins separated by SDS-PAGE can be visualised by a variety of methods. For 
Coomassie staining gels were removed from the pre-cast gel cassette and washed in 
sterile  water  to  remove  residual  running  buffer.  Coomassie  stain  consists  of  1.25g 
Coomassie Brilliant Blue R250, 444ml methanol, 56ml acetic acid in a final volume of 
1,000ml sterile water. 50ml of stain was added to the gel and placed gently shaking at 
room temperature for 2h. The Coomassie stain was then removed and replaced with 
Coomassie de-stain, 444ml methanol and 56ml acetic acid in a final volume of 1,000ml 
sterile water. The gel was then incubated with de-stain for 6h after which was replaced 
with fresh de-stain for another 6h. This removed all residual Coomassie background 
staining,  leaving  the  remaining  stain  bound  to  the  proteins  showing  detection  of  all 
proteins present in the sample. Proteins were then be measured against the molecular 
weight marker to determine their identity. The gel was then washed in sterile water with 
10% glycerol to aid the prevention of gel cracking following drying. 
 
2.7.3  Western Immuno-Blotting 
 
  Proteins separated by SDS-PAGE can be visualised by a variety of methods. 
Western-blotting allows the detection of individual proteins using specific anti-sera. The 
proteins separated by SDS-PAGE were transferred to a nitrocellulose membrane using 
Invitrogens X-Cell II blotting modular and Nu-PAGE transfer buffer containing 20% 
methanol. The proteins were transferred with an applied voltage of either 25V for 2h or   69 
10V  for  15h.  Full  transfer  of  the  pre-stained  molecular  weight  marker  onto  the 
nitrocellulose  membrane  indicated  successful  transfer  of  the  proteins.    Following 
transfer the nitrocellulose membrane was incubated or “blocked” in 5% milk powder 
(Marvel) re-constituted in 20 m< Tris-Cl; pH 7.6, 150mM NaCl and 0.1% Tween20 
(TBST), for 1h at room temperature with gentle agitation. Primary antibody, for the 
protein  wishing  to  be  detected,  was  then  added  at  the  appropriate  dilution  (general 
dilution range 1:100 to 1:10,000) to a 1% milk powder TBST solution. Details of the 
primary antibodies used as show in Table 2.4. The nitrocellulose membrane was then 
sealed in and airtight plastic carrier containing 10ml of the primary antibody TBST 
solution. This was then incubated at either room temperature for 2h or overnight at 4
oC 
both with vigorous agitation. The membrane was then removed from the plastic carrier 
and  washed  3  times  in  TBST  for  5  min  at  room  temperature.  The  appropriate 
horseradish  peroxidase  (HRP)  conjugated  anti-immunoglobulin  G  (IgG)  secondary 
antibody diluted 1:5,000 in 1% milk powder TBST solution in a sealed, airtight plastic 
carrier. This was then incubated for 1h at room temperature with vigorous agitation. The 
membrane  was  washed  again  3  times  with  TBST  before  employing  the  Amersham 
Biosciences  (Little  Chalfont,  U.K.)  enhanced  chemiluminescence  (ECL)  Western 
Immuno-blotting  kit  as  the  visualisation  protocol  for  detecting  bound  antibodies.  In 
brief,  the  bound  antibodies  were  detected  by  exposure  of  the  membrane,  following 
washing in ECL solution, to blue-light sensitive autoradiography film and developed 
using the Kodak X-Omat Model 2000 processor.    70 
 
Protein  Specificity  Type  Dilution*  Source  Supplier 
Human PDE4A 
Conserved  C-terminal 
region  of  human 
PDE4A isoforms 
Serum  1:5000  Goat  In-house 
Rat PDE4A 
Conserved  C-terminal 
region  of  rat  PDE4A 
isoforms 
Serum  1:2500  Rabbit  In-house 
PDE4B 
Conserved  C-terminal 
region  of  PDE4B 
isoforms in all species 
Serum  1:2500  Goat  In-house 
PDE4D 
Conserved  C-terminal 
region  of  PDE4D 
isoforms in all species 
Serum  1:5000  Goat  In-house 
PKA 
phosphorylated 
PDE4 
Phosphorylated  Ser 
residue  in  RRES*F 
motif in UCR1 of all 
PDE4 long isoforms 
Serum  1:1000  Rabbit  In-house 
MAPKAPK2 
phosphorylated 
PDE4 
Phosphorylated  Ser 
residue  in  LYRSDS* 
motif in UCR1 of all 
PDE4 long isoforms 
Polyclonal  1:1000  Rabbit 
Custom  – 
Cambridge 
Research 
Biochemicals   71 
 
Protein  Specificity  Type  Dilution*  Source  Supplier 
p38 MAPK 
Endogenous  levels  of 
p38 MAPK 
Polyclonal  1:1000  Rabbit 
Cell Signaling 
Technology® 
Activated  p38 
MAPK 
Endogenous  levels  of 
phosphorylated  p38 
MAPK  at  Thr180  & 
Tyr182 
Polyclonal  1:1000  Rabbit 
Cell Signaling 
Technology® 
MAPKAPK2 
Endogenous  levels  of 
MAPKAPK2 
Polyclonal  1:1000  Rabbit 
Cell Signaling 
Technology® 
Activated 
MAPKAPK2 
Endogenous  levels  of 
phosphorylated 
MAPKAPK2  at 
Thr334  only  &  not 
Thr25,  Thr222  & 
Ser272 
Polyclonal  1:1000  Rabbit 
Cell Signaling 
Technology® 
p75NTR 
Endogenous  levels  of 
p75NTR. Targetted to 
the c-Terminal end. 
Polyclonal  1:1000  Mouse  Santa-Cruz 
GST 
Recognises  GST-tag 
fusion proteins 
Polyclonal  1:1000  Rabbit  In-house 
VSV 
Recognises an epitope 
containing the five C-
terminal  amino  acids 
of VSV glycoprotein 
Monoclonal  1:5000  Mouse 
Sigma-
Aldrich® 
FLAG 
Recognises an epitope 
containing 
DYKDDDDK 
Monoclonal  1:5000  Mouse 
Sigma-
Aldrich® 
 
Table 2.4 – Anti-sera used for Western immuno-blotting.   72 
*Dilution factor is correct for Western immuno-blotting.  Antibody titrations should be 
undertaken for immuno-precipitation and immuno-histochemistry. 
 
2.8  Fusion Protein Interactions 
 
 
2.8.1  Pull-down Assays 
 
  The expression and purification of GST fusion proteins in E.coli was undertaken 
as described in Section 2.3. COS1 cells were transfected to transiently express specific 
PDE4A isoforms as described in Section 2.5 and subjected to sub-cellular fractionation 
as described in Section 2.6. Assessment of the interaction of PDE4A isoforms with GST 
fusion proteins has been described previously [McPhee et al., 1999, Huston et al., 2000 
and Rena et al., 2001].  Briefly, 400µg of the GST fusion protein, or GST alone as a 
control,  was  immobilised  on  a  40µl  bed  volume  of  Amersham  Biosciences  (Little 
Chalfont, U.K.) glutathione sepharose resin.  The resin was pelleted by centrifugation at 
2500rpm for 5min at 4
oC using a refrigerated bench-top centrifuge.  The supernatant 
was discarded.  The pellets were then re-suspended in 500µl (approximately 200µg of 
protein)  of  cytosolic,  or  S  fraction,  produced  from  COS1  cells  expressing  equal 
immuno-reactive  amounts  of  PDE4A  isoforms,  as  determined  by  Western  immuno-
blotting  with  a  PDE4A  C-terminal  specific  anti-serum.    The  protein  samples  were 
diluted in KHEM, the buffer used for sub-cellular fractionation of mammalian cells.  
The immobilised fusion protein and cytosol were incubated together for 1h end-over-
end at 4
oC.  The glutathione sepharose resin was then collected by centrifugation at 
2500rpm for 5min at 4
oC.  The supernatant was retained for Western immuno-blotting to 
measure the extent of PDE4A remaining unbound to the GST fusion protein.  The beads 
were washed three times with 500µl of KHEM by centrifugation at 2500rpm for 5min at 
4
oC.  The supernatant was discarded and the beads re-suspended in 40µl of SDS sample 
buffer to elute the bound proteins.  Protein samples of PDE4A expressed in cytosolic 
cell lysate, PDE4A bound to GST, PDE4A unbound to the GST fusion protein and 
PDE4A bound to the GST fusion protein were analysed by SDS-PAGE, as described in   73 
Section 2.7, and immuno-probed for PDE4A using a C-terminal, species and sub-family 
specific anti-serum, as described in Section 2.7. 
 
2.8.2  Peptide Arrays 
 
  Peptide  arrays  are  Whatman®  50  cellulose  membranes  on  which  peptide 
sequences  are  directly  synthesised  [Reineke  et  al.,  2001  and  Frank,  2002].    These 
peptide arrays are able to bind purified recombinant proteins and provide evidence for 
direct  protein  interaction  and  the  elucidation  of  the  critical  domains  and  residues 
involved [Espanel and Hooft van Huijsduijnen, 2005 and Bolger et al., 2006].  The 
peptide arrays used in the experiments detailed in this thesis were kindly produced by 
Dr. E. Klussmann (Forschungsinstitut für Molekulare Pharmakologie, Berlin, Germany) 
using the Intavis Bioanalyical Instruments (Köhn, Germany) AutoSpot-Robot ASS 222 
and  utilising  Fmoc-chemistry.    Recombinant  GST  fusion  proteins  were  produced  to 
homogeneity,  as  described  in  Section  2.3.  The  peptide  arrays  were  activated  by 
immersion in 100% ethanol and then washed in TBST for 10min at room temperature on 
an orbital shaker.  The peptide arrays were then incubated or blocked with 5% milk 
powder (Marvel®), re-constituted in 20mM Tris-Cl; pH 7.6, 150mM NaCl and 0.1% 
Tween20 (TBST) for 1h at room temperature with vigorous agitation.  3-10µg/ml of 
recombinant GST fusion protein, or GST alone as a control, was then diluted in 1% milk 
powder TBST solution and incubated with the peptide array in an airtight plastic carrier 
overnight at 4
oC with vigorous agitation.  The peptide array was then subjected to three 
10min washes in TBST.  The recombinant GST fusion protein was then detected for 
direct binding to the peptide array by probing with a specific primary anti-serum or an 
anti-serum specific for GST.  As a general rule the primary anti-sera were used at two-
fold less than the recommended dilution for Western immuno-blotting.  Details of the 
primary antibodies used in the experiments described in this thesis are shown in Table 
2.4.  The membrane was then washed several times with TBST before application of the 
appropriate  horseradish  peroxidase  (HRP)  conjugated  anti-immunoglobulin  G  (IgG) 
secondary  antibody  diluted  1:5000  in  1%  milk  powder  TBST  solution  in  a  sealed, 
airtight plastic carrier.  Similarly, this was incubated for 1h at room temperature, or   74 
overnight at 4oC, with vigorous agitation.  The membrane was again washed several 
times with TBST before employing the Amersham Biosciences (Little Chalfont, U.K.) 
enhanced chemiluminescence (ECL) Western immuno-blotting kit as the visualisation 
protocol for detecting bound antibodies.  Briefly, the bound antibodies were detected by 
exposure of the peptide array, following washing in ECL solution, to blue-light sensitive 
autoradiography film and developed using the Kodak® X-Omat Model 2000 processor.  
For a more detailed description of this kit or the autoradiography film processor please 
consult the manufacturers instructions.  The resolution of spots, distinct from the GST 
control  peptide  array,  on  the  autoradiography  film  were  indicative  of  a  positive 
interaction  of  the  recombinant  fusion  protein  with  the  peptide  array  and  the  critical 
sequences were analysed for putative consensus sites or binding motifs.              
 
2.8.3  Co-immunoprecipitation 
 
  Mammalian cell lines were co-transfected, as described above in Section 2.5 and 
cell lysates were produced by sub-cellular fractionation as described above in Section 
2.6.  The protein concentrations of the cytosolic, or S fractions were determined, as 
described  above,  and  the  concentrations  equalised  for  all  samples  to  contain 
approximately 250µg of protein in a 500µl volume of ice-cold KHEM.  A 30µl sample 
of the diluted lysate was removed for Western immuno-blotting to determine the relative 
immuno-reactive inputs of the co-expressed proteins for the co-immuno-precipitation 
experiment.  Anti-FLAG or anti-VSV agarose beads were pre-equilibrated in ice-cold 
KHEM to produce a 50% slurry.  60µl of the slurry was added to each 500µl protein 
sample  and  these  were  incubated  end-over-end  for  2h  at  4
oC.    The  samples  were 
centrifuged at 13000rpm for 5min at 4
oC using a bench-top refrigerated centrifuge.  30µl 
of supernatant was removed to screen for unbound proteins.  The agarose resin was 
washed three times in 500µl of ice-cold KHEM and once in 500µl of ice-cold PBS by 
centrifugation at 13000rpm for 1min at 4
oC.  Bound proteins were then eluted in SDS 
sample buffer and subjected to SDS-PAGE and Western immuno-blotting, as described 
previously.  The quantification, by densitometry, of the immuno-reactive amounts of the 
co-expressed  proteins,  in  both  the  initial  cell  lysate  and  following  co-immuno-  75 
precipitation,  was  determined  using  The  Discovery  Series™  Quantity  One®  1-D 
Analysis Software, Version 4.4.0.  These data were used to compare the interaction 
efficiency of the two proteins and assess conditions that may facilitate modulation of the 
specific  interaction.    Control  immuno-precipitations  were  undertaken  in  a  similar 
manner with cell lysates produced from cells singly transfected with the protein that was 
to be co-immuno-precipitated to screen for non-specific binding to the chosen agarose 
bead conjugate. 
 
2.9  Cell Based Assays 
 
2.9.1  Phosphodiesterase Activity Assay 
 
To measure PDE activity a radioactive cAMP hydrolysis assay was employed.  
This procedure has been described previously [Marchmont and Houslay, 1980] and is a 
modification of a historical two-step procedure [Thomson and Appleman, 1971].  PDE 
enzymes hydrolyse cAMP, which results in the formation of 5’ AMP.  In this assay, 
both  [8-3H]  adenosine  3’,  5’-  cyclic  mono-phosphate  from  Amersham  Biosciences 
(Little  Chalfont,  U.K.)  and  adenosine  3’,  5’-  cyclic  monophosphate  are  hydrolysed.  
Addition  of  Snake  Venom  from  Ophiophagus  Hannah  prevents  re-circularisation  of 
uncharged  5’  AMP  by  further  hydrolysis  to  adenosine  and  the  Dowex  slurry  binds 
charged, un-hydrolysed cAMP. 
 
2. 9.1.1  Activation of Dowex 1x8-400 Anion Exchange Resin 
 
Dowex 1x8-400 was prepared and activated by dissolving 400g of Dowex resin 
in 4l of 1M NaOH.  The solution was stirred for 15min at room temperature and the 
resin allowed to settle.  The supernatant was removed and the Dowex resin extensively 
washed thirty times with 4l of distilled water and allowed to settle after each wash.  
After  thirty  washes  the  resin  was  washed  with  4l  of  1M  HCl  for  15min  at  room 
temperature and allowed to settle.  The resin was then washed a further 5 times with 
distilled  water  and  stored  at  4
oC  as  1:1  slurry  with  distilled  water.    Following  this   76 
procedure generally produced approximately 1l of Dowex slurry.  This Dowex slurry 
was utilised in the PDE assay as a 2:1 solution of slurry to 100% ethanol.           
 
 
2.9.1.2 Assay Procedure 
 
The entire assay procedure was undertaken using 1.5ml Eppendorf® tubes per 
reaction.  The cAMP substrate solution for the assay was composed of 2µl of 1mM 3’, 
5’ cyclic adenosine mono-phosphate and 3µl of [8-
3H] 3’, 5’ cyclic adenosine mono-
phosphate per millilitre of 20mM Tris-Cl; pH 7.4 and 10mM MgCl2.  The appropriate 
volume of purified protein or cell extract was diluted to a final volume of 50µl in 20mM 
Tris-Cl; pH 7.4.  50µl in 20mM Tris-Cl; pH 7.4 was used as the blank control.  The 
exact volume of purified protein or cell extract required in the assay was pre-determined 
in a pilot assay using increasing concentrations of protein samples.  50µl of cAMP 
substrate was added to 50µl of the PDE containing sample, mixed, and these were then 
incubated in a water bath at 30
oC for 10min.  The samples were then placed in a boiling 
bath for 2min to inactivate the PDE and stop the reaction.  The tubes were then cooled 
on ice for a minimum of 15min.  25µl of 1mg/ml snake venom from Ophiophagus 
Hannah was then added to the reaction tubes, mixed, and incubated for a further 10min 
at 30
oC.  400µl of Dowex/ethanol solution was added to each reaction tube, mixed, and 
incubated on ice for a further 15min.  Following incubation the tubes were then mixed 
again  and  centrifuged  at  13,000rpm  for  3min  at  4
oC  in  a  refrigerated  bench-top 
centrifuge.  1ml of Opti-Flow SAFE 1 scintillant was added to fresh 1.5ml Eppendorf® 
tubes.  150µl of supernatant from the reaction tubes was added to an individual tube 
containing scintillant with 50µl of cAMP substrate solution added to a scintillant vial to 
determine total counts per minute for the assay.  All tubes containing scintillant were 
mixed and hydrolysed 3’, 5’ cyclic adenosine mono-phosphate and [
8-3H] 3’, 5’ cyclic 
adenosine mono-phosphate was measured using a Wallac® 1409 Liquid Scintillation 
Counter. 
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2.9.1.3   Determination of Phosphodiesterase Activity 
 
To  determine  specific  PDE  activity  contained  within  any  reaction  tube  the 
following formula was applied, 2.61 x (value – blank / average total) x 10-11 x 1012 x 
(1000 / µg protein) resulting in PDE activity in ρmoles/min/mg protein.  To assess the 
effect  of  PDE  inhibition,  the  activity  of  samples  containing  inhibitor  were  directly 
compared to an uninhibited control reaction and was expressed as the percentage of the 
aforementioned uninhibited control. 
 
2.9.2  Thermal Stability Assays 
 
Twenty assay tubes were set-up for a PDE activity assay, as described in Section 
2.10.1.  Each tube contained a pre-determined volume of cell extract, expressing the 
desired PDE4A, in a final volume of 50µl in 20mM Tris-Cl; pH 7.4.  The assay tubes 
were placed in a 55
oC water bath and one assay tube was removed to ice every 30s until 
none were remaining.  50µl of cAMP substrate was then added to 50µl of the de-natured 
PDE sample and the activity assay continued as described above.  The log10 residual 
PDE  activity  was  determined  against  a  control  cell  extract  and  the  thermal  stability 
profile plotted as a function of time, with the half-life (t1/2) determined as the time in 
which 50% of the activity remained. 
 
2.9.3  cAMP assay 
 
Intracellular cAMP was determined by using the ‘Cyclic AMP Competitive 
ELISA’ kit (Product: EMSCAMPL; ThermoFisher/Pierce). 
 
2.9.4  Fibrin Breakdown Assay 
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Fibrin matrices were prepared by addition of 0.1 U/mL thrombin to a mixture of 
2.5 U factor XIII, 2 mg fibrinogen, 2 mg Na-citrate, 0.8 mg NaCl, and 3 µg plasminogen 
per mL DMEM medium. 300 µL of this mixture was added to each well of a 12 well 
plate. After clotting at room temperature, the fibrin matrices were soaked with 0.5 mL 
DMEM supplemented with 10% NCS, and penicillin/streptomycin. NIH3T3 and MEF 
cells were seeded at high density to obtain confluent monolayers cultured in DMEM 
without  indicator  supplemented  with  10%  NCS,  2  mmol/L  L-glutamine  and 
penicillin/streptomycin. Incubations were for 8 to 12 days, and test compounds were 
added together with fresh medium where appropriate. The medium was collected and 
replaced every 2 to 3 days along with new test compounds. Invading cells in the three-
dimensional fibrin matrix were analyzed by phase contrast microscopy. To quantify the 
amount  of  fibrin  degradation,  the  supernatant  was  aspirated  and  the  remaining  gel 
weighed using an analytical balance. The decrease in gel weight corresponds to the 
increase in fibrin degradation. 
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Chapter 3            Phosphorylation of PDE4A5 by MAPKAPK2 
 
 
3.1 Introduction 
 
 
3.1.1   Mitogen-Activated Protein Kinases 
 
Mitogen activated protein kinases (MAP Kinases or MAPKs) were discovered 
approximately  20  years  ago  and  provide  among  the  most  extensive  means  of  cell 
regulation [Avruch, 2007; Kyriakus and Avruch, 2001]. MAPKs form phosphorylation 
cascades  that  control  various  cellular  functions  such  as  cell  differentiation,  cell 
proliferation,  cell  death,  embryogenesis  and  immune  and  inflammatory  responses 
[Pearson et al., 2001]. Their role in such a diverse range of functions has led to their 
being implicated in a wide range of diseases, such as asthma, COPD, cancer, cardiac 
hypertrophy and rheumatoid arthritis [Pearson et al., 2001; Dong et al., 2002]. 
 
The basic components of all MAP Kinase cascades are three core members, the 
mitogen  activated  protein  kinase  kinase  kinases  (MAPKKK),  the  mitogen  activated 
protein kinase kinases (MAPKK) and the mitogen activated protein kinases (MAPK). 
The first stage in the phosphorylation cascade is activation of the MAPKKK proteins 
through exposure to a mitogen. This results in threonine and tyrosine phosphorylation in 
the kinase domain of MAPKKK. The MAPKKK is then able to phosphorylate specific 
serine and threonine residues in the MAPKK kinase domain, leading to activation of this 
downstream protein kinase. Activated MAPKK then, in turn, is able to phosphorylate 
the MAPK kinase domain at serine and tyrosine residues in a conserved Ser-Xaa-Tyr 
region (where Xaa is any amino acid), leading to its activation and the furtherance of 
downstream signalling [Kyriakus and Avruch, 2001]. Within the super-family of MAPK 
proteins there are three members, p38 MAPK, c-Jun N-terminal kinase (JNK) and extra-
cellular signal-regulated protein kinase (ERK). The difference in specificity between 
these  three  MAPKs  is  conferred  by  the  Xaa  in  the  phosphorylation  site  motif,  as   81 
described above. In the case of p38 MAPK this amino acid is a glycine, in the case of 
JNK it is a proline and in the case of ERK it is a glutamate. The signal specificity arising 
from this comes into play when p38 MAPK is activated by MAPKK3 and MAPKK6, 
JNK is activated by MAPKK4 and MAPKK7 and ERK is activated by MAPKK1 and 
MAPKK2. However, despite this linear specificity, crosstalk between the p38 MAPK 
and JNK pathways can occur upon activation of MAPKK4, which can activate both 
pathways [Pearson et al., 2001]. 
 
Once  the  MAPK  components  of  the  phosphorylation  cascades  have  been 
activated they can go on to have a diverse range of downstream effects through a diverse 
range of final substrates. These substrates can be anything from other protein kinases, 
transcription factors and scaffold proteins to enzymes such as PDE4 [Dong et al., 2002]. 
Critically, these potent signalling effects are, however, reversible and this is achieved by 
dephosphorylation that is mediated by the actions of a family of protein phosphatases 
[Lang, 2006].   
 
 
3.1.2  p38 Mitogen Activated Protein Kinase. 
 
The p38 mitogen activated protein kinase signalling cascade plays a key role in 
inflammation and is sometimes known as a stress-activated protein kinase cascade. In 
this, its main activating stimuli are stress factors such as cytokines, heat shock, osmotic 
shock, oxidative stress and ultra-violet radiation [Avruch, 2007].  
 
There are four different isoforms of p38, namely p38α, p38β, p38δ and p38γ. 
p38α  was  the  first  of  these  isoforms  to  be  discovered,  is  thought  to  be  primarily 
responsible  for  regulation  inflammation  and  is  ubiquitously  expressed.  p38β  is  also 
ubiquitously  expressed  and  shares  more  than  70%  sequence  homology  with  p38α 
[Zhang et al., 2006]. The biological roles of p38δ and p38γ are less well understood 
although these isoforms are thought to be tissue specific with p38δ predominantly found   82 
in skeletal muscle and p38γ found in the small intestines, testes and pancreas [Schindler 
et al., 2007]. 
 
 
3.1.2.1 Activation and Inhibition of p38 MAP Kinase 
 
The p38 MAP kinase can be activated by many different extracellular factors, as 
stated above and listed in Table 3.1. Stimulation by these factors works through various 
MAPKKKs to elicit activation of MAPKK3, MAPKK4 or MAPKK6, which go on to 
activated p38. MAPKK3 and MAPKK6 show the highest levels of activity towards p38, 
with MAPKK3 favouring the α and β isoforms, whereas MAPKK6 can activate all four 
isoforms [Enslen et al., 2000]. MAPKK4 has also, somewhat curiously, been shown to 
activate  p38  under  certain  cellular  conditions.  This  is  unusual  and  is  still  being 
questioned  as  MAPKK4  is  a  component  of  the  JNK  pathway  and  was,  originally, 
thought to only operate on this pathway [Brancho et al., 2003]. Pharmacologically the 
p38 MAP Kinase pathway can be activated by Anisomycin. Anisomycin is an antibiotic 
that inhibits protein synthesis and activates the stress activated protein kinase pathways, 
including p38 MAPK, which may be through actions on Rac and Cdc42 [Grollman, 
1967;  You  et  al.,  2005].  Its  structure  is  shown  in  Figure  3.3.  Similarly  TNFα  can 
activate the p38 MAPK cascade through the TNFα receptor and recruitment of its signal 
scaffold proteins RIP and TRAF [Wajant and Scheurich, 2001]. Both of these activation 
pathways are shown in Figure 3.1. Inhibitors of the p38 MAPK pathway have been 
widely  studied  with  limited  clinical  success  [Cohen,  2009].  Pyridinyl  imidazole 
inhibitors contributed to the discovery and characterisation of p38 MAPK through their 
ability  to  inhibit  the  p38  MAPK  cascade  and  now  provide  the  most  common 
experimentally used p38 inhibitors, of which one example is SB203580, whose structure 
is shown in Figure 3.3 [Zhang et al., 2007]. 
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3.1.2.2   Downstream Effects of p38 MAP Kinase 
 
Once p38 MAPK has been activated it can then go on to activate downstream 
effectors which, when activated, transduce signals to target proteins in the cell that are 
not directly targeted by the MAP kinase. Downstream effectors of p38 MAPK tend to be 
protein kinases, with the most prominent group of these being the mitogen activated 
protein kinase activated protein kinases or MAPKAPKs. Three such isoforms can be 
activated by p38 MAPK, namely MAPKAPK2, MAPKAPK3 and MAPKAPK5 [Clifton 
et al., 1996; Ni et al., 1998]. Other protein kinases targeted downstream of the p38 
MAPK pathway include the MAPK signal-integrating kinases (MNKs), and mitogen- 
and stress-activated protein kinases (MSKs) [Roux, 2004; Arthur, 2008].  
 
The  MAPKAPK  family  is  a  curious  one  as,  despite  its  members  having 
overlapping structural properties and substrate spectrums, they do not appear to have a 
common function. Of the three isoforms activated by p38 MAPK, MAPKAPK2 and 
MAPKAPK3 are activated directly by the p38α and β isoforms of the MAPK. However 
MAPKAPK5,  also  known  as  the  p38-regulated  and  activated  kinase  (PRAK),  is 
activated by both ERK and p38 MAPK 
 
MAPKAPK2 is the most investigated substrate of p38 MAPK. Structurally it 
consists of an N-terminal proline-rich domain, a catalytic domain and contains both a 
putative nuclear localisation signal (NLS) and a nuclear export signal (NES) within its 
C-terminal domain [Meng et al., 2002]. Upon stimulation of the p38 MAPK cascade, 
p38 MAPK becomes activated and phosphorylates MAPKAPK2 at Thr222 and Ser272 
in the catalytic domain and at Thr334 in the C-terminal domain [Gaestel, 2006; Lukas et 
al., 2004]. In resting cells an inactive, auto-inhibitory complex of p38α-MAPKAPK2 is 
found in the nucleus where the nuclear localisation signal on MAPKAPK2 is functional. 
Under  stress  stimulation  MAPKK6  activates  p38α  that,  in  turn,  phosphorylates 
MAPKAPK2. This phosphorylation, in particular the phosphorylation of Thr334, leads 
to “unmasking” of the nuclear export signal of the protein and allows for translocation   84 
of the p38α-MAPKAPK2 complex out of the nucleus, allowing a population of active 
p38α-MAPKAPK2 to accrue in the cytoplasm [Engel et al., 1998].  
 
Functionally, MAPKAPK2 has been implicated in a wide variety of roles within 
the cell. These are located both within the nucleus and within the cytoplasm, such as 
post-transcriptional  regulation,  actin  remodelling,  cell  migration  and  cell  cycle 
regulation. When activated MAPKAPK2 is situated in the nucleus it is believed to play 
a  role  in  post-transcriptional  regulation.  There,  MAPKAPK2  is  thought  to  be 
responsible for stabilisation of the AU-rich elements through phosphorylation of mRNA 
binding  proteins  such  as  tristetraprolin  (TTP),  K  homology-type  splicing  regulatory 
protein (KSRP) and heterogeneous nuclear ribonucleoprotein (hnRNP). This regulation 
leads to gene expression of cytokines such as IL-6, IL-8 and TNFα [Gaestal, 2006]. 
Another  MAPKAPK2  phosphorylation  target  in  the  nucleus  is  considered  to  be  the 
transcription factor CREB (cAMP Responsive Element Binding protein), although this 
action is not unequivocal and it is has been suggested that MSK1 may actually be the 
kinase  responsible  for  CREB  phosphorylation  and  activation  under  conditions  of 
activation of the p38 MAPK pathway [Delghandi et al., 2005; Tan et al., 1996]. Once 
MAPKAPK2 is translocated out of the nucleus, following activation, it is able to act on 
a plethora of phosphorylation targets. One notable group of substrates are small heat 
shock  proteins  (Hsps),  with  Hsp25  and  Hsp27  being  identified  as  major  targets  for 
MAPKAPK2. In the case of Hsp25, MAPKAPK2 has been identified as the main kinase 
responsible for its activation. Phosphorylation of Hsp25, by MAPKAPK2, results in 
release from its role as a chaperone inhibiting actin polymerisation and thus acts to 
trigger actin remodelling and for actin polymerisation to occur [Benndorf et al., 1994]. 
Hsp27 exists as oligomers that act as ATP-independent chaperones and keep unfolded 
proteins  in  a  “folding-ready”  state  in  preparation  for  processes  such  as  actin 
remodelling. MAPKAPK2 phosphorylation of Hsp27 is thought to be responsible for 
the heat shock protein’s oligomerisation and may also regulate its chaperone properties 
[Rogalla et al., 1999].  
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Recently a new role for MAPKAPK2 has been identified as a checkpoint protein 
in  the  cell  cycle  [Reinhardt  et  al.,  2009].  The  phosphatase  family  Cdc25  removes 
inhibitory phosphate residues from the cyclic dependent kinases (Cdks), a major driving 
force in the cell cycle, thereby controlling progression of the cell cycle [Strausfeld et al., 
1991]. All three Cdc25 isoforms, Cdc25A, Cdc25B and Cdc25C have recently been 
shown to be substrates for MAPKAPK2. Within the cell cycle Cdc25A plays a role in 
the G1-S checkpoint, with Cdc25B and Cdc25C having a role in G2 phase. During DNA 
damage, MAPKAPK2 is activated; it then phosphorylates Cdc25B and Cdc25C causing 
arrest of the cell cycle [Lammer et al., 1998]. In addition to this, MAPKAPK2 can 
phosphorylate  and  activate  the  ubiquitin  ligase  HDM2,  which  degrades  the  tumour 
suppressor protein p53 [Weber et al., 2005]. p53 is responsible for cell cycle regulation 
at G1/S and entry into apoptosis therefore through this MAPKAPK2 may play another 
role in cell cycle regulation. All of these roles of MAPKAPK2 throughout the cell show 
how multifaceted and important a downstream effector of p38 MAPK it is.  
 
The  biological  functions  of  both  MAPKAPK3  and  MAPKAPK5  are  poorly 
understood  compared  to  MAPKAPK2.  MAPKAPK3  is  structurally  most  similar  to 
MAPKAPK2  and  may  have  its  nuclear  localisation  regulated  in  a  similar  way 
[Zakowski 2004]. Little is known about its functionality, however it is thought to play a 
role  in  chromatin  remodelling  through  phosphorylation  of  polycomb  group  protein 
BMI1 [Voncken et al., 2005]. MAPKAPK5 lacks the proline rich N-terminal region 
present in both MAPKAPK2 and MAPKAPK3. Again, little is known about its cellular 
function, however MAPKAPK5 knockout mice are more susceptible to skin cancer than 
wild type mice and thus it has been suggested that MAPKAPK5 may have a role as a 
tumour suppressor [Sun et al., 2007].  
 
Two other families of kinases that are downstream effectors of the p38 MAPK 
pathway, and less well understood, are the serine threonine kinases, MAPK interacting 
kinases (MNKs) and the mitogen and stress-activated protein kinases (MSKs). In the 
case of MNKs there are two isoforms, MNK1 and MNK2, and stimulation of either the 
p38 MAPK pathway or the ERK pathway can lead to their activation thus, possibly,   86 
providing  an  example  of  a  source  of  convergence  for  these  two  key  pathways. 
Structurally these kinases are similar to MAPKAPK1, MAPKAPK2 and MAPKAPK3 
proteins but with an additional basic N-terminal structure designed to determine their 
intracellular targeting [Waskiewicz et al., 1997]. Although these kinases have not been 
widely studied, recent investigations of these proteins has shown that they are auto-
inhibited in the absence of p38 and ERK phosphorylation [Jauch et al., 2006] and that, 
when activated, they provide the only kinases to phosphorylate Ser209 of eIF4E, the 
cap-binding protein, which increases translation [Mahalingam and Cooper, 2001]. They 
have also been implied in regulation of the innate immune response in macrophages 
through TNFα control [Andersson and Sundler, 2006].  
 
In the MSK family there are two isoforms; MSK1 and MSK2. These enzymes 
share approximately 50% homology with MAPKAPK1 and, of the two, MSK1 is most 
widely studied [Arthur and Cohen, 2000]. MSK1 plays a role in phosphorylation and 
activation of the transcription factors CREB and, closely related, activating transcription 
factor 1, ATF1 [Deak et al., 1998]. Recent research has indicated that both MSK1 and 
MSK2  could  play  an  important  role  in  limiting  the  production  of  pro-inflammatory 
cytokines in response to stimulation of primary macrophages. This provides a negative 
feedback system that is able to limit toll-like receptor-mediated inflammation [Ananieva 
et al., 2008]. 
 
 
3.1.3  The Immune and Inflammatory Role of p38 MAP Kinase. 
 
p38  MAPK  plays  a  key  role  in  regulation  of  the  immune  and  inflammatory 
response to pathogens. p38α was the first p38 MAPK to be shown to play a role in 
inflammation. When pyridinyl imidazoles were first discovered it was thought that they 
had  their  anti-inflammatory  effect  through  inhibition  of  5-lipoxygenase  and 
cyclooxygenase [Han et al., 1994]. However, further studies using the acute monocytic 
leukaemia cell line, THP-1, identified two 38 kDa protein kinases, namely p38α and 
p38β, as being responsible for cytokine suppression and loss of inflammation [Lee et al.,   87 
1994]. Since then the p38 MAPK signalling cascade has been shown to play a pivotal 
role  in  the  activation  and  production  of  several  pro-inflammatory  cytokines  such  as 
TNFα, interleukin 1, interleukin 6 and interleukin 8 [Lee at al., 1994]. In addition to its 
role  in  pro-inflammatory  cytokine  production  it  has  also  been  established  that  p38 
MAPK plays a key role in inducing enzymes such as COX2, which trigger eicosanoid 
production  at  sites  of  inflammation,  and  also  iNOS,  which  triggers  nitric  oxide 
production at the site of inflammation [Dean et al., 1999].  
 
To  establish  the  roles  of  the  different  p38  MAPK  isoforms  in  inflammation, 
knockout  mice  systems  have  been  used.  This  approach  showed  that  when  p38A 
knockout mice were produced they had very low cytokine production [Beardmore et al., 
2005]. It has also been reported that T helper cells, Th1, deficient in p38α did not 
produce  interferon-γ  when  stimulated  by  interleukins  12  and  18,  causing  a  lack  of 
inflammatory  response  [Berenson  et  al.,  2006].  However  when  a  knockout  mouse 
system  of  p38β  was  produced  these  mice  were  found  to  have  normal  LPS  induced 
cytokine production and, counter-intuitively, there was even an increase in inflammation 
in some systems such and the bowels and joints [Beardmore et al., 2005]. Nevertheless, 
these knockout studies clearly show that p38α MAPK is the main p38 isoform involved 
in control of inflammatory system. However as the roles of p38δ and p38γ are not fully 
established, no firm conclusion can be made about their overall importance to immune 
system function. It should also be noted that knockout mice studies have also been 
carried out to ablate the key downstream effector of the p38 MAPK pathway, namely 
MAPKAPK2 [Kotlyarov et al., 1999]. Mice generated in this way exhibited a marked 
decreases in Il-6 and TNFα in response to LPS showing that this downstream kinase 
obviously plays a role in p38α MAPKs control of inflammation.  
 
The  control  of  pro-inflammatory  cytokines  is  particularly  important 
therapeutically as their over-production is seen in many disease states such as asthma, 
Crohns  disease  and  rheumatoid  arthritis  [Russo  and  Polosa,  2005].  They  are  also 
implicated  in  playing  roles  in  other  diseases  like  heart  failure  and  insulin  resistant 
diabetes [Pomerantz et al., 2001, Takeda et al., 2005]. Due to this, blockage of their   88 
production and/or actions is obviously a key target for therapeutic development and 
because  of  this  several  pharmaceutical  companies  have  developed  a  series  of  p38α 
MAPK and MAPKAPK2 inhibitors. In the case of the p38α MAPK inhibitors only a 
few inhibitors have made it to the advanced stages of clinical trials. For example, Scios 
and Johnson and Johnson have the p38α MAPK inhibitor, SCIO 323 in phase II clinical 
trials  to  treat  rheumatoid  arthritis  [Lee  and  Dominguez,  2005].  Somewhat  less 
successfully, BIRB 796, developed by Boeringer Ingelheim, although it gave promising 
results in initial trials it was subsequently found to have limited effect in Crohn’s disease 
and  caused  dangerously  high  increases  in  liver  enzyme  synthesis  [Schreiber  et  al., 
2006]. Similarly Amgen produced AMG 548, which exhibited a high rate of inhibition 
of  pro-inflammatory  cytokines  in  healthy  males,  however  these  trials  had  to  be 
suspended as it was also shown to elevate the levels of liver enzyme synthesis [Lee and 
Dominguez, 2005]. Due to these liver complications, and the tendency of p38α MAPK 
inhibitors to put the patient at risk of infection, the focus of many companies has shifted 
from inhibitors of p38α MAPK to development of inhibitors of downstream effectors of 
the pathway such as MAPKAPK2. Development of these inhibitors is still in the very 
early stages and it was originally thought that the lack of availability of the crystal 
structure of the enzyme has precluded rational drug design. However since the crystal 
structure of unphosphorylated MAPKAPK2 was discovered in 2002, and showed that 
the kinase domain existed in an exposed, semi-activated state, and a selective inhibitor 
has still not been developed [Meng et al., 2002]. 
 
 
3.1.4  Phosphorylation of PDE4 enzymes by MAPKAPK2 
 
Phosphodiesterase-4 enzymes are subject to phosphorylation at distinct sites with 
subsequent catalytic activity regulation by ERK1/2 [Hoffmann et al., 1999; MacKenzie 
et al., 2000; Baillie et al., 2001], PKA [Sette and Conti, 1996; MacKenzie et al., 2002], 
and an unknown protein kinase thought to be part of the PI-3K signalling pathway and 
activated  by  reactive  oxygen  species  (ROS)  [MacKenzie  et  al.,  1998].  These 
phosphorylation events have been discussed previously in detail in Chapter 1.     89 
 
The p38 MAPK signalling pathway plays a fundamental role in the immune and 
inflammatory response. Previous unpublished work from the Houslay lab suggested that 
PDE4  may  be  a  phosphorylation  target  for  a  downstream  effector  of  this  pathway, 
namely MAPKAPK2. The aim of this chapter was to corroborate this and so identify 
whether  PDE4  enzymes  could  indeed  be  phosphorylated  and  regulated  through 
activation of MAPKAPK2 and elucidate the functional significance of the integration of 
cross talk between p38 MAPK and cAMP signalling.          90 
 
 
 
Figure 3.1 – Schematic representation of the p38 MAPK signalling pathway. 
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3.2  Results  
 
 
Analysis  of  the  amino  acid  sequence  for  PDE4A5  reveals  two  putative 
MAPKAPK2 phosphorylation sites with the consensus motif of Ø-X-Arg-X-X-Ser-Ø, 
where Ø are hydrophobic amino acids and X is any amino acid. [Stokoe et al., 1993; 
Rousseau et al., 2005]. Both of these regions are found within Upstream Conserved 
Region 1 as shown in Figure 3.2. The first potential site is serine 147, which lies within 
the sequence Leu-Tyr-Arg-Ser-Asp-Ser-Asp, and the second site is serine 161, within 
the motif Val-Ser-Arg-Ser-Ser-Ser-Val.  
 
Unpublished work from the Houslay laboratory by Dr Elaine Hill and Dr Derek 
Wallace  has  shown  that  a  purified  PDE4A5  MBP  fusion  protein,  generated  by 
expression in E.coli, could be phosphorylated in vitro by recombinant MAPKAPK2, but 
not  by  recombinant  p38  MAP  Kinase  [E.V.  Hill,  D.A.  Wallace  and  M.D.  Houslay, 
unpublished observations].   
 
 
3.2.1  In vivo phosphorylation of PDE4A5 by MAPKAPK2 
 
Previous  phosphorylation  experiments  were  carried  out  in  vitro  and  so  it  is 
important to determine whether MAPKAPK2 could phosphorylate PDE4A5 in vivo in 
living cells. In order to achieve this a cell system had to be used where the p38 MAP 
Kinase cascade could be successfully activated and PDE4A5 manipulated. To achieve 
this COS1 cells were treated with either the p38 MAP Kinase activator anisomycin, the 
structure of which is shown in Figure 3.3 or the inflammatory cytokine, TNFα.  
 
Figure 3.4(a) (work performed by Dr Derek Wallace) shows that endogenous 
p38 MAPK activity, indicated as dual phosphorylation of the kinase at Thr-180 and Tyr-
182, was low in the basal state, and that it was activated in a potent, time dependent 
manner by anisomycin. The activation of p38 MAPK reached at maximum at 20min and   92 
was sustained up to at least 60 min. Figure 3.4(b) shows that anisomycin also activated 
MAPKAPK2, indicated by phosphorylation at Thr-334, in a time dependent manner 
reaching a maximum at 30min and was sustained up to at least 60min. Figure 3.5 shows 
that TNFα also activates both p38 MAPK and MAPKAPK2 in a time dependent manner 
with p38 MAPK activation reaching a maximum at 5min and is sustained until 10 min 
where activity decreases but has still not returned to basal activity over a period of 25 
min studied here.MAPKAPK2 activation reaches a maximum at 5min and an activated 
state is sustained up until at least 25 min albeit at a lower level (Figure 3.5). As a 
routine, I chose to use anisomycin for activation of p38 MAPK and MAPKAPK2 in the 
majority of experiments as it provided consistent and substantial levels of activation 
over an experimentally accessible time course.  
 
In previous work performed by Dr Elaine Hill and Dr Derek Wallace PDE4A5 
was transiently over-expressed in COS1 cells, which were grown in phosphate-free cell 
media that was supplemented with [
32P]-orthophosphate.  The cells were treated with 
anisomycin or anisomycin plus the p38 MAPK inhibitor SB203580 (structure shown in 
Figure  3.3).  Lysates  were  produced,  PDE4A5  was  immuno-precipitated  and 
phosphorylation levels analysed as shown in Figure 3.6(a). This showed that anisomycin 
treatment  resulted  in  increased  phosphorylation  of  PDE4A5  to  172  +/-  8%  and 
SB203580 ablated this phosphorylation to 124 +/- 4%, which proves that anisomycin is 
induction phosphorylation of PDE4A5 through the p38 MAP Kinase pathway.   
 
However as it has been previously shown (unpublished work from the Houslay 
lab;  E.V.  Hill,  D.A.  Wallace)  that  PDE4A5  has  two  putative  p38  MAPK 
phosphorylation  sites  it  is  important  to  establish  if  this  phosphorylation  is  due  to 
MAPKAPK2 phosphorylation or p38 MAPK phosphorylation of the PDE. To do this 
the two putative phosphorylation sites for MAPKAPK2 on PDE4A5 were mutated to 
alanine  giving  the  two  mutant  PDE4A5  constructs  S147A  and  S161A.  These  were 
transfected into COS1 cells grown in phosphate-free cell media that was supplemented 
with  [
32P]-orthophosphate  and  were  treated  with  anisomycin.  Again,  lysates  were 
produced, PDE4A5 was immuno-precipitated and phosphorylation levels analysed as   93 
shown  in  Figure  3.6(b).  This  showed  that  anisomycin  is  indeed  phosphorylating 
PDE4A5  through  MAPKAPK2  as  it  is  acting  at  the  phosphorylation  site  S147A. 
PDE4A5 was used as a standard and density of phosphorylation on the phospho-blot 
marked as 100%.  When compared to this S161A gives a phosphorylation level of 90% 
+/-  2%,  whereas  S147A  gives  a  phosphorylation  level  of  40%  +/-  2%.  Successful 
generation  of  a  custom  made  antibody  that  targets  this  specific  serine  147 
phosphorylation site of PDE4A5 allowed cell lysates of COS1 cells, grown in normal 
cell media and transiently transfected with PDE4A5 treated with an anisomycin time 
course,  to  be  probed  for  MAPKAPK2  specific  phosphorylation  as  shown  in  Figure 
3.6(c).These  results  confirmed  that  PDE4A5  is  phosphorylated  at  serine  147  by 
MAPKAPK2.   94 
 
 
Figure 3.2 – Schematic representation of the basic structure of PDE4A5. 
 
Schematic  representation  of  the  basic  structure  of  PDE4A5.  UCR  =  Upstream 
Conserved  Region,  LR  =  Linker  Region  and  CT=  C-Terminus.  The  PKA 
phosphorylation site (Ser 140) and the two potential MAPKAPK2 phosphorylation sites 
(Ser 147 and Ser 161) highlighted in the Upstream Conserved Region 1.  
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Figure 3.3 - Chemical structures of anisomycin and SB203580.
SB203580 
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Figure 3.4 – Anisomycin time course of p38 MAPK and MAPKAPK2 activation in 
COS1 cells.   
 
COS1 cells were treated with anisomycin (10µg/ml) at the indicated time points (0-
60min).  Total cell extract was produced and the lysates immuno-probed with anti-sera 
specific for the respective kinase activation.  (a), top panel, is a Western blot probed 
with anti-sera able to detect endogenous levels of the dual phosphorylated (Thr-180 and 
Tyr-182), and activated, p38 MAPK.  (a), bottom panel, is the same Western blot re-
probed with an anti-serum to detect total endogenous p38 MAPK.  (b), top panel, is a 
Western  blot  of  phosphorylated,  and  activated,  MAPKAPK2,  as  indicated  by  the 
detection of the mono phosphorylated (Thr-334) form.  (b), bottom panel, is the same 
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Western blot re-probed for total endogenous MAPKAPK2, using a specific anti-serum.  
All Western blots are representative blots of at least three separate experiments. 
 
This work was performed by Dr Derek Wallace. 
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Figure 3.5 – TNFα time course of p38 MAPK and MAPKAPK2 activation in COS1 
cells.   
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COS1 cells were treated with TNFα (10µM) at the indicated time points (0-25min).  
Total cell extract was produced and the lysates immuno-probed with anti-sera specific 
for the respective kinase activation.  (a), top panel, is a Western blot probed with anti-
sera able to detect endogenous levels of the dual phosphorylated (Thr-180 and Tyr-182), 
and activated, p38 MAPK.  (a), bottom panel, is the same Western blot re-probed with 
an anti-serum to detect total endogenous p38 MAPK.  (b), top panel, is a Western blot of 
phosphorylated, and activated, MAPKAPK2, as indicated by the detection of the mono 
phosphorylated (Thr-334) form.  (b), bottom panel, is the same Western blot re-probed 
for total endogenous MAPKAPK2, using a specific anti-serum.  All Western blots are 
representative blots of at least three separate experiments. 
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Figure 3.6 – PDE4A5 is phosphorylated by MAPKAPK2 at Serine 147. 
 
COS1 cells were transiently transfected to over-express PDE4A5.  The cells were grown 
in  phosphate-free  cell  media  that  was  supplemented  with  [
32P]-orthophosphate 
overnight.  The cells were treated with anisomycin (10µg/ml) for 60min, to activate the 
p38  MAPK  phosphorylation  cascade,  or  anisomycin  plus  the  p38  MAPK  inhibitor 
SB203580 (10µM) for 60min respectively. Total cell lysate was produced.  PDE4A5 
was  immuno-precipitated  using  an  anti-PDE4A  antibody  conjugated  to  Protein  G 
agarose with un-conjugated Protein G agarose used as a control immuno-precipitation. 
The immuno-precipitated proteins were separated by SDS-PAGE and transferred to a 
nitrocellulose membrane where the radioactive proteins were resolved using phosphor 
image screen technology.  (a), top panel, is a scanned phosphor image screen of the 
phosphorylated  PDE4A5  immuno-precipitated  following  treatment  with  anisomycin 
plus or minus SB203580.  (a), bottom panel, is a Western blot of the same nitrocellulose 
membrane probed with the anti-PDE4A antibody to determine the relative immuno-
precipitation  of  PDE4A5  from  the  three  samples.  COS1  cells  were  then  transiently 
transfected to over-express either PDE4A5, Ser147Ala-PDE4A5 mutant or Ser161Ala-
PDE4A5  mutant.  The  cells  were  grown  in  phosphate-free  cell  media  that  was 
supplemented  with  [
32P]-orthophosphate  overnight.    The  cells  were  treated  with 
p-PDE4A5 
  PDE4A5 
  b  IP  b  IP  b  IP  b  IP  b  IP  b  IP  
  0      10    20     40    60     SB       Time (min) 
(c)   100 
anisomycin (10µg/ml) for 60min, to activate the p38 MAPK phosphorylation cascade. 
Total  cell  lysate  was  produced.    PDE4A5  was  immuno-precipitated  using  an  anti-
PDE4A antibody conjugated to Protein G agarose with un-conjugated Protein G agarose 
used  as  a  control  immuno-precipitation.  The  immuno-precipitated  proteins  were 
separated  by  SDS-PAGE  and  transferred  to  a  nitrocellulose  membrane  where  the 
radioactive proteins were resolved using phosphor image screen technology.  (b), top 
panel, is a scanned phosphor image screen of the phosphorylated PDE4A5, Ser147Ala-
PDE4A5  mutant  and  Ser161Ala-PDE4A5  mutant  forms  were  immuno-precipitated 
following treatment with anisomycin.  (b), bottom panel, is a Western blot of the same 
nitrocellulose membrane probed with the anti-PDE4A antibody to determine the relative 
immuno-precipitation  of  PDE4A5  from  the  three  samples.  Immuno-precipitation  of 
PDE4A5 was then carried out after various time points of treatment with anisomycin 
(10µg/ml) over a 60 min time course and the IP products produced were probed with a 
PDE4A4  Phospho-Ser147  specific  antibody,  (c).  This  work  was  performed  by  Dr 
Elaine Hill and Dr Derek Wallace.   101 
3.2.2  Functional Effects of PDE4A5 Phosphorylation 
 
PDE4 enzymes are known to be subject to regulation by three different kinases; 
PKA,  ERK1/2  and  an  unknown  kinase  downstream  of  PI3  Kinase,  as  discussed 
previously. All long form PDE4 enzymes contain a conserved PKA phosphorylation site 
within the UCR1 region that upon phosphorylation induces a 2-fold increase in PDE4 
activity [Houslay, 2001]. ERK has a conserved docking site on all PDE4 isoforms in the 
catalytic domain however it only has a functional effect on PDE4B, 4C and 4D isoforms 
as PDE4A isoforms lack the phosphorylation site for ERK [Baillie et al., 2000].  In long 
form PDE4B, 4C and 4D ERK2 phosphorylation leads to an inhibition of PDE activity, 
which  can  be  overcome  by  PKA  phosphorylation.  PDE4A4/5  can  also  be 
phosphorylated  by  an  unidentified  downstream  component  of  the  PI3K  pathway 
[MacKenzie et al., 1998; MacKenzie and Houslay, 2000] although the specific kinase 
responsible is yet to be identified.  
 
 
3.2.2.1 Phosphorylation of PDE4A5 
 
As stated above, PDE4A5 is able to be phosphorylated by PKA. A model system 
was set up to demonstrate this using COS1 cells transiently transfected to over-express 
PDE4A5. PKA was first activated by increasing intracellular cAMP levels. This was 
done using treatment with both IBMX, to block all PDE determined cAMP degradation, 
and  the  direct  activator  of  adenylyl  cyclase,  the  diterpene  forskolin.  This  treatment 
induced PKA phosphorylation of PDE4A5, which was detected using a custom made 
antibody targeted to Ser140, the PKA phosphorylation site in UCR1 [MacKenzie et al., 
2002] as shown in Figure 3.7(a). Quantification of the phosphorylation showed that the 
level of PKA phosphorylation of PDE4A5 gradually increased, reaching a maximum 
some 10-20min after forskolin challenge Figure 3.7(b).  
 
As  the  identified  site  for  MAPKAPK2  phosphorylation  on  PDE4A5  and  the 
PKA  phosphorylation  site  (Ser  147  for  MAPKAPK2  and  Ser  140  for  PKA)  are   102 
extremely  close  together  within  UCR1  it  was  important  to  establish  whether 
MAPKAPK2 phosphorylation was having an effect on the phosphorylation status of the 
PKA site. Again using the cell model of COS1 cells transiently transfected to over-
express PDE4A5, anisomycin treatment was used to activate the p38 MAPK cascade 
and therefore activate MAPKAPK2. In this case, using the PKA phosphorylation site 
antibody, no PKA phosphorylation of PDE4A5 was detected, above the basal rate as 
shown in Figure 3.8(a). The level of phosphorylation was quantified using densitometry 
and it was confirmed that PKA phosphorylation levels remained at a low basal rate 
throughout treatment, Figure 3.8(b). This shows that MAPKAPK2 phosphorylation of 
PDE4A5 does not directly affect Ser140 of PDE4A5. It was, however, also important to 
establish whether MAPKAPK2 phosphorylation was altering PKA’s ability to act at its 
target site within the long PDE4A5 isoform. As this site is in close proximity to the 
MAPKAPK2 site it is possible that steric hindrance caused by a conformational might 
prevent one kinase phosphorylate its target sites subsequent to the action of the other. 
Certainly the close proximity of these sites would prevent simultaneous phosphorylation 
by these two kinases due to steric hindrance, so phosphorylation by one kinase would 
always be expected to precede phosphorylation by the other. Using the model system 
with COS1 cells transfected to transiently express PDE4A5, these cells were pre-treated 
with anisomycin to activate MAPKAPK2 and this treatment was followed by activating 
PKA by treatment with forskolin together with IBMX. Doing this I noted that PKA 
phosphorylation  of  PDE4A5  ensued  with  similar  kinetics  and  magnitude  to  that 
observed when cells were challenged with IBMX and forskolin and no pre-treatment 
with  anisomycin  (Fig.  3.9).  Thus  Ser140  phosphorylation  levels  gradually  increased 
from 0-10 min reaching a sustained maximum at 10-20 min, Figure 3.9. This, therefore, 
shows  that  despite  the  close  proximity  of  the  phosphorylation  sites  of  PKA  and 
MAPKAPK2 on UCR1 there is no steric interference between the two kinases in the 
process of phosphorylation. 
 
The phosphorylation studies were then repeated with the PDE4A5 Ser147Ala 
mutant for the MAPKAPK2 phosphorylation site, transiently over-expressed in COS1 
cells, to establish whether mutation of the MAPKAPK2 target site had any effect on   103 
PKA phosphorylation. As with the wild type PDE4A5 it was shown that increasing 
PKA phosphorylation occurred in a time dependent manner after PKA activation, Figure 
3.10. No PKA phosphorylation above basal level was observed after activation of the 
p38 MAPK cascade. Figure 3.11, and lastly that activation of the p38 MAPK cascade 
did not affect the ability of PKA to phosphorylate PDE4A5 upon stimulation of adenylyl 
cyclase, Figure 3.12. 
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(a)  Wild Type PDE4A5 
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      Time with Fsk (min) after IBMX pre-treatment 
 
 
(b)
Figure 3.7 – Phosphorylation and activation of rat PDE4A5 by PKA.   
PDE 4A5 expression 100 kDa 
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COS1  cells  were  transfected  to  transiently  express  wild  type  rat  PDE4A5.    The 
transfected cells were pre-treated for 10min with the non-specific PDE inhibitor, IBMX 
(100µM)  before  challenge,  0-20min,  with  the  adenylyl  cyclase  activator,  forskolin 
(100µM).  (a), top panel, is a Western blot probed with a rat PDE4A C-terminal specific 
anti-serum to provide both loading and PDE4A5 expression controls. (a), bottom panel, 
is the same Western blot re-probed with the phospho-UCR1 specific anti-serum to the 
PKA  phosphorylated  serine  (S*)  residue  within  the  RRES*F  consensus  motif 
[MacKenzie et al., 2002]. (b) shows the densitometry of the phospho-UCR1 time course, 
corrected for PDE4A5 expression. All data shown are representative Western blots of 
three separate transfections and experiments +/- standard deviation.  
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(a)  Wild Type PDE4A5 
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(b)
 
Figure 3.8 – Phosphorylation and activation of rat PDE4A5 by MAPKAPK2.   
PDE 4A5 expression 100 kDa 
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COS1  cells  were  transfected  to  transiently  express  wild  type  rat  PDE4A5.    The 
transfected cells were treated for 60min with the p38 MAP Kinase activator, anisomycin 
(10µg/ml). (a), top panel, is a Western blot probed with a rat PDE4A C-terminal specific 
anti-serum to provide both loading and PDE4A5 expression controls. (a), bottom panel, 
is the same Western blot re-probed with the phospho-UCR1 specific anti-serum to the 
PKA  phosphorylated  serine  (S*)  residue  within  the  RRES*F  consensus  motif 
[MacKenzie et al., 2002]. (b) shows the densitometry of the phospho-UCR1 time course, 
corrected for PDE4A5 expression. All data shown are representative Western blots of 
three separate transfections and experiments +/- standard deviation. 
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(a)  Wild Type PDE4A5 
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     Time with Fsk (min) after Anisomycin and IBMX pre-treatment 
 
 
(b)
Figure 3.9 – Phosphorylation and activation of rat PDE4A5 by PKA and 
MAPKAPK2.   
PDE 4A5 expression 100 kDa 
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COS1  cells  were  transfected  to  transiently  express  wild  type  rat  PDE4A5.    The 
transfected  cells  were  pre-treated  for  30min  with  the  p38  MAP  Kinase  activator, 
anisomycin (10µg/ml), then treated with 10min with the non-specific PDE inhibitor, 
IBMX  (100µM)  before  challenge,  0-20min,  with  the  adenylyl  cyclase  activator, 
forskolin  (100µM).    (a),  top  panel,  is  a  Western  blot  probed  with  a  rat  PDE4A  C-
terminal specific anti-serum to provide both loading and PDE4A5 expression controls. 
(a), bottom panel, is the same Western blot re-probed with the phospho-UCR1 specific 
anti-serum  to  the  PKA  phosphorylated  serine  (S*)  residue  within  the  RRES*F 
consensus motif [MacKenzie et al., 2002]. (b) shows the densitometry of the phospho-
UCR1 time course, corrected for PDE4A5 expression. All data shown are representative 
Western blots of three separate transfections and experiments +/- standard deviation.   110 
(a)  PDE4A5 S147A mutant 
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Figure 3.10 – Phosphorylation and activation of rat PDE4A5 S147A by PKA.   
PDE 4A5 expression 100 kDa 
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COS1  cells  were  transfected  to  transiently  express  rat  PDE4A5  with  a  mutation  to 
alanine at serine 147, the predicted MAPKAPK2 phosphorylation site. The transfected 
cells were pre-treated for 10min with the non-specific PDE inhibitor, IBMX (100µM) 
before challenge, 0-20min, with the adenylyl cyclase activator, forskolin (100µM).  (a), 
top panel, is a Western blot probed with a rat PDE4A C-terminal specific anti-serum to 
provide both loading and PDE4A5 expression controls. (a), bottom panel, is the same 
Western  blot  re-probed  with  the  phospho-UCR1  specific  anti-serum  to  the  PKA 
phosphorylated serine (S*) residue within the RRES*F consensus motif [MacKenzie et 
al., 2002]. (b) shows the densitometry of the phospho-UCR1 time course, corrected for 
PDE4A5 expression. All data shown are representative Western blots of three separate 
transfections and experiments +/- standard deviation. 
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(a)  PDE4A5 S147A mutant 
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(b)
Figure 3.11 – Phosphorylation and activation of rat PDE4A5 S147A by 
MAPKAPK2.   
PDE 4A5 expression 100 kDa 
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COS1  cells  were  transfected  to  transiently  express  rat  PDE4A5  with  a  mutation  to 
alanine at serine 147, the predicted MAPKAPK2 phosphorylation site. The transfected 
cells were treated for 60min with the p38 MAP Kinase activator, anisomycin (10µg/ml). 
(a), top panel, is a Western blot probed with a rat PDE4A C-terminal specific anti-serum 
to provide both loading and PDE4A5 expression controls. (a), bottom panel, is the same 
Western  blot  re-probed  with  the  phospho-UCR1  specific  anti-serum  to  the  PKA 
phosphorylated serine (S*) residue within the RRES*F consensus motif [MacKenzie et 
al., 2002]. (b) shows the densitometry of the phospho-UCR1 time course, corrected for 
PDE4A5 expression. All data shown are representative Western blots of three separate 
transfections and experiments +/- standard deviation. 
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(a)  PDE4A5 S147A mutant 
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     Time with Fsk (min) after Anisomycin and IBMX pre-treatment 
 
 
 
(b)
 
Figure 3.12 – Phosphorylation and activation of rat PDE4A5 S147A by PKA and 
MAPKAPK2.  
PDE 4A5 expression 100 kDa 
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COS1  cells  were  transfected  to  transiently  express  rat  PDE4A5  with  a  mutation  to 
alanine at serine 147, the predicted MAPKAPK2 phosphorylation site. The transfected 
cells  were  pre-treated  for  30min  with  the  p38  MAP  Kinase  activator,  anisomycin 
(10µg/ml),  then  treated  with  10min  with  the  non-specific  PDE  inhibitor,  IBMX 
(100µM)  before  challenge,  0-20min,  with  the  adenylyl  cyclase  activator,  forskolin 
(100µM).  (a), top panel, is a Western blot probed with a rat PDE4A C-terminal specific 
anti-serum to provide both loading and PDE4A5 expression controls. (a), bottom panel, 
is the same Western blot re-probed with the phospho-UCR1 specific anti-serum to the 
PKA  phosphorylated  serine  (S*)  residue  within  the  RRES*F  consensus  motif 
[MacKenzie et al., 2002]. (b) shows the densitometry of the phospho-UCR1 time course, 
corrected for PDE4A5 expression. All data shown are representative Western blots of 
three separate transfections and experiments +/- standard deviation. 
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3.2.2.2  Enzymatic Effect of MAPKAPK2 phosphorylation of PDE4A5. 
 
As it has been established above that MAPKAPK2 phosphorylation of PDE4A5 
has no effect on PKA phosphorylation of the enzyme it was then essential to establish 
whether  phosphorylation  had  an  effect  on  the  function  of  the  enzyme.  To  establish 
functionality of PDE4A5 the cell model of PDE4A5 transiently over expressed in COS1 
cells  was  utilised  again.  Basal  PDE4A5  enzymatic  activity  was  established  in 
unstimulated (resting) cells and taken as an activity level of 100% for further analysis, 
Figure 3.13. PKA was activated by pre-treatment with both IBMX, to block all PDE 
controlled  cAMP  degradation,  plus  the  adenylyl  cyclase  activator,  forskolin.  PKA 
phosphorylation of PDE4A5 resulted in an increase in its enzymatic activity which, in a 
similar manner to that seen for the phosphorylation of PDE4A5, reached a plateau some 
10-20 min after forskolin challenge with activity after 10 min challenge being some 266 
+/- 5% above the control basal level and, at 20 min, some 280 +/- 4 % above the control 
basal level (mean ± SD; n= 3).  
 
Phosphorylation  of  PDE4A5  by  MAPKAPK2  was  elicited  by  anisomycin 
treatment of transfected COS1 cells. This phosphorylation of PDE4A5 caused no change 
in PDE4A5 enzymatic activity above the basal level of 100%. However, perhaps most 
interestingly, when MAPKAPK2 phosphorylation of PDE4A5 was followed by PKA 
phosphorylation,  the  enzymatic  activity  was  increased,  showing  that  PKA 
phosphorylation can activate the MAPKAPK2-phosphorylated PDE4A5. However, the 
magnitude  of  activation  by  PKA  was  at  a  much  lower  level  that  seen  with  PKA 
phosphorylation alone, only ever reaching levels of 160 +/- 2% at 10 min and 174 +/- 
4% at 20 min (mean ± SD; n=3) compared to the activity of non-PKA phosphorylated 
PDE4A5. This is significantly different to PKA phosphorylation alone with a p value of 
0.021.  These data suggest that, while MAPKAPK2 phosphorylation alone does not 
affect PDE4A5 activity, it acts to ablate the PKA phosphorylation induced increase in 
PDE4A5 activity. 
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Once  again  to  establish  that  the  effect  of  MAPKAPK2  was  due  to 
phosphorylation  at  Ser147  of  PDE4A5  the  Ser147Ala  mutant  and,  additionally,  a 
phosphorylation mimetic Ser147Asp mutant, were each transiently over expressed in 
COS1 cells and their enzymatic activity determined, Figure 3.14. Both mutants had a 
similar basal level of enzymatic activity to PDE4A5 wild type at 97 +/- 5% and 97 +/- 
5% (mean ± SD; n=3) compared to wild-type PDE4A5. For subsequent comparative 
analyses then note that these were set to a relative activity level of 100%.  
 
 PKA  phosphorylation  of  PDE4A5  Ser147Ala  resulted  in  an  increase  in 
enzymatic activity, which reached a plateau at 10-20 min with activity at 20 min being 
290 +/- 6% above the control (mean ± SD; n=3), untreated basal level. MAPKAPK2 
phosphorylation of PDE4A5 Ser147Ala, like the wild type, showed no difference in 
enzymatic  activity  from  the  basal  rate.  However,  in  the  case  of  prior  MAPKAPK2 
phosphorylation  followed  by  PKA  phosphorylation,  the  enzymatic  activity  was 
increased  in  a  similar  manner  to  that  observed  with  PKA  phosphorylation  alone, 
attaining the same high rate of 287 +/- 4% at 20 min (mean ± SD; n=3), Figure 3.14(a).  
 
Conversely PKA phosphorylation of PDE4A5 Ser147Asp resulted in a much 
slower increase in enzymatic activity, which reached plateau at the much lower level of 
190 +/- 4% (mean ± SD; n=3) compared to the non-PKA phosphorylated form of this 
mutant enzyme. Strikingly, this reduction level of activation was similar to that observed 
upon  PKA  phosphorylation  of  the  wild-type  PDE4A5  that  had  been  prior 
phosphorylated by MAPKAPK2 phosphorylation, which reached a plateau of activation 
at  183  +/-  7%  (mean  ±  SD;  n=3).  Again  no  effect  on  the  activity  of  the  wild-type 
PDE4A5 was seen with MAPKAPK2 phosphorylation alone, Figure 3.14(b). These data 
suggest that, MAPKAPK2 is indeed phosphorylating PDE4A5 through Ser147, as when 
this  site  is  mutated  to  alanine,  which  cannot  be  phosphorylated,  then  even  when 
MAPKAPK2 and PKA are both activated in cells, PDE4A5 activity was increased to its 
maximal  PKA  phosphorylated  state.  Conversely,  if  Ser147  was  mutated  to  the 
phosphorylation  mimetic  aspartate  then,  under  conditions  of  PKA  activation  alone, 
PDE4A5 activity never rose to its full activation rate (Figure 3.14 (b)). Instead it rose to   118 
only to approximately half of this, thereby mimicking the affect of pre-treatment of cells 
expressing wild-type PDE4A5 with anisomycin so as to MAPKAPK2 phosphorylate 
PDE4A5 prior to its phosphorylation by PKA.  
 
 
 
Figure  3.13  –  Phosphorylation  and  activation  of  rat  PDE4A5  by  PKA  and 
MAPKAPK2. 
   
COS1  cells  were  transfected  to  transiently  express  wild  type  rat  PDE4A5.    The 
transfected  cells  were  subjected  to  three  different  treatments.  They  were  either  pre-
treated  for  10  min  with  the  non-specific  PDE  inhibitor,  IBMX  (100µM)  before 
challenge, 0-20 min, with the adenylyl cyclase activator, forskolin (100µM). Or they 
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were  treated  for  60  min  with  the  p38  MAP  Kinase  pathway  activator,  anisomycin 
(10µg/ml). Or they were pre-treated for 30 min with anisomycin (10µg/ml), and then 
treated  for  10  min  with  IBMX  (100µM)  before  challenge,  0-20  min,  with  forskolin 
(100µM). The figure above shows the effect of PKA phosphorylation, MAPKAPK2 
phosphorylation and MAPKAPK2 phosphorylation prior to PKA phosphorylation on 
PDE4A5 enzymatic activity.  Assays were done using 1µM cAMP as substrate with 
COS1  cell  lysates  expressing  equal  immuno-reactive  amounts  of  PDE4A5,  as 
determined by the quantification of PDE4A5 expression.  All data shown are mean data 
+/- standard deviation of the three separate transfections and experiments. 
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Figure 3.14 – Phosphorylation and activation of rat PDE4A5 S147A and S147D by 
PKA and MAPKAPK2. 
   
COS1 cells were transfected to transiently express rat PDE4A5 with a mutation to either 
alanine or aspartate at serine 147, the predicted MAPKAPK2 phosphorylation site.  The 
transfected  cells  were  subjected  to  three  different  treatments.  They  were  either  pre-
treated  for  10  min  with  the  non-specific  PDE  inhibitor,  IBMX  (100  µM)  before 
challenge, 0-20 min, with the adenylyl cyclase activator, forskolin (100 µM). Or they 
were treated for 60 min with the p38 MAP Kinase pathway activator, anisomycin (10 
µg/ml).  Or  they  were  pre-treated  for  30min  with  anisomycin  (10  µg/ml),  and  then 
treated for 10min with IBMX (100uM) before challenge, 0-20min, with forskolin (100 
µM). (a) shows the effect of PKA phosphorylation, MAPKAPK2 phosphorylation and 
MAPKAPK2  phosphorylation  prior  to  PKA  phosphorylation  on  PDE4A5  S147A 
enzymatic activity.  Assays were done using 1µM cAMP as substrate with COS1 cell 
lysates expressing equal immuno-reactive amounts of PDE4A5 S147A, as determined 
by  the  quantification  of  PDE4A5  S147A  expression.  (b)  shows  the  effect  of  PKA 
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phosphorylation, MAPKAPK2 phosphorylation and MAPKAPK2 phosphorylation prior 
to PKA phosphorylation on PDE4A5 S147D enzymatic activity.  Assays were done 
using  1  µM  cAMP  as  substrate  with  COS1  cell  lysates  expressing  equal  immuno-
reactive amounts of PDE4A5 S147D, as determined by the quantification of PDE4A5 
S147D expression.  All data shown are mean data +/- standard deviation of the three 
separate transfections and experiments. 
 
 
 
3.2.3  Cellular Response to MAPKAPK2 Phosphorylation of PDE4A5. 
 
After establishing the effect of MAPKAPK2 phosphorylation on PDE4A5 it was 
important to understand how this might affect cellular metabolism of cAMP in the cell 
as a whole. This was done by measuring whole cell cAMP concentration in COS1 cells 
transiently  over-expressing  PDE4A5;  a  system  that  was  used  as  a  paradigm  (Figure 
3.15).  In  these  experiments  the  diterpene,  forskolin  was  used  to  activate  adenylyl 
cyclase directly and, to allow comparison, cAMP levels within cells expressed as a 
percentage of resting cell level (taken as 100%). Doing this, intracellular cAMP reached 
a maximum of 236 +/- 9% at 5 min and returned to resting levels, 96 +/- 3%, by 15 min 
(mean ± SD; n=3). The transient nature of this rise is thought to be due to cAMP levels 
being raised in the cell and causing the activation of PKA which then phosphorylates 
and  activates  PDE4A5,  leading  to  increased  cAMP  breakdown  and  a  subsequent 
decrease in intracellular cAMP levels. To confirm that PKA activation plays a major 
factor influencing the transience fo this effect and so stimulating a decrease in cAMP 
concentration back to a basal level experiment were then performed with addition of the 
PKA  inhibitor,  KT5720  that  was  added  prior  to  forskolin  treatment.  KT5720  pre-
treatment resulted in a peak cAMP concentration of 246 +/- 2% occurring at 5 minutes 
however this level remained sustained for up to 15 min where it was 221 +/- 6% (mean 
±  SD;  n=3).  This  shows  that  PKA  activation  plays  a  vital  role  in  the  regulation  of 
cellular cAMP concentration after a period of 5 min, working as negative feedback 
regulator through activation of PDE4A5.    122 
With this basic model of cellular cAMP concentration ascertained it was then 
crucial to discover if MAPKAPK2 phosphorylation plays a role regulating intracellular 
cAMP levels. Using the same cell model, anisomycin pre-treatment was carried out to 
activate the p38 MAPK cascade and cause PDE4A5 phosphorylation; this was followed 
by adenylyl cyclase activation through forskolin. Again cAMP concentration reached a 
peak level of 240 +/- 7% at 5 minutes however after 15 min, despite some lowering of 
cellular cAMP levels, the overall cAMP level only fell to 153 +/- 4% and not back to the 
basal  steady-state  level  (mean  ±  SD;  n=3).  To  confirm  that  this  effect  was  due  to 
activation of the p38 MAPK cascade an additional pre-treatment was done, in this case 
with SB203580, a specific p38 MAPK inhibitor. When this was carried out, forskolin 
challenge now showed peak cAMP concentration of 243 +/- 5% at 5 min and a return to 
basal rate of 97% +/- 7% after 15 min, mimicking the effect seen by simply challenging 
with forskolin alone (mean ± SD; n=3). These data show that activation of the p38 
MAPK cascade within this cell system leads to a profound attenuation of the transient 
nature of cAMP accumulation subsequent to adenylyl cyclase activation. This appears to 
be achieved by it re-mapping the nature of the feed-back inhibition process driven by 
PKA activation of PDE4A5. It was then important to confirm if this was occurring 
through  MAPKAPK2  phosphorylation  of  PDE4A5  as  the  experimental  work  above 
would imply.  
 
Two cell models were created using COS1 cells, one transiently over-expressing 
the Ser147Ala-PDE4A5 MAPKAPK2 phosphorylation null mutant, Figure 3.16(a), and 
one transiently over-expressing the Ser147Asp-PDE4A5 MAPKAPK2 phosphorylation 
mimetic  mutant,  Figure  3.16(b).  These  models  were  both  subjected  to  (i)  forskolin 
treatment alone, to activate adenylyl cyclase and raise cAMP levels; (ii) KT5720 pre-
treatment followed by forskolin treatment, to inhibit PKA activation and raise cellular 
cAMP and (iii) anisomycin pre-treatment followed by forskolin treatment, to activate 
the p38 MAPK cascade and raise cAMP levels.  
 
In  the  case  of  the  Ser147Ala-PDE4A5  mutant,  when  adenylyl  cyclase  was 
activated cAMP concentration in the cell reached a maximum of 256 +/- 5% at 5 min   123 
and returned fully to resting rate 93 +/- 7% by 15 min (mean ± SD; n=3) . Then using 
the PKA inhibitor KT5720 before forskolin treatment, peak cAMP concentration of 260 
+/- 2% occurs at 5 min and this level remained sustained up to 15 min where it was 230 
+/-  3%  (mean  ±  SD;  n=3).  This  implies  that  in  cell  model  expressing  Ser147Ala-
PDE4A5 cAMP concentration is controlled similarly to the wild type PDE4A5 in that 
adenylyl  cyclase  raises  cellular  cAMP  concentration  and  PKA  operates  a  negative 
feedback  loop  of  this  through  Ser147Ala-PDE4A5.  However  when  the  p38  MAPK 
cascade was activated prior to raising cAMP levels cellular cAMP level rose to 248 +/- 
8% at 5 min and fell back to basal rate of 87 +/- 7% after 15 min (mean ± SD; n=3) . 
This lack of effect implies that in the wild type PDE4A5 system the p38 MAPK cascade 
is exhibiting its effect through MAPKAPK2 phosphorylation of PDE4A5. This concept 
is  confirmed  using  the  Ser147Asp-PDE4A5  phosphorylation  mimetic  mutant  where 
under adenylyl cyclase activation alone cAMP concentration rises to 251 +/- 2% but 
after 15 min only falls to 157 +/- 7%, not the basal level (mean ± SD; n=3).  
 
These data show that MAPKAPK2 phosphorylation of PDE4A5 acts to attenuate 
the  PKA  phosphorylation  induced  activation  of  PDE4A5.  This  has  a  functional 
consequence in cells in re-mapping the functionality of the feedback cycle focused on 
PDE4A5  and  mediated  by  PKA.  This  changes  the  profound  transience  of  cAMP 
accumulation to one where a sustained increase in cellular cAMP levels is evident.  
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Figure  3.15  –  Cellular  cyclic  AMP  concentration  in  PDE4A5  expressing  cells 
following Phosphorylation by PKA and MAPKAPK2. 
 
COS1  cells  were  transfected  to  transiently  express  wild  type  rat  PDE4A5.  The 
transfected  cells  were  subjected  to  one  of  four  pre-treatments:  pre-treated  with 
anisomycin (10 µg/ml) for 30 min to activate MAPKAPK2. Pre-treated with KT5720 
(10 µM) for 30 min to block PKA activation. Pre-treated with SB203580 (25 µM) to 
inhibit the p38 MAP kinase pathway for 30 min followed by anisomycin (10µg/ml) 
treatment for 30 min to activate MAPKAPK2. And lastly, without pre-treatment. The 
cells were then subjected to a 0-15 min time course with Forskolin (100 µM) to activate 
PKA. The figure above shows cAMP concentration in cells following these treatments. 
cAMP  concentration  within  the  cell  was  measured  using  a  commercial  cAMP 
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competitive  ELISA  assay  kit.  cAMP  concentration  is  measured  as  a  percentage  of 
resting cell cAMP concentration. All data shown are mean data +/- standard deviation of 
three separate transfections and experiments.  
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Figure 3.16 – Cellular cyclic AMP concentration in PDE4A5 S147A and S147D 
expressing cells following Phosphorylation. 
 
COS1 cells were transfected to transiently express rat PDE4A5 with a mutation to either 
(a) alanine or (b) aspartate at Ser147, the predicted MAPKAPK2 phosphorylation site. 
The transfected cells were subjected to one of three pre-treatments: pre-treated with 
anisomycin (10 µg/ml) for 30 min, pre-treated with KT5720 (10 µM) for 30 min or 
without pre-treatment. The cells were then subjected to a 0-15 min time course with 
Forskolin (100 µM). The figure above shows cAMP concentration in cells following 
these treatments. cAMP concentration within the cell was measured using a commercial 
cAMP competitive ELISA assay kit. cAMP concentration is measured as a percentage 
of resting cell cAMP concentration. All data shown are mean data +/- standard deviation 
of three separate transfections and experiments.  
 
(b) 
Time (min) 
c
A
M
P
 
c
o
n
c
e
n
t
r
a
t
i
o
n
 
(
%
 
o
f
 
r
e
s
t
i
n
g
 
c
e
l
l
 
r
a
t
e
)
   127 
3.2.4  Rolipram Inhibition of MAPKAPK2 Phosphorylated PDE4A5  
 
As previously mentioned PDE4A5 can exhibit two binding states for rolipram 
[Jacobitz et al., 1996], the normal Low Affinity Rolipram Binding State (LARBS) and 
the higher sensitivity state, High Affinity Rolipram Binding State (HARBS).  It was 
therefore important to establish if MAPKAPK2 phosphorylation of PDE4A5 altered its 
level of inhibition, and therefore binding affinity, of the PDE4 inhibitor rolipram. A cell 
model  of  COS1  cells  transiently  transfected  to  express  PDE4A5  was  exposed  to 
MAPKAPK2  phosphorylation  alone,  PKA  phosphorylation  alone  and  MAPKAPK2 
phosphorylation prior to PKA phosphorylation (all treatments as described previously), 
Figure 3.17(a). PDE enzymatic activity was then measured in a basal state and in the 
presence of rolipram. This showed that using 10 µM of rolipram for non-phosphorylated 
PDE4A5, PDE activity was inhibited by 50 +- 5% (mean ± SD; n=3). Similarly this was 
the case for MAPKAPK2 phosphorylated PDE4A5 where PDE activity at the basal rate 
was 99 +/- 3% and 47 +/- 7% in the rolipram inhibited state, PKA phosphorylated 
PDE4A5 where PDE activity at the basal rate was 265 +/- 4% and 137 +/- 3% in the 
rolipram  inhibited  state  and  MAPKAPK2  and  PKA  phosphorylated  PDE4A5  where 
PDE activity at the basal rate was 160 +/- 2% and 85 +/- 4% in the rolipram inhibited 
state. These data show that PKA phosphorylation, MAPKAPK2 phosphorylation and a 
combination of both do not affect the ability of rolipram to inhibit PDE4A5. To confirm 
mutations at the MAPKAPK2 mutation site Ser147 had no affect on rolipram inhibition 
either  the  above  experiment  was  repeated  with  COS1  cells  transiently  expressing 
Ser147Ala-PDE4A5  (Figure  3.17(b))  and  Ser147Asp-PDE4A5  (Figure  3.17(c)) 
respectively. This showed that using the optimal EC50 concentration of rolipram for non-
phosphorylated PDE4A5, PDE activity was inhibited by 50 +- 5%. Similarly this was 
the  case  for  MAPKAPK2  phosphorylated  Ser147Ala-PDE4A5  and  Ser147Asp-
PDE4A5, where PDE activity at the basal rate was 94 +/- 4% and 41 +/- 4%; and 102 
+/- 4% and 48 +/- 2% respectively in the rolipram inhibited state, PKA phosphorylated 
Ser147Ala-PDE4A5 and Ser147Asp-PDE4A5, where PDE activity at the basal rate was 
275 +/- 6% and 143 +/- 4%; and 162 +/- 5% and 79 +/- 7%, respectively, in the rolipram 
inhibited  state  and  MAPKAPK2  and  PKA  phosphorylated  Ser147Ala-PDE4A5  and   128 
Ser147Asp-PDE4A5, where PDE activity at the basal rate was 275 +/- 6% and 136 +/- 
4%; and 164 +/- 3% and 81+/- 4% respectively in the rolipram inhibited state. These 
data show that mutation of PDE4A5 at Ser147 to either alanine or aspartate does not 
affect the ability of rolipram to inhibit the enzyme.  All data are mean ± SD; n=3. 
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Figure  3.17  –  Inhibition  of  rat  PDE4A5  wild  type,  S147A  and  S147D  mutants 
activity by rolipram, following phosphorylation by PKA and MAPKAPK2. 
   
COS1 cells were transfected to transiently express either (a) wild type rat PDE4A5, (b) 
PDE4A5  with  a  mutation  to  alanine  at  Ser147,  or  (c)  PDE4A5  with  a  mutation  to 
aspartate at Ser147. The transfected cells were subjected to three different treatments. 
They were either pre-treated for 10min with the non-specific PDE inhibitor, IBMX (100 
µM) before 20 min challenge with the adenylyl cyclase activator, forskolin (100 µM), 
treated for 60 min with the p38 MAP Kinase pathway activator, anisomycin (10 µg/ml). 
Or they were pre-treated for 30min with anisomycin (10 µg/ml), and then treated for 
10min  with  IBMX  (100  µM)  before  20min  challenge  with  forskolin  (100  µM). 
Phosphodiesterase activity assays were carried out under resting cell conditions and in 
presence of the PDE4 inhibitor Rolipram (10uM). Assays were done using 1µM cAMP 
as substrate with COS1 cell lysates expressing equal immuno-reactive amounts of (a) 
PDE4A5 wild type, (b) PDE4A5 Ser147Ala or (c) PDE4A5 Ser147Asp as determined 
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by the quantification of expression.  All data shown are mean data +/- standard deviation 
of the three separate transfections and experiments. 
 
 
 
3.2.5  Thermo-stability of PDE4A5 after Phosphorylation 
 
At  this  juncture  I  wished  to  try  and  gain  evidence  that  MAPKAPK2 
phosphorylation of PDE4A5 caused a conformational change in PDE4A5 that might be 
consistent with my observation that it caused a decrease in the ability of PKA to activate 
PDE4A5. As shown previously this was not due to hindrance of PKA phosphorylation. 
Thus  as  far  as  activity  changes  occur,  any  such  conformational  change  caused  by 
MAPKAPK2  phosphorylation  is  effectively  silent  until  the  enzyme  is  PKA 
phosphorylated.    Conformational  changes  can,  however,  be  expected  to  affect  the 
stability of proteins.  This can very simply be assessed using a thermal inactivation 
procedure.  The denaturation of proteins by heat occurs as a first-order
 process that, in 
the  case  of  enzymes,  can  be  followed  by  analysis  of  the  exponential
  decay  in  their 
catalytic activity. A semi-log plot of the log %
 activity remaining against time thus 
allows for a determination
 of the half-life of inactivation (t1/2).  
 
Using a cell model of COS1 cells over-expressing PDE4A5 subjected to the 
various conditions described previously, treatment
 at 55°C causes the inactivation of 
PDE4A5 as a single exponential, Figure 3.18. From the data it is shown that wild type 
PDE4A5 reaches a half-life of inactivation at approximately 7.5 min. However if cells 
expressing PDE4A5 are subjected to forskolin treatment to increase intracellular cAMP 
levels and activate PKA and PDE4A5 taken for thermal inactivation studies then a half-
life of inactivation is not reached until approximately 12 minutes. This shows that PKA 
phosphorylation of PDE4A5 results in an increase in structural stability of the enzyme. 
When MAPKAPK2 phosphorylation of PDE4A5 using the p38 MAPK activator was 
elicited then the half-life of inactivation of the enzyme decreased slightly from the wild-
type non-phosphorylated enzyme, to a level of approximately 6.5 min implying that   131 
MAPKAPK2  phosphorylation  of  PDE4A5  is  responsible  for  decreased  structural 
stability of the enzyme. This result was confirmed to be due to the p38 MAPK pathway 
through  use  of  the  p38  MAPK  inhibitor  SB203580,  which  took  the  half-life  of 
inactivation back to approximately 7.5 min, a similar rate to that of wild type non-
phosphorylated PDE4A5.  
 
I then set out to see how MAPKAPK2 phosphorylation in combination with 
PKA phosphorylation affected the stability of PDE4A5. Pre-treatment with anisomycin 
followed  by  adenylyl  cyclase  activation  by  forskolin  resulted  in  the  half-life  of 
inactivation of approximately 4.5 min. This is significantly lower than the half-lives 
seen for the non-phosphorylated wild type PDE4A5, for PKA phosphorylated PDE4A5 
and for MAPKAPK2 phosphorylated PDE4A5. This implies that dual phosphorylation 
of PDE4A5 by PKA and MAPKAPK2 leads to a distinct change in structure, seen here 
as a loss of thermal stability. This is consistent with my data showing that after these 
phosphorylation  events,  MAPKAPK2  phosphorylation  has  a  functional  effect  on 
PDE4A5 in attenuating its ability to be activated by PKA.  
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Figure 3.18 – Thermo-stability of PDE4A5.   
 
Recombinant PDE4A5 was transiently expressed in COS1 cells. The transfected cells 
were subjected to one of four treatments: treated with anisomycin (10 µg/ml) for 60 min 
to  activate  MAPKAPK2,  treated  for  10min  with  IBMX  (100  µM)  before  20  min 
Forskolin (100 µM) challenge to activate PKA, pre-treated with anisomycin (10 µg/ml) 
for  30min  then  treated  for  10min  with  IBMX  (100  µM)  before  20min  Forskolin 
(100µM) challenge to activated MAPKAPK2 prior to PKA activation, or pre-treated 
with SB203580 (25 µM) to 30 min followed by anisomycin (10 µg/ml) treatment for 30 
min,  to  block  them  stimulate  activation  of  MAPKAPK2  through  the  p38  MAPK 
cascade.  Total  cell  lysate  was  produced.    Lysates  were  incubated  at  55
oC  for  the 
indicated times and then assayed for PDE4 activity using 1 µM cAMP as substrate.  The 
log% residual activity was calculated and plotted as a function of increasing time.  The 
half-life (t1/2) was determined as the time at which 50% of the total PDE4 activity at 
time zero remained.  Data shown are from three separate experiments using fractions 
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from  three  separate  transfections  and  are  expressed  as  mean  values  +/-  standard 
deviation. 
 
 
 
3.2.6  PDE4D3 is Phosphorylated by MAPKAPK2. 
 
Now that the role of MAPKAPK2 phosphorylation in PDE4A5 function and 
activity has been established it raises question as to whether PDE4A5 is the only long 
form PDE4 that undergoes these phosphorylation events. As stated previously PDE4A5 
plays  an  important  role  in  inflammation  along  with  the  p38  MAP  Kinase  cascade 
[Schieven,  2005]  but  its  expression  levels  are  low  in  most  cell  systems  where  the 
PDE4D family are the largest expressed PDE4 group. Under analysis of sequence line 
ups of PDE4A5 and all other long form PDE4 isoforms consensus is seen between the 
UCR1  phosphorylation  sites  of  the  enzymes.  Indeed  PDE4D3  contains  a  consensus 
MAPKAPK2 phosphorylation site identical to that found in PDE4A5, namely Leu-Tyr-
Arg-Ser-Asp-Ser-Asp.  This  sequence  fits  exactly  the  MAPKAPK2  phosphorylation 
consensus motif previously discovered: Ø-X-Arg-X-X-Ser-Ø, where Ø are hydrophobic 
amino acids and X is any amino acid. [Stokoe et al., 1993; Rousseau et al., 2005]. To 
confirm if PDE4D3 is phosphorylated by MAPKAPK2 enzymatic activity studies were 
carried out, similar to those shown above with PDE4A5.  To establish functionality of 
PDE4D3  the  cell  model  of  PDE4D3  transiently  over  expressed  in  COS1  cells  was 
utilised again. Basal PDE4D3 enzymatic activity was established in unstimulated cells 
and  taken  as  an  activity  level  of  100%  for  further  analysis,  Figure  3.19(a).  PKA 
phosphorylation of the enzyme resulted in an increase in enzymatic activity of PDE4D3, 
which reaches a plateau at 10-20 min with activity at 10min being 240 +/- 7% and at 20 
min being 269 +/- 15%, above the control basal level. MAPKAPK2 phosphorylation of 
PDE4D3 showed no altering in enzymatic activity above the basal level of 100%. Then 
when  MAPKAPK2  phosphorylation  of  PDE4D3  was  followed  by  PKA 
phosphorylation, the enzymatic activity was increased, as with PKA phosphorylation 
alone, but the increase occurred at a slower rate and plateaus at a much lower level only   134 
ever reaching levels of 174 +/- 3% at 10 min and 182 +/- 4% at 20 min. These data 
suggest that PDE4D3 undergoes phosphorylation by MAPKAPK2 resulting in similar 
enzymatic  effects  in  that,  while  MAPKAPK2  phosphorylation  alone  does  not  affect 
PDE4D3  activity,  it  acts  to  ablate  the  PKA  phosphorylation  induced  increase  in 
PDE4D3 activity. (mean ± SD; n=3) 
 
To  confirm  this  effect  of  MAPKAPK2  was  due  to  its  phosphorylation  of 
PDE4D3 mutants of the potential MAPKAPK2 phosphorylation site on PDE4D3 were 
made. This site was, from the sequence line up data, Ser61 on PDE4D3 and mutations 
were made at this site to alanine, to act as a MAPKAPK2 phosphorylation null mutant 
and to aspartate a phosphorylation mimetic mutant. These were separately transiently 
over expressed in COS1 cells and their enzymatic activity established, Figure 3.19(b) 
and (c). Both mutants had a similar basal level of enzymatic activity to PDE4D3 wild 
type (80 +/- 5 %; n= 3) and were set to activity level of 100% for comparative analyses. 
PKA  phosphorylation  of  Ser61Ala-PDE4D3  resulted  in  an  increase  in  enzymatic 
activity, which reaches a plateau at 10-20 min with activity at 20 min being 264 +/- 6% 
above the control basal level. MAPKAPK2 phosphorylation of Ser61Ala-PDE4D3, like 
the wild type, showed no difference in enzymatic activity from the basal rate but in the 
case of MAPKAPK2 phosphorylation followed by PKA phosphorylation, the enzymatic 
activity was increased, as with PKA phosphorylation alone, to the same high rate of 257 
+/-  5%  at  20  min,  Figure  3.19(b).  Conversely  PKA  phosphorylation  of  Ser61Asp-
PDE4D3  resulted  it  was  at  a  slower  increase  in  enzymatic  activity,  which  reaches 
plateau at the much lower level of 186 +/- 3%. This level was similar to MAPKAPK2 
phosphorylation  followed  by  PKA  phosphorylation  of  Ser61Asp-PDE4D3,  which 
reaches  its  plateau  at  190  +/-  2%.  Again  no  effect  on  activity  was  seen  with 
MAPKAPK2  phosphorylation  alone,  Figure  3.19(c).  These  data  suggest  that, 
MAPKAPK2 is indeed phosphorylating PDE4D3 through Ser61 giving highly similar 
results to those shown with PDE4A5 Ser147 mutants. These data indicate that some 
otherPDE4 long forms can be phosphorylated by MAPKAPK2 resulting in ablation of 
PKA phosphorylation induced increase in PDE4 activity. (mean ± SD; n=3) 
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Figure 3.19 – Phosphorylation and activation of rat PDE4D3 wild type, S61A and 
S61D by PKA and MAPKAPK2. 
   
COS1 cells were transfected to transiently express rat PDE4D3 wild type, or with a 
mutation  to  either  alanine  or  aspartate  at  Ser61,  the  predicted  MAPKAPK2 
phosphorylation site.  The transfected cells were subjected to three different treatments. 
They were either pre-treated for 10 min with the non-specific PDE inhibitor, IBMX (100 
µM) before challenge, 0-20 min, with the adenylyl cyclase activator, forskolin (100 
µM). Or they were treated for 60min with the p38 MAP Kinase pathway activator, 
anisomycin (10 µg/ml). Or they were pre-treated for 30min with anisomycin (10 µg/ml), 
and then treated for 10 min with IBMX (100 µM) before challenge, 0-20 min, with 
forskolin  (100  µM).  (a)  shows  the  effect  of  PKA  phosphorylation,  MAPKAPK2 
phosphorylation and MAPKAPK2 phosphorylation prior to PKA phosphorylation on 
PDE4D3 enzymatic activity.  Assays were done using 1µM cAMP as substrate with 
COS1  cell  lysates  expressing  equal  immuno-reactive  amounts  of  PDE4D3,  as 
determined by the quantification of PDE4D3 expression. (b) shows the effect of PKA 
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phosphorylation, MAPKAPK2 phosphorylation and MAPKAPK2 phosphorylation prior 
to PKA phosphorylation on PDE4D3 Ser61Ala enzymatic activity.  Assays were done 
using 1µM cAMP as substrate with COS1 cell lysates expressing equal immuno-reactive 
amounts of PDE4D3 Ser61Ala, as determined by the quantification of PDE4D3 S61A 
expression.    (c)  shows  the  effect  of  PKA  phosphorylation,  MAPKAPK2 
phosphorylation and MAPKAPK2 phosphorylation prior to PKA phosphorylation on 
PDE4D3 S61D enzymatic activity.  Assays were done using 1µM cAMP as substrate 
with  COS1  cell  lysates  expressing  equal  immuno-reactive  amounts  of  PDE4D3 
Ser61Asp, as determined by the quantification of PDE4D3 S61D expression.   All data 
shown  are  mean  data  +/-  standard  deviation  of  the  three  separate  transfections  and 
experiments. 
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3.3  Discussion 
 
 
The  p38  MAP  Kinase  phosphorylation  cascade  plays  an  important  role  in 
regulation of immune and inflammatory systems in response to injury, infection and 
tissue damage [Schindler, 2007]. p38 MAPK has this effect by regulating the function of 
many  immune  and  inflammatory  cells  including  macrophages,  monocytes,  T-
lymphocytes and mast cells, as well as regulating cell cytokine expression, adhesion and 
migration [Dong et al., 2002]. It has therefore been hypothesized that inhibition of the 
p38 MAPK cascade may be useful therapeutically in diseases of excessive immune of 
inflammatory reactions, such as COPD, asthma and rheumatoid arthritis [Cuenda and 
Rousseau, 2007]. 
 
Activation of p38 MAPK and subsequently MAPKAPK2 in most cells can be 
induced with anisomycin or TNFα. Anisomycin activates the cascade by synergistically 
acting  with  growth  factors  through  stimulation  of  the  G-proteins,  Rac  and  Cdc42 
(Figures 3.1 and 3.4) [Cahill et al., 1996]. It should be noted that anisomycin leads to 
delayed onset of MAPKAPK2 activation. For faster activation the pro-inflammatory 
cytokine TNFα could be used for p38 MAPK and MAPKAPK2 activation (Figure 3.5). 
TNFα has its affect through the TNF receptor, recruitment of TRAF2, and activation of 
ASK (Figure 3.4) [Ichijo et al., 1997 and Nishitoh et al., 1998]. Initial work from the 
Houslay laboratory has shown that there may be potential signalling cross talk between 
the  p38  MAPK  cascade  and  the  regulation  of  intra-cellular  cAMP  concentrations 
[MacKenzie  and  Houslay,  2000].  These  effects  are  consistent  with  the  wealth  of 
published data that implicates both PDE4 [Jin and Conti, 2002, Houslay et al., 2005 and 
Zhang  et  al.,  2005]  and  p38  MAPK  inhibition  as  potential  ways  of  lowering  pro-
inflammatory cytokine production and the overall inflammatory response.  
 
Analysis of the primary amino acid sequence of phosphodiesterase 4A5 shows 
that it contains two potential MAPKAPK2 phosphorylation consensus sequences. The 
consensus  sequence,  Ø-Xaa-Arg-Xaa-Xaa-Ser*-Ø  where  Ø  represents  a  hydrophobic   139 
amino acid, was seen at serine 147 and serine 161 within PDE4A5.  Serine 161 (Val-
Ser-Arg-Ser-Ser-Ser*-Val)  is  surrounded  by  optimal  residues  for  MAPKAPK2 
phosphorylation,  whereas  serine  147  (Leu-Tyr-Arg-Ser-Asp-Ser*-Asp)  contains  a 
hydrophilic C-terminal aspartic acid residue at a site indicated to be hydrophobic in the 
consensus sequence [Rousseau et al., 2005].  However the requirement for a C-terminal 
hydrophobic residue, and indeed even the requirement for an optimal consensus motif, 
has  been  recently  questioned  so  both  Ser147  and  Ser161  are  possible  MAPKAPK2 
phosphorylation  target  sites  based  on  our  current  knowledge  [Stokoe  et  al.,  1993, 
Rousseau et al., 2005].  
 
Previous unpublished work from the Houslay lab showed that recombinant MBP 
fusion protein of PDE4A5 could undergo in vitro phosphorylation with recombinant, 
active  MAPKAPK2.  This  provided  initial  evidence  that  PDE4A5  was  substrate  of 
MAPKAPK2. These initial experiments alluded to PDE4A5 being phosphorylated at 
Ser147 by MAPKAPK2.  This study was followed on using an in vivo phosphorylation 
system  in  which  COS1  cells  over-expressing  PDE4A5,  in  the  presence  of  [
32P]-
orthophosphate were treated with anisomycin to trigger the p38 MAPK cascade.  This 
confirmed that PDE4A5 undergoes phosphorylation by MAPKAPK2 in a cell system. 
Additionally it was shown that phosphorylation did occur at Ser147 but other sites may 
also be available because the level of phosphorylation was not completely ablated with 
the Ser147Ala mutant form of PDE4A5.  However, as with all in vivo protein kinase 
phosphorylation  assays  there  is  a  tendency  for  background  or  indiscriminate 
phosphorylation to occur [Berwick and Tavaré, 2004]. 
 
Proving that proteins are genuine substrates for specific protein kinases is very 
difficult  given  the  promiscuous  nature  of  in  vitro  phosphorylation  assays,  and  the 
complexity  and  integration  of  cell  signalling  pathways.    To  address  such  concerns 
certain  criteria  should  be  satisfied  to  formally  identify  protein  kinase  substrates 
[Berwick and Tavaré, 2004].  The work previously done in the Houslay lab satisfied 
these  criteria  by  showing  that  (1)  the  recombinant  in  vitro  phosphorylation  of  the 
proposed  substrate  and  reduction  of  phosphorylation  using  site-specific  alanine   140 
mutant(s), (2) proving that the phosphorylation can occur in intact cells to a stimuli that 
activates  the  protein  kinase  in  a  stimulus  and  concentration-dependent  time  course 
(Figure 3.4), (3) matching the phosphorylation site in vivo to the phosphorylation site in 
vitro (Figures 3.2 and 3.6) and (4) ablating, or at least attenuating, the phosphorylation 
using  specific  inhibitors  (Figures  3.6)  [Berwick  and  Tavaré,  2004].    As  PDE4A5 
satisfies each of these criteria for MAPKAPK2 phosphorylation it was concluded that 
PDE4A5  is  a  bone  fide  substrate  of  MAPKAPK2  in  cells,  with  phosphorylation 
occurring at a single serine residue (Serine 147). 
 
As  described  previously  PDE4  enzymes  are  phosphorylated  by  a  cAMP-
dependent protein kinase, known to as PKA [Sette et al., 1994].  Further work identified 
a conserved single serine residue (Ser54 in PDE4D3 and Ser140 in PDE4A5) within the 
Upstream  Conserved  Region  1  (UCR1)  as  the  phosphorylation  target  for  PKA  and 
showed that phosphorylation at this site conferred enzyme activation [Sette and Conti, 
1996, Hoffman et al., 1998 and MacKenzie et al., 2002].  This was the first evidence 
that the UCR1 domain participates in the regulation of catalytic activity, and therefore 
must interact with the catalytic unit in some way.  PKA phosphorylation is proposed to 
stop  an  inhibitory  constraint  placed  upon  the  catalytic  machinery  by  Upstream 
Conserved  Region  2  through  disruption  of  the  intra-molecular  interactions  between 
UCR1 and UCR2 [Lim et al., 1999 and Beard et al., 2000].  It is thought that resolution 
of the crystal structure of the UCR domains of full-length PDE4 isoforms may provide 
insight  into  how  these  domains  regulate  the  catalytic  unit  and  the  effect  of  PKA 
phosphorylation on this but, unfortunately, this structure has yet to be solved. 
 
PDE4A5 enzyme activity is greatly enhanced following PKA phosphorylation 
(Figure 3.7) [MacKenzie et al., 2002 and Bolger et al., 2003].  Conversely, MAPKAPK2 
phosphorylation  of  PDE4A5  has  no  overt  functional  effect  upon  catalytic  activity 
(Figure  3.8).    As  UCR1  is  conserved  across  the  PDE4  gene  families,  it  might  be 
expected that MAPKAPK2 phosphorylates all PDE4 long isoforms. The MAPKAPK2 
phosphorylation site (Ser147) is located 7 amino acid residues upstream of the PKA 
phosphorylation  site  (Ser140).    It  was  hypothesised  that  phosphorylation  by   141 
MAPKAPK2 may not confer an overt functional effect on its own but may play a role in 
controlling  the  effect  of  PKA  on  PDE4A5.  It  was  shown  that  MAPKAPK2 
phosphorylation did not alter the ability of PKA to phosphorylated PDE4A5 (Figure 
3.9), however it did delay both the onset and amplitude of PKA induced activity of the 
phosphodiesterase (Figure 3.10). This was confirmed through mutation of the Ser147 
phosphorylation site to alanine (Figures 3.11, 3.12, 3.13 and 3.14), which exhibited full 
PDE4A5  activation  despite  activation  of  the  p38  MAPK-MAPKAPK2  pathway  and 
through  use  of  a  phospho-mimetic  mutant  where  Ser147  was  mutated  to  aspartate 
(Figure 3.14), which exhibited delay in onset and attenuated level of enzyme activation.  
This study was repeated using the long form phosphodiesterase, PDE4D3 to see if this 
result was specific to PDE4A5 or likely to be a pan PDE4 long isoform phenomenon. 
The  results  seen  for  PDE4D3  followed  the  same  trend  as  PDE4A5  (Figure  3.19) 
indicating that this effect is likely to be a pan PDE4 long isoform wide effect with a 
MAPKAPK2 consensus phosphorylation site conserved in all long form PDE4s. 
 
This  indicates  that  in  cells  where  the  p38  MAPK-MAPKAPK2  signalling 
pathway is active, activation of PKA in a negative feedback system to control local 
cAMP concentrations through PDE4 long isoforms is likely to be attenuated due to 
active  MAPKAPK2.  To  demonstrate  this  intracellular  cAMP  levels  were  monitored 
following p38 MAPK-MAPKAPK2 activation in a system containing over-expressed 
PDE4A5, (Figure 3.15). The normal response of this system to raising cAMP, using an 
activator such as forskolin, is activation of PKA that, in turn, leads phosphorylation and 
activation of the long PDE4 leading to a decrease in cAMP levels back to resting rate. 
This effect can most easily be captured experimentally in transfected systems where a 
PDE4 long isoforms is over-expressed and provides the dominant (>98%) cAMP PDE 
activity in these cells. However, this serves as a paradigm for compartments in cells 
where PDE4 long isoforms are sequestered and similarly provide the dominant PDE 
activity in that locality.   
 
When  PKA  activity  was  pharmacologically  inhibited  prior  to  increasing 
intracellular cAMP levels with forskolin then such a feedback loop is cancelled out as   142 
there is no mechanism to phosphorylate and activate PDE4. Under such circumstances 
the transient nature of the rise in intracellular cAMP to forskolin challenge is lost and a 
sustained increase in cAMP occurs due to a new steady state rate of cAMP generation 
and hydrolysis being reached due to the combined action of forskolin-activated adenylyl 
cyclase  and  active,  but  not  activated,  PDE4.  While  activation  of  the  p38  MAPK-
MAPKAPK2 pathway alone has no effect of steady state, resting intracellular cAMP 
levels due to its inability to affect PDE4 activity per se it now in attenuating activation 
of  PDE4  by  PKA,  reprograms  the  negative  feedback  effect  and  thus  severely 
compromises  the  transient  nature  of  the  cAMP  increase,  allowing  for  a  sustained 
increase in cAMP levels, which do not returning to basal levels within a 20 min time 
frame.   
 
As  with  treatment  with  SB203580,  mutation  of  the  MAPKAPK2 
phosphorylation  site  in  PDE4A5,  namely  Ser147  to  alanine,  ablated  this  effect  of 
anisomycin, confirming that MAPKAPK2 phosphorylation at this site is the responsible 
phosphorylation site for this reaction (Figure 3.16).  
 
These experiments fully support the hypothesis that when PKA is activated in a 
negative feedback system to control local cAMP concentration, activation of the p38 
MAPK-MAPKAPK2  signalling  pathway  attenuates  phosphodiesterase  activation  by 
PKA through MAPKAPK2 phosphorylation at a site in UCR1. 
 
Phosphorylation  of  PDE4D3  by  PKA  conferred  both  activation  of 
phosphodiesterase activity and increased sensitivity to rolipram inhibition [Hoffmann et 
al., 1998]. In all other long PDE4 isoforms the activation is exhibited but no altered 
rolipram inhibition is presented [MacKenzie et al., 2002]. In addition to this PDE4A4, 
the human homolog of PDE4A5 has been shown previously to exhibit altered rolipram 
inhibition states, thought to be due to protein interaction with the phosphodiesterase 
[Jacobitz et al., 1996]. However use of the MAPKAPK2 phosphorylation site mutant 
Ser147Ala and Ser147Asp in PDE4A5, along with in cell p38 MAPK-MAPKAPK2 
activation shows that MAPKAPK2 phosphorylation did not alter PDE4A5 sensitivity to   143 
rolipram inhibition (Figure 3.17). This, however, may not be the case for PDE4D3 and 
the application of a MAPKAPK2 phospho-mimetic mutant may yield different results 
and would have to be fully studied before any conclusions about its activity could be 
made.  
 
Although  it  had  been  successfully  concluded  that  the  attenuating  effect  of 
MAPKAPK2 phosphorylation on PDE4A5 is not due to hindrance of PKA acting at its 
phosphorylation site or affecting its inhibition state, it is still unclear how MAPKAPK2 
phosphorylation is altering PDE4A5’s activity. To resolve this the full 3D structure of 
the PDE enzyme would have to be considered. In the case of the PKA phosphorylated 
PDE4A5  when  the  conformational  status  of  the  enzyme  was  evaluated  using  a 
thermostability assay it was shown that the PKA phosphorylated and activated enzyme 
was more structurally stable and less easily denatured by thermal inactivation than the 
non-phosphorylated enzyme (Figure 3.18). MAPKAPK2 phosphorylation of PDE4A5 
alone  slightly  lowered  the  stability  of  the  enzyme  to  below  the  level  seen  in  the 
unactivated  (basal  state)  enzyme,  as  evident  from  its  faster  thermal  inactivation.  It 
should, however, be noted that this decrease appears to be stimuli dependent as this 
effect is seen more prominently when anisomycin was used to activate the p38 MAPK-
MAPKAPK2 pathway than when TNFα was used (Figure 3.18). This may be due to the 
two treatments acting through different signalling pathways or may be purely due to the 
fact that anisomycin is used for a prolonged period of time so with 1h treatment optimal 
phosphorylation  will  be  reached.  However  with  TNFα  activation  of  the  signalling 
pathway the window for activation is much shorter, being between 5 and 10 min so it 
would be easy for the optimal phosphorylation of PDE4A5 to be missed. This effect 
needs  to  be  investigated  in  more  detail  before  a  full  conclusion  can  be  made. 
Interestingly, when phosphorylation of PDE4A5 occurs by both PKA and MAPKAPK2 
stability of the enzyme is drastically altered with enzyme being denatured at a much 
faster rate than the non-activated enzyme (Figure 3.18). This implied that MAPKAPK2 
phosphorylation  is  causing  a  dominant  conformational  change  as  evidenced  by  the 
decrease stability of the enzyme in its PKA activated state. This result explains the 
dominant  functional  effect  that  MAPKAPK2  phosphorylation  exerts  on  PDE4A5   144 
activity  seen  as  an  attenuated,  PKA  mediated,  activation  state  of  PDE4A5  under 
MAPKAPK2 phosphorylation.   
 
This  alteration  in  activation  state  may  be  playing  a  role  in  modifying  the 
negative feedback loop usually controlled by PKA. In this loop in response to rising 
cAMP  levels  PKA  is  activated,  this  phosphorylates  and  activates  a  long  PDE4 
phosphodiesterase, which, in turn, lowers the cellular levels of cAMP back to basal. 
However  when  the  p38  MAPK-MAPKAPK2  pathway  is  activated  MAPKAPK2 
phosphorylates the long PDE4, lowering its ability to be activated by PKA, leading it 
into reduced activation, and therefore not allowing cAMP levels to return as quickly to 
basal. As has been previously described MAPKAPK2 is thought to play a vital role in 
increasing TNFα and Il-6 production upon inflammatory stimulus. Conversely, cAMP is 
known  to  block  the  action  of  pro-inflammatory  mediators  [Barber  et  al.,  2004]. 
Inhibition  of  PDE4  leads  to  elevation  in  intracellular  cAMP  concentration  and  a 
reduction in inflammatory response.  Therefore it is proposed that MAPKAPK2 may be 
phosphorylating  long  PDE4  isoforms,  attenuating  their  activation  by  PKA,  as  a 
protective feedback system to prevent over-load of the inflammatory system. This would 
mean that when the p38 MAPK-MAPKAPK2 signalling pathway was activated and 
causing release of pro-inflammatory cytokines, if cAMP levels were raised its PKA 
dependent  feedback  system  would  not  be  fully  activated,  due  to  MAPKAPK2 
phosphorylation  of  PDE4,  keeping  cAMP  from  returning  to  its  basal  levels. 
Subsequently this would mean that inflammatory responses would not be activated by 
low  cAMP  levels,  and  there  would  not  be  two  separate  pathways  invoking  an 
inflammatory response causing the system to become overloaded.  
 
This  may  be  interesting  therapeutically  as  it  raises  the  question  of  whether 
inhibiting  PDE4  fully  during  this  process  would  prevent  an  excessive  inflammatory 
response as is seen in diseases such as asthma and rheumatoid arthritis. This may also 
explain  why  p38α  MAPK  and  MAPKAPK2  inhibition  has  had  limited  success  as 
although inhibiting these kinases blocks pro-inflammatory cytokine release it leaves the   145 
cyclic  AMP  pathway  uncontrolled,  allowing  cAMP  levels  to  be  kept  at  a  low  rate 
through PDE4 action and creating another inflammatory response.  
 
 In conclusion MAPKAPK2 phosphorylated PDE4A5, and possibly other PDE4 
isoforms, leading to attenuation of PKA mediated activation following an increase in 
intracellular cAMP concentration.    146 
Chapter 4            Interaction of PDE4 with p75NTR 
       and their role in Fibrinolysis 
 
 
 
4.1 Introduction 
 
 
4.1.1  Neurotrophins 
 
  The family of growth factor proteins, neurotrophins play an important role in 
influencing several important cellular activities such as proliferation, differentiation and 
cell growth [Levi-Montalcini et al., 1995]. The neurotrophin family consists of four 
members  in  humans:  brain-derived  neurotrophic  factor  (BDNF),  neurotrophin  3, 
neurotrophin 4/5 together with the most commonly occurring and the most commonly 
investigated species, namely nerve growth factor (NGF) [Dechant & Neumann, 2002]. 
Structurally these important proteins are all similar, existing as homodimers and having 
a  duplicate  site  for  binding  to  receptors  [Cowan  et  al.,  2001].  Occasionally  a  fifth 
protein  is  included  in  this  family,  namely  novel  neurotrophin  1  (NNT-1).  However 
NNT-1 is, technically, a cytokine and as it bears no structural resemblance to the other 
family members [Senaldi et al., 1999] it will not be discussed here.  
 
  Nerve  growth  factor  was  the  first  of  the  neurotrophins  to  be  identified.  It  is 
composed of 2 chains of 118 amino acids containing 3 disulfide bonds arranged in a 
cysteine  knot,  which  is  essential  for  its  activity  [Silverman  &  Bradshaw,  1982; 
Wiesmann & de Vos, 2001]. Functionally NGF was originally established as playing a 
vital role as a growth factor in nerve proliferation and survival [Levi-Montaclcini et al., 
2005]. However it was then also found to play an important role as a mediator in airway 
inflammation  [Frossard  et  al.,  2004].  A  precursor  to  NGF  has  also  been  reported, 
namely proNGF [Ibanez, 2002]. ProNGF is an important component of mature NGF 
folding, production and secretion. ProNGF has been shown to be the dominant form of 
NGF in the brain [Rattenholl et al., 2001; Fahnestock et al., 2001]. 
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  Originally  identified  in  the  brain,  brain  derived  neurotrophic  factor  was  the 
second neurotrophin to be discovered [Leibrock et al., 1989]. It was initially thought to 
only be expressed in nerve tissue but has since been shown to be produced in a wide 
variety of immune cells such as macrophages, T cells and B cells [Kerschensteiner et al., 
1999].  
 
The next neurotrophin to be discovered was neurotrophin 3. This neurotrophin 
acts on certain neurons in the peripheral and central nervous system to help support 
survival and differentiation of neurons [Maisonpierre et al., 1990].  
 
The  last,  and  most  recently  discovered  neurotrophin  in  this  family  is 
neurotrophin  4/5.  This  neurotrophin  has  not  been  studied  as  widely  as  the  others. 
However it is considered to act similarly to BDNF [Patapoutian & Reichardt, 2001]. 
 
4.1.2  Neurotrophin Receptors 
 
There  are  four  different  types  of  known  receptors  for  neurotrophins  [Chao, 
2003]. Three of these belong to the tyrosine kinase receptor family (Trk receptors) and 
bind neurotrophins with high affinity. In marked contrast to this, the fourth receptor for 
neurotrophins is a low affinity receptor that is known as the p75 neurotrophin receptor 
(p75NTR) [Rodriguez-Tebar et al., 1990]. 
 
4.1.2.1 TrkA 
 
The TrkA receptor is expressed throughout the central and peripheral nervous 
systems, as well as being expressed in non-neuronal cells such as immune and structural 
cells [Muragaki et al., 1995; Levi-Montalcini et al., 1995]. Each of the Trk receptors has 
a preferred ligand and in the case of TrkA receptor it is NGF, which it binds with high 
(picomolar) affinity, however it also shows some interaction with neurotrophin 3 [Sutter 
et al., 1979; Clary and Reichardt., 1994].  
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Structurally  TrkA  is  a  140kDa  glycoprotein  [Weier  et  al.,  1995].  Several 
isoforms  have  been  identified,  all  of  which  consist  of  an  extracellular  neurotrophin 
binding region, a unique transmembrane helix and an intracellular domain with tyrosine 
kinase activity [Wiesmann & de Vos., 2001; Windisch et al., 1995]. The model of ligand 
binding  and  subsequent  autophosphorylation  of  the  receptor  occurs  in  a  conserved 
manner throughout all of the Trk receptor isoforms [Heldin. 1995]. In the case of TrkA, 
NGF binds to the D5 extracellular domain of the receptor through two areas [Wiesmann 
& de Vos, 2001]: a specificity patch that confers ligand specificity, and a conserved 
binding patch that is found in all Trk receptors [Wiesmann et al., 1999; McInnes & 
Sykes, 1997]. NGF binding leads to dimerisation of the receptor, resulting in activation 
of its intrinsic tyrosyl kinase activity through trans-phosphorylation of tyrosine residues 
670, 674, 675 (in the activation loop of the kinase domain) and, subsequently, tyrosines 
490, 751, 785 (outside the kinase domain), which result in activation of downstream 
signalling pathways [Jing et al., 1992; Heldin, 1995;].  
 
Taking  a  more  in-depth  look  at  the  phosphorylation  sites  outside  the  kinase 
domain gives an insight into how downstream signalling pathways are triggered. In the 
case of tyrosine 490, when this tyrosine becomes phosphorylated it interacts with the src 
homology 2 (SH2) domain of the adaptor protein shc2, resulting in its phosphorylation 
and subsequent binding and phosphorylation of Grb2. Grb2 can then go on to bind Sos 
leading to activation of the Ras/Raf pathway resulting in downstream processes such as 
proliferation  and  survival  [McCormick,  1995,  Nimnual  et  al.,  1998;  Stephens  et  al., 
1994]. Similarly, phosphorylated tyrosine 785 confers binding to the SH2 domain of 
phospholipase C-γ which then becomes tyrosine phosphorylated and activated, leading 
to PIP2 breakdown and the generation of DAG and IP3. The generated DAG allows for 
activation  of  protein  kinase  C  and  the  MKK  pathways  that  play  a  role  in  cell 
proliferation and survival [Stephens et al., 1994; York et al., 2000]. The phosphorylation 
of tyrosine 751 allows binding to the SH2 domain of PI3 Kinase, activating the Akt and 
MKK pathways, resulting in neuroprotective downstream effects [Ohmichi et al., 1992].  
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4.1.2.2   TrkB 
 
The TrkB receptor is ubiquitously expressed throughout both the central and 
peripheral nervous system as well as playing an important role in other areas such as the 
respiratory system [Klein et al., 1990; Nassenstein et al., 2006]. The main ligand for this 
receptor is BDNF. However it has also been shown to interact with neurotrophin 4, 
which may be a result of this protein having similarity to BDNF [Klein et al., 1991; 
Klein et al., 1992]. 
 
Structurally TrkB is similar to TrkA in that, despite there being three known 
isoforms, these all consist of a basic set structure: an extracellular BDNF (or NT-4) 
binding domain, a transmembrane domain and an intracellular domain [Barbacid, 1995; 
Strohmaier et al., 1996]. The intracellular domains differ between different isoforms 
with one isoform having tyrosine kinase activity while the other two, lesser known and 
little  understood,  isoforms  tightly  bind  the  Rho  displacement  factor  Rho-GDI  and 
facilitates the release of prenylated RhoA [Fryer et al., 1996; Yamashita et al., 2003]. 
Activation of the TrkB receptor occurs in a similar manner to activation of TrkA as 
described previously in that BDNF binds to the D5 extracellular domain of the TrkB 
receptor leading to dimerisation and resulting in activation of kinase activity through 
phosphorylation of tyrosine residues in the activation loop of kinase domain and also 
tyrosine residues outside the kinase domain that recruit proteins (e.g. PLC-γ, PI3K) that 
subsequently allow activation of various downstream signalling pathways [Jing et al., 
1992; Heldin, 1995]. 
 
The “long”, tyrosine kinase form of the TrkB receptor signals cell survival and 
synaptic plasticity downstream through tyrosine phosphorylation in a similar manner as 
TrkA [Nonomura et al., 1996; Zirrgiebel et al., 1995; Glass et al., 1991]. While the 
“short” Rho-GDI form is found mostly located in the human brain and while its function 
is  not  fully  understood,  it  is  thought  to  play  a  role  in  signalling  that  regulates  cell 
morphology and calcium influx [Fryer et al., 1996; Kryl & Barker, 2000]. 
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4.1.2.3 TrkC 
 
The  TrkC  receptor  is  the  least  studied  of  the  Trk  family  of  receptors.  It  is 
ubiquitously expressed throughout the brain, with its mRNA levels being highest in the 
hippocampus, an area important for learning and memory processes [Lamballe et al., 
1994]. The ligand for this receptor is neurotrophin 3 [Lamballe et al., 1994]. 
 
Structurally  it  is  similar  to  both  TrkA  and  Trk  B  in  that  it  consists  of  an 
extracellular  NT-3  binding  domain,  a  transmembrane  domain  and  an  intracellular 
domain. The intracellular domain has tyrosine kinase activity similar to that described in 
TrkA, playing a role in cell survival and synaptic plasticity. However it has also been 
shown to have potentially important role in cellular stress response [Faure et al., 2006]. 
 
4.1.3  p75NTR 
 
4.1.3.1   Ligands, Structure and Activation 
 
p75NTR was the first of the neurotrophin receptors to be identified and was 
originally shown to act as a low affinity receptor for NGF. Since then it has been shown 
to be able to bind all members of neurotrophin family and it is generally accepted that 
all  neurotrophins  are  bound  with  similar  (low)  affinity  with  a  fast  dissociation  rate 
[Barker, 2007]. 
 
Structurally, like the Trk receptors, p75NTR is a 75 kDa, highly conserved, type 
I transmembrane protein. It consists of four extracellular cysteine rich domains (CRDs), 
a transmembrane domain and an intracellular region (ICD) containing a death domain 
(DD). Unusually the receptor itself does not contain a catalytic region, such as the SH1 
tyrosyl  kinase  domain  found  in  members  of  the  Trk  receptor  family,  but  instead  is 
thought to sequester other signalling molecules to elicit downstream effects. Ligands for 
p75NTR bind electrostatically through interaction between the negative amino acids on 
to specific regions of the receptor (site 1: in the junction of the CRD1-CRD2 regions   151 
and site 2: in the junction of the CRD3-CRD4 regions) and positive amino acids on the 
neurotrophins. Interestingly the p75NTR receptor can also bind pro-neurotrophins and 
this is thought to occur with a higher affinity than mature neurotrophin binding [Lee at 
al., 2001].  
 
4.1.4  p75NTR Signalling Pathways 
 
Classically  p75NTR  is  thought  to  have  four  main  downstream  phenotypic 
actions: these are effects on cell survival, cell death, neurite outgrowth and fibrinolysis 
[Dechant & Barde, 2002; Sachs et al., 2007]. 
 
  4.1.4.1 Cell Survival 
 
In  the  case  of  cell  survival,  the  binding  of  a  neurotrophin,  such  as  NGF,  to 
p75NTR results in activation of NF-κB, which, in turn, induces activation of inhibitors 
of  apoptosis  (IAPs)  through  three  separate  pathways.  The  first  of  these  is  through 
recruitment  of  the  receptor  interacting  protein  2  (RIP-2)  to  the  intracellular  portion 
(ICD)  of  the  p75NTR  receptor  [Khursigara  et  al.,  2001].  The  second  is  through 
recruitment of TRAF and activation of the Il-1 receptor associated kinase (IRAK) and 
atypical PKC [Khursigara et al., 1999]. The third is through activation of PI3 Kinase 
and, subsequently, Akt/PKB [Roux et al., 2001].  
 
It has also been suggested that p75NTR may play a role in cell survival through 
p75NTR directly interacting with TrkA with TrkA/p75NTR acting as co-receptors for 
NGF  [Yoon  et  al.,  1998;  Lachyankar  et  al.,  2003].  The  precise  mechanism  of  this 
interaction  is,  as  yet,  unknown  but  it  has  been  suggested  that  this  occurs  through 
interaction of all 3 domains of each receptors (i.e., the extracellular, juxtamembrane and 
intracellular  domains  of  TrkA  and  p75NTR  all  interact  with  their  counterparts). 
However this hypothesis remains controversial as other studies have not confirmed this 
view.  It  has,  however,  been  suggested  that  the  nucleoporin  p62,  the  TNF  Receptor 
Associated Factor, TRAF6 and/or the neurotrophin receptor homologue NRH2 may be   152 
working  as  adaptor  proteins,  binding  the  2  receptors  into  a  complex  [Chao,  2003; 
Wehrman  et  al.,  2007].  The  downstream  effect  of  the  interaction  between  these 
receptors has been proposed to prevent any apoptotic signal via the DD of p75NTR and 
redirect p75NTR signalling towards those allowing for cell survival such as the MAPK 
pathways. This suggests that the NF-κB pathway controlled by the p75NTR receptor 
and  the  MAPK  pathways  controlled  by  the  Trk  receptors  could  be  working 
synergistically to promote survival [Chao, 2003; Yoon et al., 1998].  
 
  4.1.4.2 Cell Death 
 
p75NTR has also been shown to play a role in cell death. It is thought that the 
receptor can influence programmed cell death through several routes. The two principal 
routes  are,  firstly  p75NTR  interaction  with  adaptor  proteins  and  secondly  ceramide 
synthesis [Roux & Barker, 2002]. 
 
In the case of adaptor protein interaction, several different potential interacting 
adaptor  proteins  have  been  identified.  These  include  the  neurotrophin  receptor 
interacting  factor  (NRIF)  that  binds  to  the  death  and  juxtamembrane  domains  of 
p75NTR, resulting in downstream JNK MAPK pathway activation [Casademunt et al., 
1999]. Neurotrophin receptor associated cell death executor (NADE) works in a similar 
manner, interacting with p75NTR and promoting activation of the JNK MAPK pathway 
[Mukai et al., 2000]. In both of these cases activated JNK then goes on to phosphorylate 
the pro-apoptotic proteins p53, Bad and Bax leading to release of cytochrome C and 
caspase activation, resulting in apoptotic cell death [Roux & Barker, 2002]. 
 
In ceramide synthesis-mediated apoptosis, p75NTR seemingly induces activation 
of the sphingomyelinase group of enzymes. These cleave sphingomyelin into ceramides, 
which then go on to activate JNK that, in turn, results in apoptotic cell death in the way 
described above [Blochl & Blochl, 2007]. 
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One other proposed way in which p75NTR is thought to lead to apoptosis is 
through interaction with its co-receptor, Sortilin. However, this mechanism is not yet 
fully understood. It has been suggested, however, that the role of TrkA and role or 
sortilin as co-receptors may be mutually exclusive with one co-receptor controlling cell 
death and one controlling cell survival [Bronfman & Fainzilber, 2004]. 
 
4.1.4.3 Functional Regulation 
 
p75NTR has also been shown to play a role in functional regulation outside of 
cell survival and cell death. In one example of this, the Nogo receptor forms a complex 
with  p75NTR,  which  results  in  neurite  outgrowth  [Wang  et  al.,  2002].  This  works 
through  activation  of  the  p75NTR/NOGO-R  complex  by  growth  inhibitor  proteins 
allowing  p75NTR  to  bind  Rho-GDI  (Rho-GDP  Dissociation  Inhibitor)  and  act  as  a 
displacement  factor  for  RhoA  release  triggering  concomitant  neurite  outgrowth 
[Yamashita & Tohyama, 2003]. Another example is the functional role p75NTR plays in 
fibrinolysis, which will be described in more detail later in section 4.1.6. 
 
4.1.5  The role of p75NTR in respiratory inflammation 
 
  Although p75NTR is most commonly known for its role in the nervous system it 
has also been shown to play a role in inflammation of the respiratory system [Freund-
Michel & Frossard, 2008].  
 
For this to be fully appreciated then the expression pattern of p75NTR and its 
regulation throughout the respiratory system must be fully understood. The first, and 
most obvious site of p75NTR expression in this system is in the sensory neurons that 
innervate  the  lungs  [Levi-Montaclini,  1987].  In  mice  with  excess  NGF  it  has  been 
shown that there is hyper-innervation of these nerves, which increases neuronal growth 
and survival [Hoyle et al., 1998] and leads to inflammation. B lymphocytes have also 
been shown to express p75NTR [Torcia et al., 1996]. In these cells the neurotrophin, 
NGF is thought to have an autocrine effect [Lambiase et al., 1997] with activation of   154 
p75NTR resulting in release of immunoglobins and differentiation and proliferation of B 
lymphocytes [Ehrhard et al., 1994] enhancing inflammation. 
 
p75NTR is also expressed in eosinphils in the lungs of asthma patients following 
allergen  attack  [Nassenstein  et  al.,  2003]  but  not  in  peripheral  systems.  This  again 
implies  that  p75NTR  plays  a  role  in  airway  inflammation,  in  this  instance  possibly 
through promoting the survival of eosinophila and of their ability to release Il-1 and Il-3 
[Chevalier et al., 1994]. 
 
Basophils  have  also  been  shown  to  express  p75NTR  and  activation  of  the 
receptor in these cells causes IL-13 and histamine release. Interestingly Il-13 levels have 
been shown to be up-regulated in asthmatic patients [Burgi et al., 1996], suggesting a 
potential role of p75NTR. Finally, structural cells such as human pulmonary fibroblasts 
have also been shown to express p75NTR with a potential role in fibrosis and this will 
be discussed in detail later [Olgart & Frossard, 2001]. 
 
With the details of p75NTR expression throughout this system now beginning to 
be understood, several studies have been carried out looking at the overall effect of 
p75NTR  in  inflammation.  Initial  studies  into  this  showed  that  NGF  induces 
inflammation of the respiratory system largely through its binding to p75NTR. These 
studies  were  carried  out  using  p75NTR  knock-out  mice  and  p75NTR  antibodies  in 
asthmatic  inflammation  model  systems  and  showed  that  in  the  absence  of  p75NTR 
inflammation was reduced [Kerzel et al., 2003; Tokuoka et al., 2001]. However, studies 
using p75NTR knock-out mice showed that bronchial hyper-responsiveness does not 
occur in response to irritant stimuli like capsaicin [Kerzel et al., 2003]. From this it 
would seem that p75NTR plays an important role in the response of the bronchii to 
irritation. 
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4.1.6  The role of p75NTR in fibrinolysis and its potential role in inflammation 
 
In  spinal  cord  injury  models  it  has  been  shown  that  p75NTR  expression  is 
increased at the site of injury with an increase in fibrin deposition also observed [Stark 
el al., 2001]. In work carried out in collaboration between the Houslay laboratory in the 
University of Glasgow and the Akassoglou laboratory at University of California San 
Diego, USA (now at the Gladstone Institute in San Francisco, USA) the role of p75NTR 
in fibrinolysis and importance of cAMP signalling to this has been uncovered. This 
research showed that p75NTR plays an important role in proteolytic activity and results 
in a decrease in fibrin degradation. The pathway in which this was shown to work is 
shown  in  Figure  4.1.  This  shows  that  when  p75NTR  interacts  with  cAMP 
phosphodiesterase, PDE4A5, this confers a localised decrease in cyclic AMP around 
p75NTR. This localised decrease in cAMP negates inhibitory regulation of p75NTR by 
cAMP  and  leads  to  its  activation  causing  a  reduction  in  expression  of  tissue 
Plasminogen  Activator  and  an  increase  in  Plasminogen  Activator  Inhibitor-1.  This 
results in a reduction of plasmin and plasmin-dependent extracellular proteolysis and, 
therefore, promotes reduced fibrin degradation and ECM remodelling. Some of work 
that  elucidated  this  is  shown  here.  This  discovery  is  likely  to  be  of  physiological 
significance as defects in fibrinolysis have been seen in lung inflammation [Renz et al., 
2004] and PDE4A isoforms are also known to play a very important role in respiratory 
disorders as PDE4A4, the human homologue of rodent PDE4A5 is up-regulated in the 
lungs of COPD patients [Barber et al., 2004] and also binds to p75NTR.  
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Figure  4.1  –  Schematic  model  of  the  role  of  p75NTR  in  cAMP-mediated 
plasminogen activation. 
 
The  proposed  model  is  that  PDE4A5  interacts  with  the  p75  Neurotrophin  Receptor 
resulting  in  degradation  of  cAMP.  Decrease  in  cAMP  reduces  expression  of  tissue 
Plasminogen Activator and increases Plasminogen Activator Inhibitor-1. This results in 
reduction  of  plasmin  and  plasmin-dependent  extracellular  proteolysis,  resulting  in 
reduced fibrin degradation and ECM remodelling.  
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4.2  Results 
 
4.2.1  The p75 neurotrophin receptor interacts with Phosphodiesterase 4A 
 
In a previous study in which I was a co-author [Sachs et al, 2007] it has been 
demonstrated  that  p75NTR  can  interact  with  the  long  PDE4A  isoforms,  PDE4A5. 
Figure 4.1 is modified from this publication. In this work our collaborators showed that 
when  p75NTR  was  co-immunoprecipitated  from  NIH3T3  fibroblast  cells  stably 
expressing  p75NTR,  then  probing  this  immunoprecipitate  with  anti-PDE4A  antisera 
identified an endogenous PDE4A species migrating at approximately 100 kDa, the size 
of PDE4A5, figure 4.2(a). The afore mentioned stably transfected NIH3T3 cell line was 
used as a model from then on and referred to here as NIH3T3-p75NTR. The next logical 
step was to establish the functional consequence of this interaction. This was done by 
our  collaborators  who  generated  a  genetically  modified  A-kinase  activity  reporter 
(AKAR2) to contain a membrane-targeted fluorescence reporter of PKA activity (pm-
AKAR2.2),  allowing  for  measurement  of  fluorescence  resonance  energy  transfer 
(FRET) measurement of PKA phosphorylation in living cells. In wild type NIH3T3 cells 
there is a dramatic emission ratio change for pm-AKAR2.2 in response to forskolin, 
figure 4.2(b). However in NIH3T3-p75NTR cells there was an attenuated response to 
forskolin compared to in the wild type. These results seemed to indicate that there was 
reduced  PKA  activity  at  the  plasma  membrane  upon  expression  of  p75NTR.  This 
implies that p75NTR targets cAMP degradation to the membrane, which is consistent 
with the notion that p75NTR sequesters a cAMP-degrading phosphodiesterase. 
 
It was then important to establish the specificity of the interaction of p75NTR 
with phosphodiesterase-4. A series of mapping studies were carried out using truncated 
mutants  of  p75NTR.  The  forms  used  were  full  length  (FL)  p75NTR,  and  mutants 
missing the distal 3 amino acids, Δ3, the distal 62 amino acids Δ62, the distal 83 amino 
acids, Δ83 and finally missing the distal 151 amino acids, Δ151 (figure 4.2(c)). Of these 
five  forms  only  Δ151  did  not  co-immunoprecipitate  with  PDE4A,  suggesting  that   158 
interaction between p75NTR and PDE4A must occur somewhere in the juxtamembrane 
region of p75NTR, with the required amino acid regions being between amino acids 275 
and 343, figure 4.2(c). Now that the region of interaction of the PDE4A on p75NTR had 
been  shown  the  next  logical  step  was  to  establish  the  region  of  interaction  on  the 
phosphodiesterase.  
 
This work then lead to our laboratory’s role in the collaboration. As the PDE4 
family contains several consensus sites in its difference isoforms it had to be elucidated 
whether interaction between PDE4 and p75NTR was specific to one family. To establish 
this,  Dr  George  Baillie  purified  recombinant  proteins  of  typical  long  form 
phosphodiesterases, namely PDE4A4, PDE4A5 and PDE4D5. These were individually 
incubated with purified recombinant p75NTR and examined for the ability to be co-
immunoprecipitated. Both PDE4A4 and PDE4A5 were shown to interact with p75NTR 
in this way, however PDE4D5 did not (Figure 4.2(d)).  At this point the publication 
states that interaction between p75NTR and PDE4A4/5 is specific to those isoforms. 
However although these data may imply that this is a PDE4A specific effect, it does not 
actually show that it is specific to the PDE4A4/5 isoforms rather than the PDE4A family 
as a whole. Following on from this I began my role in this collaboration. I transfected 
PDE4A isoforms into NIH3T3-p75NTR cells for co-immunoprecipitation studies to be 
carried out. This showed that various PDE4A long form isoforms, namely PDE4A5, 
PDE4A5, PDE4A10 and PDE4A11, as well as the PDE4A1 short isoform, interact with 
p75NTR  within  the  cell.  This  indicates  that  p75NTR  interaction  is  not  specific  to 
PDE4A4/5 as originally thought [Sachs et al., 2007] but is a ‘pan’ PDE4A isoform 
interaction,  figure  4.3.  It  should,  however,  be  noted  that  studies  using  an  isoform-
specific  antisera  have  shown  that  the  PDE  immuno-precipitated  endogenously  with 
p75NTR in NIH3T3 cells is indeed PDE4A5. However, my studies indicate that PDE4A 
isoforms other than just PDE4A4/5 may interact endogenously with p75NTR in various 
other cell types.  
 
My  preliminary  peptide  array  mapping  technology  was  then  used  to  try  and 
elucidate  specific  regions  of  PDE4A5  where  p75NTR  binds,  figure  4.4.  These  data   159 
showed that there are five potential binding regions for p75NTR on PDE4A5. One is 
located in the N-terminal at amino acids 16-60, one in UCR2 at amino acids 251-276, 
two  in  the  catalytic  region  at  amino  acids  396-420  and  666-700  and  one  in  the  C-
terminus at amino acids 801-830. It should be noted, however, that extensive mutation 
studies and peptide competition studies need to be carried out for the involvement of 
such possible interaction sites to be confirmed. 
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Figure 4.2 -  p75NTR interacts with PDE4A5 [Sachs et al, 2007].  
 
This figure is modified from Sachs et al, 2007, an article in which I am a co-author. (a) 
Co-immunoprecipitation of p75NTR with endogenous PDE4A5 in NIH3T3 fibroblast 
cells  that  stably  express  p75NTR.  Immunoprecipitation  was  carried  out  with  anti-
p75NTR  and  probed  with  anti-PDE4A  or  anti-p75NTR.    (b)  FRET  emission  ratio 
change of NIH3T3 and NIH3T3 p75NTR stable cells for the cytoplasmic FRET PKA 
sensor  (pm-AKAR2.2)  in  response  to  forskolin.  FRET  change  represents  membrane 
activation  of  PKA  (c)  Mapping  of  the  p75NTR  sites  required  for  interaction  with 
PDE4A5  using  truncation  of  p75NTR.  Schematic  diagram  of  HA-tagged  p75NTR 
(a)  (b) 
(c) 
(d)   161 
intracellular deletions. TM, transmembrane domain; DD, death domain.  Truncates were 
transiently  transfected  into  NIH3T3  cells.  Lysates  were  immunoprecipitated  with  an 
anti-HA  antibody  and  probed  with  anti-PDE4A  or  anti-p75NTR.  (d)  Co-
immunoprecipitation  of  purified,  recombinant  p75NTR  with  purified,  recombinant 
PDE4A4,  PDE4A5  and  PDE4D3.  Immunoprecipitation  was  carried  out  with 
Glutathione Sepharose beads and probed with anti-GST or anti-MBP. 
 
 
 
Figure 4.3 – p75NTR co-immunoprecipitates with long form PDE4A isoforms in 
transiently transfected NIH3T3 cells.   
 
NIH3T3  cells  were  transiently  transfected  with  HA-tagged  p75NTR  and  long  form 
PDE4A isoforms, PDE4A1, PDE4A4, PDE4A5 and PDE4A11.  BEADS = beads alone, 
L = lysate input control, IP = immunoprecipitate output. Total cell extract was produced 
and the lysates immunoprecipitated with HA anti-sera conjugated agarose beads. These 
IPs were then probed with anti-PDE4A (top panel) and anti-p75NTR (bottom panel) 
anti-sera.  All  Western  blots  are  representative  blots  of  at  least  three  separate 
experiments.   162 
 
 
 
 
Figure 4.4 – Peptide Array mapping of p75NTR’s binding sites on PDE4A5. 
 
Five  amino  acid  overlapping  25mer  peptides  representing  the  sequence  of  PDE4A5 
were spotted onto nitrocellulose membrane. Purified, recombinant His-tagged p75NTR 
was overlaid onto this and anti-His anti-sera was used to detect binding. The schematic 
shows structural areas of binding along with their sequence. All peptide array blots are 
representative of at least three separate experiments. 
 
 
 
4.2.2  Functional effect of p75NTR interaction with PDE4A5. 
 
As previously mentioned, there was reduced PKA activity (thought to be a result 
of lowered cAMP levels) at the plasma membrane upon expression of p75NTR. This 
indicates that p75NTR, through binding of the cAMP hydrolysing enzyme PDE4, may 
lead to compartmentalised cAMP degradation to the membrane. It was important to 
attain whether this effect was purely due to the location of PDE4 at the membrane, due   163 
to an overall increase in PDE levels or if the PDE interaction with p75NTR is somehow 
making the enzyme more basally active leading to increased levels of hydrolysis. The 
protein expression level of PDE4A was not different when I compared levels in wild 
type  NIH3T3  cells  and  NIH3T3-p75NTR  (Fig.  4.5  (a)).    These  data  indicate  that 
expression levels of PDE4A are not affected by expression of p75NTR in these cells. 
This disproves the notion that p75NTR increases local cAMP degradation by altering 
PDE4A expression level and, instead is consistent with it sequestering PDE4A5. To 
study whether PDE4 interaction with p75NTR increases the basal activity levels of the 
PDE4  enzyme  wild  type  NIH3T3  cells  were  transiently  transfected  to  over-express 
PDE4A5, lysates were collected and these were incubated with varying concentrations 
of purified recombinant p75NTR before cAMP PDE activity assays were carried out. 
This showed that p75NTR interaction with PDE4A5 did not alter the activity of this 
enzyme and also did not alter its ability to be inhibited by the PDE4 inhibitor rolipram, 
figure 4.5 (b). This disproves the notion that interaction of p75NTR with PDE4A5 is 
increasing its enzymatic activity therefore showing that the decrease in PKA activity at 
the plasma membrane is not due to increased enzymatic activity of PDE4A5 but is rather 
due to the increased presence of PDE4A5 located to p75NTR.  
 
 
(a) 
 
 
 
80 kDa 
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(b) 
 
 
Figure 4.5 – PDE4 expression in NIH3T3 cells and Phosphodiesterase activity of 
PDE4A5 following p75NTR interaction. 
   
(a) Total cell extract of NIH3T3 cells and NIH3T3 p75NTR stable cells were collected 
and immuno-blotted for PDE4A expression levels using an anti-PDE4A specific anti-
sera. The band at approximately 100 kDa corresponds to PDE4A5 whereas the lower to 
bands at approximately 80 and 66 kDa correspond to lower forms such at PDE4A1 and 
PDE4A7.  (b) NIH3T3 cells were transfected to transiently express rat PDE4A5.  Total 
cell lysate was collected and incubated at 4
oC with three different concentrations of 
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p75NTR (2.5 µg, 5 µg and 10 µg) for 3 hours. An enzymatic activity assay was then 
carried  out  on  the  samples  along  with  a  PDE4A5  alone  control  lysate.  A  second 
enzymatic activity assay was carried out on the same samples with the PDE4-specific 
inhibitor, Rolipram (10 µM). Assays were done using 1 µM cAMP as substrate with 
NIH3T3  cell  lysates  expressing  equal  immuno-reactive  amounts  of  PDE4A5,  as 
determined by the quantification of PDE4A5 expression.  All data shown are mean data 
+/- standard deviation of the three separate transfection experiments. 
 
 
 
4.2.3  PDE4A5 controls p75NTRs role in fibrinolysis and this is in turn mediated 
by MAPKAPK2. 
 
p75NTR is known to play a role in the control of fibrin degradation. In the 
presence of p75NTR the process of fibrinolysis is inhibited. This is evident in figure 4.6 
where I compared wild type NIH3T3 cells to NIH3T3-p75NTR cells in a 3D fibrin gel 
model, used to assess quantitatively fibrin breakdown. In this system, after 9 days, the 
wild  type  cells  exhibited  58  %  +/-  3  %  fibrin  degradation  whereas  the  cells  stably 
expressing  p75NTR  only  exhibited  19  %  +/-  2  %  fibrin  degradation,  this  was  a 
significant difference with a p value of 0.002. Interestingly, when this experiment was 
repeated in the presence of the PDE4 inhibitor rolipram (10 µM) fibrin degradation in 
the wild type cells was unaffected with degradation being 60 % +/- 3 % whereas in the 
NIH3T3-p75NTR cells fibrin degradation dramatically increased to 51 % +/- 9 % with a 
p value of 0.02 when compared to untreated cells.  
 
This  implies  that  PDE4  plays  an  important  role  in  p75NTR’s  control  of 
fibrinolysis  and  that  disruption  of  this  interaction  results  in  alteration  of  fibrin 
degradation. Indeed in Sachs et al., 2007 it is described how this interaction is thought to 
play a role in fibrin degradation and Figure 4.1 provides a modified description of this. 
In short, p75NTR interacts with PDE4A, this interaction leads to reduced local cyclic 
AMP  levels  and  therefore  low  levels  of  PKA  activation.  This  decreased  level  of   166 
cAMP/PKA  reduces  expression  of  tissue  Plasminogen  Activator  and  increases 
Plasminogen Activator Inhibitor-1. This results in reduction of plasmin and plasmin-
dependent extracellular proteolysis, leading to reduction in fibrin degradation.  It should 
be noted that it is not known how, presumably, locally activated PKA inhibits p75NTR 
functioning and allows fibrin breakdown. One possibility is that p75NTR is thought to 
signal through Rho [Yamashita et al., 2003] and as PKA can phosphorylate and inhibit 
the  functioning  of  Rho-GTPases  then  this  might  be  one  possible  route  [Qiao  et  al., 
2003].  
 
In previous chapters it has been mentioned that PDE4 can be phosphorylated by 
MAPKAPK2 and I set out to see if this might affect the interaction of PDE4A5 with 
p75NTR and the role of this receptor in fibrinolysis. Co-immunoprecipitation studies in 
NIH3T3-p75NTR showed that after stimulation of MAPKAPK2 through activation of 
p38MAPK using either anisomycin or TNFα, then an increased amount of endogenous 
PDE4A5 is pulled down with p75NTR (figure 4.7). When MAPKAPK2 activation is 
inhibited using SB203580 this increase was negated. It is known that p75NTR does not 
contain  a  phosphorylation  site  for  MAPKAPK2  so,  presumably,  this  increase  in 
interaction was occurring through the MAPKAPK2 phosphorylation of PDE4A5. To 
gain  insight  into  this,  NIH3T3-p75NTR  cells  were  transiently  transfected  to  over-
express PDE4A5 S147A, a mutant form of PDE4A5 that cannot be phosphorylated by 
MAPKAPK2. In co-immunoprecipitation studies using this mutant it was shown that 
upon MAPKAPK2 stimulation there was no longer an increase in interaction between 
p75NTR  and  PDE4A5,  implying  that  the  previous  increase  in  interaction  seen  was 
indeed due to MAPKAPK2 phosphorylation of PDE4A5. 
  
However  what  still  remained  unclear  was  what,  if  any,  role  this  increased 
interaction  would  play  in  p75NTR  and  PDE4  mediated  fibrinolysis.  To  test  this,  as 
previously, wild type NIH3T3 cells were compared to NIH3T3-p75NTR cells both of 
which had been seeded into 3D fibrin gel matrices. The cell-matrices were exposed to 
treatment with anisomycin (10 mg/ml) and fibrin degradation was studied after 9 days, 
figure  4.8.  In  the  wild  type  NIH3T3  cells  no  significant  difference  was  seen  when   167 
comparing fibrin degradation of no treatment 58 % +/- 4 % to anisomycin treatment 57 
% +/- 3 % with a p value of 0.43. However when comparing the two treatments in the 
NIH3T3-p75NTR cells a significant difference is seen with no treatment giving 19 % 
+/- 2 % fibrin degradation whereas anisomycin treatment resulted in 1.4 % +/- 1.1 % 
degradation with a p value of 0.004.  
 
This profound loss of fibrin degradation in anisomycin-treated NIH3T3-p75NTR 
cells was hypothesised to be due to the increased sequestration of PDE4A by p75NTR, 
further  lowering  local  cAMP  levels  and  thereby  further  inhibiting  the  fibrinolysis 
pathway through the pathway elucidated by Sachs et al 2007. To confirm that this effect 
was due to activation of the p38MAPK pathway, and not due to anisomycin having any 
other  ‘off-target’  cellular  effect,  the  experiment  was  repeated  with  the  p38  MAPK 
inhibitor SB203580 along with anisomycin. Results for these treatments of NIH3T3-
p75NTR  show  a  marked  difference  between  the  anisomycin  plus  SB203580  treated 
cells, at 18 % +/- 2 % fibrin degradation compared to anisomycin treatment alone at 1.4 
% +/- 1.1 %, with a p value of 0.005. This shows that the loss of fibrin degradation is 
due to activation of the p38MAPK pathway. In addition to this, I also carried out a 
treatment with both anisomycin and rolipram added together in the NIH3T3-p75NTR 
cells. This led to a level of fibrin degradation of 35 % +/- 3 %, which is a level of 
degradation that lies between that observed upon treatment with rolipram alone and with 
anisomycin alone. This suggests that the effects of p38MAPK pathway activation and 
PDE4 inhibition are competing with each other.   168 
(a) 
 
 
 
(b) 
 
Figure 4.6 – Expression of p75NTR regulates fibrinolysis in NIH3T3 fibroblasts 
and is PDE4 dependent. 
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NIH3T3 cells and NIH3T3 p75NTR stable cells were seeded into 3-Dimensional fibrin 
gels and incubated at 37
oC for 9 days. Cells were either left untreated or subjected to 
prolonged treatment with the PDE4-specific inhibitor, rolipram (10 µM) for 8 days. (a) 
is  10X  magnification  images  of  fibrin  gels  and  lytic  zones.  (b)  is  quantification  of 
degradation of the 3D fibrin gels calculated by weighing after 9 days. All data shown are 
representative mean data +/- standard deviation of three separate experiments. 
 
 
 
(a) 
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(b) 
 
 
(c) 
 
 
Figure 4.7 – MAPKAPK2 phosphorylation of PDE4A5 increases the level of 
PDE4A5 that co-immunoprecipitates with p75NTR. 
 
 (a) NIH3T3 p75NTR stable cells were either; left untreated, challenged for 10min with 
the p38 MAP Kinase activator, TNFα (10 µg/ml), or pre-treated with SB203580 (25   171 
µM) to inhibit the p38 MAP kinase pathway for 30min followed by 10min TNFα  (10 
µg/ml) challenge. Total cell extract was produced and the lysates immunoprecipitated 
with anti-p75NTR anti-sera bound to agarose beads. These IPs were then probed with 
anti-PDE4A for endogenous PDE4A (top panel) and anti-p75NTR (bottom panel) anti-
sera.  (b)  NIH3T3  p75NTR  stable  cells  were  transitently  transfected  to  express  rat 
PDE4A5. The transfected cells were either; left untreated, challenged for 60min with the 
p38 MAP Kinase activator, anisomycin (10 µg/ml), or pre-treated with the p38 MAP 
Kinase  inhibitor,  SB203580  (25 µM)  for  30min  followed  by  60min  anisomycin  (10 
µg/ml) challenge. Total cell extract was produced and the lysates immunoprecipitated 
with anti-p75NTR anti-sera bound to agarose beads. These IPs were then probed with 
anti-PDE4A (top panel) (NB transfection was done using a PDE4A5-VSV construct 
here  however  immuno-blotting  was  carried  out  with  PDE4A  specific  antisera,  it  is 
assumed  that  the  doublet  band  seen  represents  endogenous  PDE4A5  as  well  as  the 
PDE4A5-VSV  transfected  construct)  and  anti-p75NTR  (bottom  panel)  anti-sera.  (c) 
NIH3T3  p75NTR  stable  cells  were  transiently  transfected  to  express  the  null 
MAPKAPK2 phosphorylation mutant of rat PDE4A5 (S147A). The transfected cells 
were either; left untreated, challenged for 60min with the p38 MAP Kinase activator, 
anisomycin (10 µg/ml), or pre-treated with SB203580 (25 µM) to inhibit the p38 MAP 
kinase pathway for 30min followed by 60min anisomycin (10 µg/ml) challenge. Total 
cell extract was produced and the lysates immunoprecipitated with anti-p75NTR anti-
sera bound to agarose beads. These IPs were then probed with anti-PDE4A (top panel) 
and anti-p75NTR (bottom panel) anti-sera. All Western blots are representative blots of 
at least three separate experiments.   172 
(a)
 
 
(b) 
 
Figure  4.8  –  MAPKAPK2  Phosphorylation  regulates  p75NTR  mediated 
fibrinolysis in NIH3T3 fibroblasts and is PDE4 dependent. 
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NIH3T3 cells and NIH3T3 p75NTR stable cells were seeded into 3-Dimensional fibrin 
gels and incubated at 37
oC for 9 days. Cells were either; left untreated, subjected to 
prolonged treatment with the p38 MAP Kinase activator anisomycin (1 µg/ml) for 8 
days, pre-treated with SB203580 (25 µM) to inhibit the p38 MAP kinase pathway for 
one day followed by prolonged treatment with both SB203580 and the p38 MAP Kinase 
activator  anisomycin  (1  µg/ml)  for  8  days,  or  pre-treated  with  the  PDE4-specific 
inhibitor, rolipram (10 µM) for one day followed by prolonged treatment with both 
rolipram and the p38 MAP Kinase activator anisomycin (1 µg/ml) for 8 days. (a) is 10X 
magnification images of fibrin gels and lytic zones. (b) is quantification of degradation 
of  the  3D  fibrin  gels  calculated  by  weighing  after  9  days.  All  data  shown  are 
representative mean data +/- standard deviation of three separate experiments. 
 
 
 
Having  identified  a  novel  role  for  the  p38MAPK  pathway  in  modulating 
regulation of fibrin breakdown through the p75NTR/PDE4A system in a model cell 
system it was important to establish whether this effect could be shown in a primary cell 
system. To do this Mouse embryonic Fibroblast cells (MEFs) were used. Wild type 
MEFs were obtained from both c57 black mice and, in addition, from c57 black mice 
developed  by  Prof  Marco  Conti’s  Laboratory  (UCSF,  San  Francisco,  USA)  to  have 
PDE4A knocked out by deletion of a catalytic unit encoding exon, referred to hereafter 
as  PDE4A  (-/-).    Initial  tests  were  performed  on  these  MEFs  to  confirm  that  they 
expressed both p75NTR and PDE4A (in the wild type) and lacked PDE4A expression 
(in the PDE4A (-/-) knockout), data not shown. Phosphodiesterase activity assays were 
also performed to compare overall PDE and PDE4 activity levels in the wild type MEFs 
and those from the PDE4A-/- knockout. These results showed that knocking out PDE4A 
has  only  a  very  small  effect  on  total  cAMP  phosphodiesterase  activity.  These  data 
confirm  what  has  been  previously  shown  in  the  Houslay  lab  (unpublished)  where 
PDE4A has very low expression level in many non-neuronal cell types. 
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I found that I could use this primary cell system to perform fibrin degradation 
assays as described above. Thus both wild type MEFs and PDE4A (-/-) MEFs were 
seeded  into  3D  fibrin  gel  matrices  and  degradation  studied  after  9  days,  figure  4.9. 
Comparison between the wild type and the PDE4A (-/-) cells showed that while wild 
type cells had a level of fibrin degradation of 20 % +/- 1.7 %, the PDE4A (-/-) MEFs 
cells showed a significantly higher level of degradation at 66 % +/- 9 % with a p value 
of 0.009. This is consistent with a role for PDE4A in regulating p75NTR functioning in 
inhibiting fibrin degradation [Sachs et al., 2007]. It also is consistent with my studies 
showing that pan PDE4 inhibition with rolipram treatment potentiating fibrin breakdown 
in the NIH3T3-p75NTR cell model.  
 
Consistent with this finding, I noted that when wild type MEFs were treated with 
the PDE4 inhibitor rolipram (10 µM) then fibrin degradation rose to 57 % +/- 3 %, 
showing that loss of ‘pan’ PDE4 activity in the fibrin degradation pathway leads to an 
increase  in  fibrinolysis.  However,  I  was  able  to  show  that  loss  of  PDE4A  alone  is 
responsible for this change of fibrinolysis in that when the PDE4A (-/-) MEFs were 
treated with rolipram then fibrin degradation was unchanged from untreated cells, being 
some 60 % +/- 6 % after 9 days. These results show no significant difference to that of 
untreated  PDE4A  (-/-)  MEFs,  with  a  p  value  of  0.23,  figure  4.9.  This  shows  that 
inhibition of the PDE4B and PDE4D isoforms still present in PDE4A (-/-) MEF cells 
does not affect fibrin degradation indicating the regulatory effect of p75NTR involves 
purely PDE4A, presumably through its specific sequestration to the p75NTR. 
 
The next stage in investigating the role of PDE4A in the inhibitory effect of 
p75NTR  on  fibrin  degradation  in  MEFs  was  to  establish  if  MAPKAPK2 
phosphorylation of PDE4A5 due to activation of the p38MAPK pathway played a role 
in alteration of fibrinolysis, figure 4.9. Comparison of the wild type MEF cells and the 
PDE4A-/- MEF cells, in fibrin degradation assays, showed that prolonged exposure to 
anisomycin (10mg/ml) resulted in 3 % +/- 2 % degradation in the wild type, whereas 59 
% +/- 5 % was shown in the PDE4A (-/-) cells. When these data were compared to the 
results  for  degradation  in  the  absence  of  added  anisomycin,  the  PDE4A  (-/-)  cells   175 
showed no significant difference %, p value of 0.25, to the untreated degradation level 
of 66 % +/- 10 observed.  However, in marked contrast to this when using the wild type 
MEFs  a  significant  difference  was  seen,  in  that  under  anisomycin  challenge  fibrin 
degradation in wild type MEFs is fully ablated. The anisomycin experiment was then 
repeated in the presence of the p38 MAP Kinase inhibitor SB203580, which is shown to 
have no effect on the level of fibrin degradation in the PDE4A (-/-) MEFs but, in the 
case of the wild type MEFs, it returns the degradation level back to ones that are similar 
to the level seen upon no treatment, namely 20 % +/- 5 %, confirming that this effect 
was indeed due to activation of the p38 MAP Kinase signalling cascade and not any off-
target effect of anisomycin on these cells. 
 
Although this confirmed that the p38 MAP Kinase pathway seems to play a role 
in loss of fibrin degradation I needed to design experiments to determine whether the 
observed effects were due to PDE4A phosphorylation by MAPKAPK2 or not, figure 
4.10.  To  do  this  PDE4A  (-/-)  MEFs  were  efficiently  transfected  (>  65-80%)  using 
Amaxa® technology to express either PDE4A5 or the MAPKAPK2 phosphorylation 
null mutant of PDE4A5, namely S147A-PDE4A5, figure 4.10. Such transfected cells 
were seeded into 3D fibrin gel matrices and exposed to a series of treatments, as was 
done previously. Re-introduction of PDE4A5 into the knockout MEFs was shown to 
“rescue” (recapitulate) the effect seen in wild type cells with degradation levels of 22 % 
+/- 9 % under no stimulation and, indeed, a similar level of degradation (23 % +/- 7 %) 
was  seen  in  the  cells  re-expressing  the  MAPKAPK2  phosphorylation  null  S147A-
PDE4A5 mutant, which I have shown previously (Chapter 3) to have similar cAMP-
degrading PDE activity to wild-type PDE4A5. Cells transfected with either of these two 
constructs showed a similar increase in fibrin degradation upon rolipram challenge with 
wild-type  PDE4A5  transfected  cells  having  a  level  of  58  %  +/-  10  %  and  S147A-
PDE4A5  transfected  cells  having  a  level  of  62  %  +/-  9  %.  However  a  significant 
difference is seen between the MEFs transfected with these two cell constructs in the 
case of anisomycin challenge where wild-type PDE4A5 transfected cells show reduced 
fibrin degradation, 4 % +/- 3 % (p value of 0.031) when compared to untreated cells 
whereas the S147A-PDE4A5 transfected cells do not show any significant difference   176 
compared to untreated cells, with degradation remaining at a level of 25 % +/- 4 % (p 
value of 0.37). Challenge with the p38 MAPK inhibitor SB203580 ablated the effect of 
anisomycin in wild-type PDE4A5 transfected cells (Figure 4.10 c). These data indicate 
that the loss of fibrin degradation seen in wild type MEFs upon anisomycin stimulation 
is likely to be due to the MAPKAPK2 phosphorylation of PDE4A5.  
 
To confirm the role of functionality of PDE4A5 in this system the PDE4A (-/-) 
MEF cells were transfected to express a catalytically inactive form of PDE4A5, figure 
4.11.  This  construct  D591A-PDE4A5  has  a  single  alanine  mutation  of  an  essential 
Asp591 that is located deep in the catalytic pocket which renders it catalytically inactive 
[McCahill et al., 2005]. In the case of PDE4A (-/-) MEFs transfected with this construct, 
then in the fibrin degradation assay, fibrinolysis levels were unchanged by transfection, 
being at a high level of 65 % +/- 5 %.  Additionally there was no significant difference 
seen  in  this  level  upon  challenge  with  either  rolipram  alone,  anisomycin  alone  or 
anisomycin  +  SB203580.    This  shows  that  catalytically  active  PDE4A  must  be 
transfected in for it to have an effect on p75NTR-mediated inhibition of fibrinolysis.  
 
These data all indicate that PDE4A plays a critical role in the ability of p75NTR 
to inhibit fibrin degradation. In order to explore this further I set out to investigate 
whether removing an isoform PDE4 from a different sub-family would an effect of 
fibrin  degradation.  To  do  this  PDE4B  (-/-)  MEFs  were  seeded  into  3D  fibrin  gel 
matrices and degradation was compared with that of wild-type MEFs, figure 4.12. This 
showed  that  both  wild  type  and  PDE4B  (-/-)  MEFs  had  a  similar  level  of  fibrin 
degradation of 20 % +/- 2 % and 17 % +/- 5 %, respectively, with a p value of 0.18. This 
shows  that  loss  of  PDE4B  does  not  affect  p75NTR  mediated  inhibition  of  fibrin 
degradation.  I  also  showed  that  under  challenge  with  either  rolipram  alone  or 
anisomycin  alone  or  anisomycin  +  SB203580  there  was  no  significant  difference 
between the data obtained using wild type MEFs compared to the PDE4B (-/-) MEFS.  
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(|a)
 
 
(b) 
Figure  4.9  –  MAPKAPK2  Phosphorylation  regulates  p75NTR  mediated 
fibrinolysis in Mouse Embryonic Fibroblasts and is PDE4A dependent. 
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Mouse Embryonic Fibroblasts (MEFs) and PDE4A knock-out (4A-/-) mouse embryonic 
fibroblasts were seeded into 3-Dimensional fibrin gels and incubated at 37
oC for 9 days. 
Cells  were  either;  left  untreated,  subjected  to  prolonged  treatment  with  the  PDE4-
specific inhibitor, rolipram (10 µM) for 8 days, subjected to prolonged treatment with 
the p38 MAP Kinase activator anisomycin (1 µg/ml) for 8 days, or pre-treated with 
SB203580 (25 µM) to inhibit the p38 MAP kinase pathway for one day followed by 
prolonged  treatment  with  both  SB203580  and  the  p38  MAP  Kinase  activator 
anisomycin (1 µg/ml) for 8 days. (a) is 10X magnification images of fibrin gels and lytic 
zones. (b) is quantification of degradation of the 3D fibrin gels calculated by weighing 
after 9 days. All data shown are representative mean data +/- standard deviation of three 
separate experiments.   179 
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(d)
 
 
Figure  4.10  –  MAPKAPK2  Phosphorylation  of  PDE4A5  regulates  p75NTR 
mediated fibrinolysis in Mouse Embryonic Fibroblasts. 
   
PDE4A  knock-out,  PDE4A  (-/-),  mouse  embryonic  fibroblasts  were  transiently 
transfected to express PDE4A5 and the null MAPKAPK2 phosphorylation mutant of rat 
PDE4A5 (S147A). (a) and (b) shows western blots of lysates of these cells, immuno-
probed with a PDE4A specific antibody. They were then seeded into 3-Dimensional 
fibrin gels and incubated at 37
oC for 9 days. Cells were either; left untreated, subjected 
to prolonged treatment with the PDE4-specific inhibitor, rolipram (10 µM) for 8 days, 
subjected to prolonged treatment with the p38 MAP Kinase activator anisomycin (1 
µg/ml) for 8 days, or pre-treated with SB203580 (25 µM) to inhibit the p38 MAP kinase 
pathway for one day followed by prolonged treatment with both SB203580 and the p38 
Treatment 
F
i
b
r
i
n
 
d
e
g
r
a
d
a
t
i
o
n
 
(
%
 
l
o
s
s
 
o
f
 
i
n
i
t
i
a
l
 
g
e
l
 
w
e
i
g
h
t
)
   181 
MAP Kinase activator anisomycin (1 µg/ml) for 8 days. (c) is 10X magnification images 
of fibrin gels and lytic zones. (d) is quantification of degradation of the 3D fibrin gels 
calculated by weighing after 9 days. All data shown are representative mean data +/- 
standard deviation of three separate experiments. 
 
 
 
(a) 
 
 
(b) 
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(c)
 
 
Figure 4.11 – PDE4A5 function regulates p75NTR mediated fibrinolysis in Mouse 
Embryonic Fibroblasts. 
   
PDE4A  knock-out  PDE4A  (-/-)  mouse  embryonic  fibroblasts  were  transiently 
transfected  to  express  PDE4A5  and  catalytically  inactive  mutant  of  rat  PDE4A5 
(PDE4A5-CI), western blot of PDE4A5 catalytically inactive reintroduction is shown in 
(a), blots were probed with a PDE4A specific antibody. They were then seeded into 3-
Dimensional  fibrin  gels  and  incubated  at  37
oC  for  9  days.  Cells  were  either;  left 
untreated, subjected to prolonged treatment with the PDE4-specific inhibitor, rolipram 
(10  µM)  for  8  days,  subjected  to  prolonged  treatment  with  the  p38  MAP  Kinase 
activator anisomycin (1 µg/ml) for 8 days, or pre-treated with SB203580 (25 µM) to 
inhibit the p38 MAP kinase pathway for one day followed by prolonged treatment with 
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both SB203580 and the p38 MAP Kinase activator anisomycin (1 µg/ml) for 8 days. (b) 
is  10X  magnification  images  of  fibrin  gels  and  lytic  zones.  (c)  is  quantification  of 
degradation of the 3D fibrin gels calculated by weighing after 9 days. All data shown are 
representative mean data +/- standard deviation of three separate experiments. 
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(a)
 
 
 
(b) 
Figure  4.12  –  Fibrinolysis  in  mouse  embryonic  fibroblasts  and  is  not  PDE4B 
dependent. 
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Mouse  Embryonic  Fibroblasts  (MEFs)  and  PDE4B  knock-out,  PDE4B  (-/-)  mouse 
embryonic fibroblasts were seeded into 3-Dimensional fibrin gels and incubated at 37
oC 
for 9 days. Cells were either; left untreated, subjected to prolonged treatment with the 
PDE4-specific inhibitor, rolipram (10 µM) for 8 days, subjected to prolonged treatment 
with the p38 MAP Kinase activator anisomycin (1 µg/ml) for 8 days, or pre-treated with 
SB203580 (25 µM) to inhibit the p38 MAP kinase pathway for one day followed by 
prolonged  treatment  with  both  SB203580  and  the  p38  MAP  Kinase  activator 
anisomycin (1 µg/ml) for 8 days. (a) is 10X magnification images of fibrin gels and lytic 
zones. (b) is quantification of degradation of the 3D fibrin gels calculated by weighing 
after 9 days. All data shown are representative mean data +/- standard deviation of three 
separate experiments. 
 
 
 
 
 
4.3  Discussion 
 
 
 
Inappropriate  fibrin  deposition  after  injury  and  in  disease  states  is  a  major 
pathological  condition  which  is  largely  untreatable  clinically  [Adams  et  al.,  2004]. 
Understanding  the  molecular  means  through  which  fibrin  breakdown  is  inhibited  is 
important  in  understanding  molecular  pathologies  and  identifying  new  therapeutic 
targets.  The  p75  neurotrophin  receptor  is  up-regulated  in  injury  and  many  fibrotic 
disease states and can markedly inhibit fibrin breakdown. In this study and through 
collaboration with the Akassoglou lab at UCSD we have shown that to achieve this 
inhibitory  action  of  p75NTR,  it  needs  to  sequester  PDE4A5  [Sachs  et  al.,  2007]. 
Interestingly  many  PDE4  selective  inhibitors  have  already  been  developed  to  treat 
inflammatory lung disease, where fibrosis is a major issue. A key part of the efficacy of 
these drugs relates to their being potent inhibitors of the action of TNFα [Houslay et al., 
2005; Spina, 2008]. TNFα is already known to have potent pro-fibrotic actions, the 
molecular basis of this is poorly understood. It is however known that a key signalling   186 
pathway  activated  by  TNF– α  [Itatsu  et  al.,  2009]  is  the  stress-activated,  p38  MAP 
kinase cascade [Dent et al., 2003; Uhlik et al., 2003; Xu et al., 2006], which plays a 
fundamental role in regulating the immune and inflammatory response to infection and 
tissue injury [Dong et al., 2002]. 
 
MAPKAPK2  is  an  important  downstream  protein  kinase  in  the  p38  MAPK 
pathways. It is phosphorylated and activated by p38 MAPK [Ben-Levy et al., 1998; 
Meng et al., 2002; Stokoe et al. 1992]. Relatively few substrates for MAPKAPK2 have 
been identified to date limiting the understanding of the consequences of its activation. 
In chapter 3 it was shown that MAPKAPK2 can phosphorylate PDE4A5, leading to 
attenuation of its activation through PKA phosphorylation.  
 
Using NIH3T3 cells as a model system and MEFs as a primary cell system, I 
have shown that in cells containing both p75NTR and PDE4A5 there was only a very 
low level of fibrin degradation, consistent with the hypothesis that PDE4A5 activity and 
p75NTR play a role in inhibiting fibrin breakdown. This is further proved through the 
use of the PDE4 specific inhibitor, Rolipram and MEF 4A (-/-) knockout cells where I 
showed  that  fibrin  degradation  is  greatly  enhanced.  However,  I  also  observed  that 
anisomycin treatment, and therefore activation of MAPKAPK2, profoundly decreases 
fibrin  breakdown  in  wild-type  cells  whilst  it  fails  to  inhibit  the  enhanced  fibrin 
breakdown  seen  in  PDE4A  (-/-)  knockout  MEFs.  This  indicates  that  anisomycin  is 
exerting  its  inhibitory  effect  through  PDE4A5,  which  is  confirmed  by  anisomycins 
inability  to  inhibit  the  amplified  rate  of  fibrin  breakdown  seen  in  wild-type  MEFs 
treated with rolipram to pharmacologically ablate PDE4 activity. These results were 
recapitulated  through  transfection  of  PDE4A5  back  in  to  the  PDE4A  (-/-)  knockout 
MEFs, with this experiment resulting in restoration of the loss of fibrin degradation seen 
in wild type MEFs. Demonstration of a role for MAPKAPK2 in this regulatory system 
was shown by transfection of the MAPKAPK2 phosphorylation-defective Ser147Ala-
PDE4A5 mutant into PDE4A (-/-) knockout MEFs. Whilst this mutant PDE4A5, which 
has identical activity to wild-type PDE4A5 led to a similar decrease in fibrin breakdown 
as seen with the wild-type PDE4A5, now anisomycin failed to cause any inhibition of   187 
fibrin breakdown in cells transfected with this MAPKAPK2-phosphorylation defective 
mutant PDE4A5.   
 
I  propose  that  phosphorylation  of  PDE4A5  by  MAPKAPK2  causes  a 
conformational change in PDE4A5 of which one functional, phenotypic output is an 
enhanced ability to interact with p75NTR and consequent decrease in fibrin breakdown 
in fibroblasts expressing these species. This novel regulatory mechanism may provide 
an  important  contributor  to  the  pro-inflammatory  and  pro-fibrotic  actions  associated 
with activation of the p38 MAPK/MAPKAPK2 phosphorylation cascade by TNFα and 
other inflammatory activating species. It may also provide and explanation as to why 
PDE4 inhibitors can reduce not only the progression of fibrosis but also aid remodelling 
by facilitating fibrin breakdown [Cortijo et al., 2009; de Visser et al., 2008; Videla et al., 
2006].  
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Chapter 5                  Multi-functional Docking Domains  
                                                              On PDE4A5  
 
5.1 Introduction 
 
With completion of the human genome project giving us a greater insight into 
disease  the  requirement  for  a  quick,  effective  method  of  peptide  screening,  for  the 
development  of  new  peptide  therapeutics  (biologics),  has  become  of  increasing 
importance.  Several  high  throughput  techniques  for  doing  this  have  been  developed 
recently. One interesting technique for high throughput analysis of potential therapeutic 
targets is the SPOT-synthesis peptide library method. This method uses combinatorial 
chemistry to simultaneously create a number of different peptides in a library for use in 
screening  specific  targets  for  defining  protein-protein  interaction  surfaces,  peptide 
agonists/antagonists  and  peptides  binding  to  enzymes  as  substrates,  inhibitors  and 
regulators [Frank, 2002].  
 
In this technique short peptide chains are synthesized on a cellulose membrane 
where, for example, they can be overlaid with a tagged purified recombinant protein to 
elucidate whether interaction of the peptide and protein can occur or treated with an 
enzyme, such as a protein kinase to determine if they act as either a substrate or inhibitor 
[Kofler et al., 2005; Baillie et al., 2007; Sachs et al., 2007]. In the case of the work done 
in the study described here, peptides 25 amino acids in length, each overlapping by 5 
residues, were synthesized to span the entire sequence of proteins such as PDE4A5. This 
peptide array was then overlaid with the potential interacting protein of interest and, in 
combination with analysis of 3D protein structures, the putative location of interaction 
sites can be elucidated [Bolger et al., 2006]. The role of individual amino acids within 
these  potential  linear  binding  epitopes  can  then  be  investigated  by  the  creation  of 
scanning amino acid substitution arrays. In these, every amino acid in a 25mer sequence 
is replaced by alanine, in turn, to create a library of ‘mutant’ peptides from the parent 
interacting peptide. Using this one can establish if binding is altered with a particular   189 
amino  acid  substitution  and,  therefore,  identify  the  potential  importance  of  specific 
amino acids in the native peptide sequence in binding of the interacting protein. Once 
potentially important individual amino acids are elucidated through this technique they 
can then, once more, be altered to various other amino acids to allow optimization of 
protein binding through increasing affinity and selectivity [Gold et al., 2006]. Following 
this, membrane permeable peptides can be made to try and disrupt specific protein-
protein  interactions  within  the  cell.  These  offer  the  potential  for  developing  smaller 
peptides and peptidomimetics for potential therapeutic use in particular instances.   
 
Despite this technique providing a highly specific, detailed way to establish the 
nature  of  protein-protein  interactions  it  should  be  noted  that  it  must  be  used  with 
caution. Using small length peptides does not take in to account the steric chemistry of 
the proteins and therefore could give false positive results or miss detecting binding 
involving a number of amino acids that are far separated in the linear sequence but 
coalesce to form a complex binding site within the 3-D protein structure. To eliminate 
false positive interactions other biological techniques, such as co-immunoprecipitation, 
site-directed mutagenesis and bioinformational analyses, must be used in parallel with 
this technique. 
 
Through use of SPOT-synthesis technology binding sites on PDE4 isoforms for 
beta-arrestin, RACK1 [Bolger et al., 2006], DISC1 [Murdoch et al., 2007] and Nudel 
[Collins  et  al.,  2008]  have  been  identified.  Here  I  have  identified  a  potential 
multifunctional docking site on the conserved catalytic unit of PDE4 isoforms. In other 
systems it has been suggested that proteins can contain multifunctional docking sites 
that allow them to bind a host of rapidly exchanging signaling molecules and potentially 
act  as  a  scaffold  for  signaling  [Ponzetto  et  al.,  1994].  Examples  of  this  have  been 
identified in c-Kit, a pro-oncogenic stem cell factor receptor that can associate with 
three different members of the Src family through two separate multifunctional docking 
sites  [Wollberg  et  al.,  2003]  and  in  the  hepatocyte  growth  factor  receptor  where  a 
multifunctional binding site has been shown to interact with various SH2 containing 
signal transducers [Ponzetto et al., 1994].   190 
 
The discovery of a multifunctional docking site on PDE4 enzymes may allow for 
a deeper understanding in the role of these enzymes in signal scaffolding, provide a 
means of fidelity that constrains the number of partner proteins that a PDE4 isoform can 
engage with at any one time, may help untangle the issue of complicated side effects 
associated with therapeutic PDE inhibitors and may offer a new means of designing 
therapeutics using agents that modulate interaction at such sites.   
 
 
 
5.2 Results 
 
With the discovery of peptide array mapping technology the identification of potential 
sites of interaction between proteins has become easier. Interestingly, the fidelity and 
efficiency of phosphorylation of proteins, including certain PDE4 species, by the MAPK 
signaling  pathway-related  kinase,  ERK  requires  docking  sites  in  addition  to  the 
consensus recognition site surrounding the target serine [Sharrocks et al., 2000]. These 
KIM and FQF sites greatly facilitate phosphorylation by allowing ERK to dock onto the 
target molecule.  As stated in previous chapters (Chapter 3) the kinase, MAPKAPK2 has 
been shown to phosphorylate PDE4. Clearly MAPKAPK2 has to interact directly with 
PDE4A5 to phosphorylate it. Here I set out to see if PDE4A5 and MAPKAPK2 bind to 
each other and be co-immunoprecipated and also to see if interaction sites could be 
identified using scanning peptide array technology.  
 
5.2.1  A Potential Multifunctional Docking Domain 
 
Previous work has shown that long form PDE4s contain an FQF binding motif 
that has been observed to play a critical role in its ability to bind several important 
regulatory proteins, such as ERK and beta-arrestin [Bolger et al., 2006] for example. To 
confirm whether this region is also critical for the interaction of MAPKAPK2 and other 
binding partners to PDE4A5, 5-residue overlapping 25-mer peptide arrays were made   191 
with amino acid sequences representing this area for both PDE4A5 and PDE4D5 (amino 
acids 667-716 on PDE4A5 and amino acids 651-700 on PDE4D5). The PDE4A5 arrays 
were probed with purified recombinant GST alone and purified recombinant versions of 
two interactors known to bind to PDE4A5, namely the Src family tyrosyl kinase Lyn 
and MAPKAPK2, figure 5.2(a). Previously it had been shown that the SH3 domain of 
Lyn binds to the unique N-terminal domain of PDE4A5 [Beard et al., 2002]. These 
results showed that both full-length Lyn and MAPKAPK2 bind at the general site of the 
FQF motif, whereas GST alone does not. This identifies then a new binding site for Lyn 
on PDE4A5, namely within the FQF region, adding it to the growing number of proteins 
that bind to PDE4 isoforms at >1 interaction site.   
 
The  PDE4D5  arrays  were  probed  with  purified  recombinant  GST  alone  and 
purified recombinant versions of the known interactors, the sumo-conjugating enzyme 
UBC9, ERK and beta-arrestin, figure 5.2(b). These results showed that UBC9, ERK and 
beta-arrestin all bind at the general site of the FQF motif, whereas again GST alone does 
not. To confirm that this was due to the FQF portion of this region alanine scans were 
produced of the FQF region and its surrounding amino acids in both PDE4A5, figure 
5.3(a)  and  PDE4D5,  figure  5.3(b).  These  were  overlaid  with  the  same  proteins 
mentioned above and all five of the proteins showed decreased binding when either of 
the phenylalanines of the FQF motif were mutated to alanine. 
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Figure 5.1 – Sequence alignments of Phosphodiesterase 4 Long Isoforms   193 
 
 
 
 
 
 
  
 
Figure 5.2 – Various proteins bind to a conserved region in the catalytic domain of 
long form PDE4s. 
 
Peptide arrays were generated for the catalytic domain sequence of A.A. 667-716 on 
PDE4A5 and A.A. 651-700 on PDE4D5. These were probed with different purified 
recombinant  proteins.  (a)  PDE4A5  was  overlaid  with  GST  alone,  GST  tagged  Lyn   194 
which is a protein tyrosine kinase and GST tagged MAPKAPK2. GST-specific anti-sera 
was then used to detect the areas of binding to the membrane. (b) PDE4D5 was overlaid 
with GST alone, GST tagged UBC9 which is an E2 ligase enzyme, GST tagged β-
arrestin which is a signal scaffold protein and GST tagged extracellular regulated kinase 
(ERK).  GST-specific  anti-sera  was  then  used  to  detect  the  areas  of  binding  to  the 
membrane.  All  peptide  arrays  are  representative  arrays  of  at  least  three  separate 
experiments.  
 
 
 
 
 
 
 
Figure 5.3 – Alanine Scanning of PDE4A5 and PDE4D5 sequences surrounding the 
FQF motif.  
 
Peptide array technology was used to synthesise alanine scanning arrays of PDE4A5 and 
PDE4D5  on  a  Whatman  50  membrane.  This  was  done  using  specific  sequences 
highlighted in Figure 5.6. These are amino acids 687-706, in PDE4A5 and amino acids 
664-685 in PDE4D5. A control spot was created with each sequence the each amino 
acid  in  turn  was  mutated  to  alanine.  The  membrane  was  probed  with  purified 
recombinant GST-tagged Lyn or MAPKAPK2 for PDE4A5 or GST-tagged ERK, B-  195 
Arrestin or UBC9. GST-specific anti-sera was then used to detect the areas of protein 
binding to the membrane. Highlighted are the main amino acids where conversion to 
alanine ablates binding. All peptide arrays are representative arrays of at least three 
separate experiments. 
 
 
 
5.2.2  Phosphodiesterase-4 may interact with MAPKAPK2 
 
To further test the hypothesis that PDE4 isoforms might sequester MAPKAPK2 co-
immunoprecipitation studies were carried out. These experiments were performed using 
HEK293 cells, figure 5.4(b), (c) and (d), for PDE4B, PDE4C and PDE4D isoforms and 
using COS1 cells transiently transfected to express PDE4A5, as PDE4A isoforms exist 
in such low levels endogenously they cannot be easily detected, figure 5.4(a). Lysates 
were  made  and  endogenous  MAPKAPK2  was  immunoprecipitated  using  Protein  G 
beads coupled to a commercially available MAPKAPK2 antibody. Western blots were 
then run and probed with antibodies specific for PDE4A, PDE4B, PDE4C and PDE4D. 
These  results  showed  that  long  form  versions  from  all  PDE4  subtypes  could  co-
immunoprecipitate with MAPKAPK2.   196 
 
 
 
 
Figure  5.4  –  MAPKAPK2  interacts  with  PDE4  long  form  isoforms  in  HEK293 
cells. 
 
HEK293 cells were transiently transfected with PDE4A5, (a). Total cell extract was 
produced and the lysates immunoprecipitated with MAPKAPK2 anti-sera conjugated to 
Protein  G  agarose  beads.  This  IP  was  then  probed  with  anti-PDE4A  anti-sera  and 
MAPKAPK2 anti-sera (data not shown). (b), (c) and (d) Total cell extract was produced 
from untransfected wild type HEK293 cells. The lysates were immunoprecipitated with 
MAPKAPK2  conjugated  to  Protein  G  agarose  beads  and  resultant  IPs  probed  with 
PDE4B, PDE4C and PDE4D anti-sera respectively and MAPKAPK2 anti-sera (data not 
shown). All Western blots are representative blots of at least three separate experiments. 
 
 
 
(a)                                                                  (c) 
 
 
 
 
 
 
(b)                                                                  (d)   197 
5.2.3 Phosphodiesterase 4A5 directly interacts with MAPKAPK2 at four specific 
sites 
 
Further studies into the interaction of PDE4 with MAPKAPK2 were focused on 
PDE4A5 as this has been the focus of my studies as described in previous chapters. In 
these I showed that MAPKAPK2 has a functional link in regulating PDE4A5.  
A full-length peptide array of PDE4A5 was made. This consisted of peptide 
“spots” of 25 amino acids that overlapped by five amino acids, making up the entire 
PDE4A5 sequence. This array was then overlaid with purified recombinant GST tagged 
MAPKAPK2 and the location of binding sites established by probing with GST specific 
anti-sera and processed in a similar fashion to a western blot. The results showed that 
when spots previously shown to bind GST alone were discounted; four potential binding 
sites for MAPKAPK2 on PDE4A5 were identifiable, figure 5.5. These sites were amino 
acids  131-155  within  UCR1,  amino  acids  582-606  and  647-671  within  the  catalytic 
region and amino acids 682-702 within the C-terminal region.  
 
To gain further insight into particular amino acids that were important in each of 
these regions and to confirm the fidelity of interaction at such sites, alanine scanning 
peptide arrays were created for each region. These alanine scan arrays were then probed 
with  purified  recombinant  GST  tagged  MAPKAPK2  and  probed  as  described 
previously, figure 5.6. These data show that in the first region identified, in UCR1, 
mutation of amino acids phenylalanine 141, leucine 142 and tyrosine 143 to alanine 
ablated  binding.  This  suggests  that  such  residues  may  play  a  crucial  role  in  the 
interaction  of  PDE4A5  with  MAPKAPK2.  In  the  first  catalytic  region  sequence, 
potentially important amino acids identified as required for binding were Trp 591, Thr 
592, Ile 595, Glu 598 and Phe 599. In the second catalytic region sequence potentially 
important amino acids that were identified as required for binding were Ile 654, Leu 
655, Asp 656, Trp 664, Tyr 665, His 666, Ser 667, Ile 669 and Gln 671. Finally in the 
C-terminal region the amino acids Phe 693, Gln 694, Phe 695, Thr 698, Leu 699, Glu 
700, Glu 701, Glu 702 and Glu 703 were shown to be potentially important amino acids 
required for binding.  
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Surface  exposure  of  these  potentially  important  residues  was  then  evaluated 
using  molecular  modeling  on  PDE4A4,  the  human  orthologue  of  PDE4A5,  as  the 
structure of this human isoform is known [Terry et al., 20003] and the sequence of their 
catalytic units is highly conserved. This analysis showed that amino acids Phe 141, Leu 
142 and Tyr 143; Ile 654, Leu 655 and Asp 656; Trp 664, Tyr 665, His 666 and Ser 667; 
Phe 693, Gln 694, Phe 695 and Thr 698, Leu 699, Glu 700, Glu 701, all were well 
exposed at surface and so could potential interact with MAPKAPK2, Figure 5.7.  
 
 
Figure 5.5 – MAPKAPK2 binds to specific regions of PDE4A5 on a full length 
overlapping Peptide Array. 
 
Peptide array technology was used to synthesise a full-length array of PDE4A5 on a 
Whatman 50 membrane. This consisted of 25 amino acid spots that overlapped by 5   199 
amino  acids.  The  membrane  was  probed  with  purified  recombinant  GST-tagged 
MAPKAPK2. GST-specific anti-sera was then used to detect the areas of MAPKAPK2 
binding to the membrane. Highlighted are the four main regions of most intense binding 
and their sequences. All peptide arrays are representative arrays of at least three separate 
experiments. 
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Figure 5.6 – Alanine Scanning of specific PDE4A5 sequences highlights regions of 
MAPKAPK2 binding. 
 
Peptide array technology was used to synthesise alanine scanning arrays of PDE4A5 on 
a Whatman 50 membrane. This was done using specific sequences highlighted in Figure 
5.5. These are amino acids 131-155, 582-606, 647-671, 682-702. A control spot was 
created with each sequence the each amino acid in turn was mutated to alanine. The 
membrane  was  probed  with  purified  recombinant  GST-tagged  MAPKAPK2.  GST-
specific  anti-sera  was  then  used  to  detect  the  areas  of  MAPKAPK2  binding  to  the 
membrane. Highlighted are the main amino acids where conversion to alanine ablates 
binding.  All  peptide  arrays  are  representative  arrays  of  at  least  three  separate 
experiments.   201 
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Figure 5.7 – Molecular model of PDE4A5 with potential MAPKAPK2 binding 
regions highlighted 
 
This figure was generated in Rasmol by Dr David Adams, University of Strathclyde and 
is of the PDE4A catalytic unit [Wang et al., 2007]. It shows a molecular model of 
potential MAPKAPK2 binding regions, identified using peptide arrays, on the PDE4A 
catalytic unit and can be used to highlight whether they show surface exposure or not. 
 
Site directed mutagenesis was then used to mutate groups of these amino acids to 
alanine in a mammalian expressing pcDNA vector of PDE4A5. Such mutated forms of 
PDE4A5 were then subjected to co-immunoprecipitation studies with MAPKAPK2 after 
over-expression  of  the  mutants  in  COS1  cells,  Figure  5.8.  These  data  showed  that 
mutation of the cluster of Phe 141, Leu 142 and Tyr 143, to alanine, in UCR1 almost 
completely disrupted binding to a level of 3.0 % +/- 3.8 % whereas mutations at the 
other  sites  did  not  elicit  such  a  dramatic  reduction  in  the  interaction  of  with 
MAPKAPK2. Thus mutation of the cluster of Ile 654, Leu 655 and Asp 656 to alanine 
lowered interaction to 88 % +/- 5%, while mutation of the cluster of Trp 664, Tyr 665, 
His 666 and Ser 667 to alanine in PDE4A5 lowered interaction with MAPKAPK2 to 80 
% +/- 7 %, and mutation of the cluster of Phe 693, Gln 694 and Phe 695 to alanine 
lowered interaction with MAPKAPK2 to 63 % +/- 2 % and mutation of the cluster of 
Tyr  698,  Leu  699,  Glu  700  and  Glu  701  to  alanine  lowering  interaction  with 
MAPKAPK2 to 67 % +/- 4 %.   
 
These data show that, to some extent, all of the areas predicted from the scanning 
peptide array analysis to be necessary for the interaction of PDE4A5 with MAPKAPK2 
do indeed appear to play a contributory role, with the Phe-Leu-Tyr motif or, as I term it, 
the  ‘FLY’  site  in  UCR1  region  seemingly  being  most  vital.  It  is  also  apparent  that 
several  of  these  sites  are  conserved  between  several  species  of  long  form  PDE4  as 
shown in the line-up detailed in figure 5.1. 
 
To confirm whether this ‘FLY’ site was indeed a real docking domain a full 
length  overlapping  25mer  peptide  array  was  made  for  another  known  MAPKAPK2   203 
substrate TSC2, (Tuberous Sclerosis 2) and this was overlaid with MAPKAPK2-GST, 
Figure 5.9. One main region of binding was shown on this array from amino acids 1236-
1271. This contained amino acids 1248-Ala-Leu-Tyr-Lys-Ser-Leu-Ser-1255 somewhat 
similar to the binding site seen on PDE4. 
 
 
 
 
100 kDa 
100 kDa 
      IP                 Lysate 
(a)   204 
 
Figure 5.8 – MAPKAPK2 interaction with PDE4A5 mutants in HEK293 cells. 
 
Mutations of PDE4A5 were created where specific binding sites highlighted in peptide 
arrays were mutated to alanine. These were F141, L142 and Y143 to triple alanine, I654, 
L655 and D656 to triple alanine, W664, Y665, H666 and S667 to quadruple alanine, 
F693, Q694 and F695 to triple alanine and T698, L699, E700 and E701 to quadruple 
alanine. HEK293 cells were transiently transfected with PDE4A5. Total cell extract was 
produced and the lysates immunoprecipitated with MAPKAPK2 anti-sera conjugated to 
Protein G agarose beads. (a) This IP was then probed with anti-PDE4A anti-sera and 
MAPKAPK2 anti-sera (data not shown). (b) Percentage difference in binding compared 
to  the  control  was  then  calculated  using  densitometry.  All  Western  blots  are 
representative  blots  of  at  least  three  separate  experiments.
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Figure  5.9  –  MAPKAPK2  binds  to  specific  regions  of  TSC2  on  a  full  length 
overlapping Peptide Array. 
 
Peptide  array  technology  was  used  to  synthesise  a  full-length  array  of  TSC2  on  a 
Whatman 50 membrane. This consisted of 25 amino acid spots that overlapped by 5 
amino  acids.  The  membrane  was  probed  with  purified  recombinant  GST-tagged 
MAPKAPK2. GST-specific anti-sera was then used to detect the areas of MAPKAPK2 
binding to the membrane. Highlighted are the four main regions of most intense binding 
and their sequences. All peptide arrays are representative arrays of at least three separate 
experiments. 
 
 
 
5.3 Discussion 
 
There are many complex interactions in signaling pathways. However, in recent 
years it has become clear that signaling cascades do not work in isolation but, instead, 
many  different  signaling  cascades  can  interact  so  as  to  functionally  integrate  their 
output. The fundamental question now being posed is not only the temporal control of 
such interactions but whether these may indeed be controlled spatially.    206 
 
It  has  been  hypothesized  that  signaling  systems  may  be  controlled  spatially 
through  the  presence  of  protein  recognition  ‘modules’  or  ‘motifs’  that  control  the 
targeting of specific proteins, such as kinases, phosphatases and phosphodiesterases, to 
distinct sites in cells [Sharrocks et al., 2000; Scott and Pawson, 2009; Houslay, 2010]. 
The ERK signaling cascade provides an exemplar of this notion as aberrant activation of 
this pathway can lead to uncontrolled proliferation and, thereby, cancer. One way of 
controlling this pathway is to keep critical components spatially separate in the cell and 
control  functional  interactions.  Additionally,  interactions  between  proteins  in  this 
pathway  are  used  to  enhance signaling,  ensuring  fidelity  of  action  and  potential  for 
maximizing action.  This latter point is particularly pertinent for the action of protein 
kinases to be defined to specific substrates for not only can there be consensus substrate 
motifs that direct phosphorylation to target amino acids but it appears that fidelity and 
efficiency of action of certain kinases can be driven by additional docking and substrate 
specificity  motifs  that  are  spatially  discrete  from  the  site  of  phosphorylation.  The 
exemplar of this is the interaction between the ERK and JNK kinases with authentic 
substrates where two such binding motifs have been identified in addition to the proline-
directed substrate motif that surrounds the phosphorylation target. These are the kinase 
interacting motif (KIM docking motif) that has been shown to act as a target site for 
both  ERK  and  JNK  with  the  consensus  motif  Val-Xaa-Xaa-Lys-Lys-Xaa6-Leu-Leu-
Leu-Xaa122-phosphoSer and the Phe-Xaa-Phe specificity site (FxF docking motif) that 
until now was thought to only confer specificity with regards to ERK action [Sharrocks 
et al., 2000].   
 
 
5.3.1 Kinase Interaction Motif 
 
The presence of these KIM and FxF docking sites have been described on a 
small  number  of  signaling  proteins.  The  KIM  docking  motif  has  been  shown  to  be 
present on the p90 ribosomal S6 protein kinase (RSK), where it targets ERK to the 
kinase allowing for kinase activation via ERK phosphorylation [Smith et al., 1998]. It is   207 
also  present  on  the  protein  tyrosine  phosphatase  PTP-SL  where  it  allows  for  ERK 
targeting to the enzyme and also confers ERK phosphorylation of this enzyme [Pulido et 
al., 1998]. It should be noted, however, that ERK is not the only MAP kinase which can 
be targeted to the KIM docking motif, indeed JNK can also be targeted here. In the case 
of the transcription factor c-Jun, JNK is targeted to its KIM motif, binds, phosphorylates 
and allows for transcriptional activity to occur [Karin, 1995]. 
 
5.3.2 Phe-Xaa-Phe docking motif 
 
The FxF docking site is similar in function to the KIM site in that originally it 
was thought to target for ERK specifically. Its presence was originally identified in the 
transcription factor LIN-1 where it was shown to target for ERK to allow for efficient 
phosphorylation of the factor and for transcriptional activity to occur [Jacobs et al., 
1998]. The transcription factor Elk-1 also has an FxF motif where ERK interacts [Jacobs 
et al., 1999]. It has been hypothesized that this motif contributes to the binding affinity 
of ERK although it is unclear whether this docking motif actually works in a ‘classical’ 
direct binding manner like the KIM motif or if it works through some other mechanism 
[Jacobs et al., 1999]. Indeed here it has been shown that ERK is not the only protein that 
can bind to this site in certain cases (other protein binders include RACK1 and DISC1 
for examples [Bolger et al., 2006; Murdoch et al., 2007] implying that this site works in 
a much more complicated multi-functional manner which will be discussed further later.  
 
5.3.3 Docking motifs on Phosphodiesterase PDE4D 
 
Phosphodiesterases are a prime example of signaling proteins that are involved 
in signaling cascade cross-talk indeed some ‘docking motifs’ on these have already been 
identified [Houslay and Adams, 2003; Houslay 2010]. 
 
The phosphodiesterase isoform, PDE4D3 was the first PDE4D long form to be 
isolated and, as such, has been routinely studied by many investigators. Studies on this 
enzyme  looking  for  binding  motifs  have  shown  that  PDE4D3  contains  both  a  KIM   208 
binding motif, on the β-hairpin loop of its catalytic domain and an FxF binding motif on 
an  exposed  α-helix  of  the  catalytic  domain  [MacKenzie  et  al.,  2000;  Houslay  and 
Adams, 2003]. In the case of this long form phosphodiesterase, the targeted binding of 
ERK to these two motifs allows for phosphorylation of the enzyme at Ser579, leading to 
inhibition  of  enzymatic  activity  [Hoffmann  et  al.,  1999].  The  importance  of  these 
docking/specificity sites was shown through mutation studies where mutation of the key 
binding residues to alanine in either the KIM or the FxF motif led to a loss of ERK 
interaction  and  a  loss  of  ERK  regulated  inhibition  of  the  enzyme  in  intact  cells 
[MacKenzie et al., 2000].  
 
5.3.4 Phe-Xaa-Phe is a binding domain for many proteins on PDE4 
 
During the binding motif studies on PDE4D3 it was highlighted [MacKenzie et 
al., 2000] that both the KIM and FxF binding sites were not only present on this isoform 
of PDE4 but are conserved throughout all of the long form family members as shown 
here in the sequence alignment in Figure 5.1.  
 
To my surprise, peptide array mapping studies of the kinase MAPKAPK2 on the 
PDE4A isoform PDE4A5 identified, for the first time, that this MAPK kinase family 
member can also bind at the same FxF site where ERK is able to bind (Figure 5.2). 
Indeed, subsequent to this, we set out to determine whether other known interacting 
partners of PDE4 might also interact with PDE4D3 at this site (Figure 5.3). The results 
of this identified that the Src tyrosyl kinase Lyn, the sumo-conjugating enzyme UBC9 
and the signaling scaffolding protein b-arrestin can all also potentially bind at this motif. 
This work implies that instead of the FxF being an ERK specific, or even MAP Kinase 
specific  binding  site  it  may  instead  provide  a  multi-functional  docking  domain  for 
several partner proteins of PDE4.  
 
Functionally it is not yet fully clear what effect this may have in vivo but it can 
by hypothesized that the presence of a multi-functional docking site like this may lead 
aid in the fidelity of compartmentalization of signaling through PDE4 species in the cell.   209 
In  doing  this  such  a  site  may  confer  fidelity  of  functionality  by  only  allowing  one 
partner from such a pool using this multi-functional docking site to be engaged with a 
PDE4 enzyme at any one specific time. This would serve to prevent several conflicting 
signaling events to be triggered simultaneously and might also minimize any potential 
for  forming  aggregates.  For  example,  it  could  be  surmised  that,  targeting  of 
MAPKAPK2  to  the  motif,  allowing  for  MAPKAPK2  phosphorylation  of  the  PDE 
enzyme would prevent binding of other protein interactors of the enzyme, such as β-
Arrestin, which may cause a conformational change in the enzyme or ERK which may 
inhibit the enzymes activity. Indeed the purpose of this docking motif may be to provide 
a simple mechanism for spatial regulation of PDE4 isoform function throughout the cell.  
 
 
5.3.5 Does MAPKAPK2 have a docking motif? 
 
Discovery of this apparent multi-functional docking motif in the catalytic region 
of  PDE4  highlighted  the  potential  for  further  docking  motifs  in  this  enzyme.  Using 
MAPKAPK2, the functional interaction of which is discussed in Chapter 3, as a model 
then potential binding sites for this kinase on PDE4 were mapped using peptide arrays 
and mutagenesis, Figure 5.5. Through this study it was shown that mutagenesis of only 
one  of  the  five  potential  binding  sites  for  MAPKAPK2  on  PDE4  fully  ablated 
interaction between these two proteins. This site was Phe-Leu-Tyr referred to here as the 
FLY domain. While, functionally, the significance of this is not yet known, it provides 
interest as a potential docking domain for MAPKAPK2 due to its obvious crucial role in 
determining  PDE4:MAPKAPK2  interaction.  However,  might  other  MAPKAPK2 
substrates exhibit this motif? Indeed when further MAPKAPK2 substrates were studied 
some  key  substrates  were  shown  to  contain  a  similar  motif.  The  well-established 
MAPKAPK2 substrate TSC2 [Li et al., 2003] appears to contain a similar sequence to 
this that lies between amino acids 1236-1271 (Figure 5.9). However in this sequence the 
phenylalanine is replaced with alanine, giving a sequence of Ala-Leu-Tyr. While at first 
sight  this  sequence  may  not  immediately  seem  similar  to  the  docking  site  of 
MAPKAPK2 on PDE4 on closer inspection, and with expansion to look at the sequence   210 
surrounding  this  binding  site,  similarities  become  more  apparent.  While  in  PDE4, 
MAPKAPK2 binding involves a region with the sequence 141-Phe-Leu-Tyr-Arg-Ser-
Asp-Ser-147, in the case of TSC2 binding is seen at the sequence 1248-Ala-Leu-Tyr-
Lys-Ser-Leu-Ser-1255.This seems to suggest that while it was initially thought that a 
FLY domain was responsible for the interaction of MAPKAPK2 with its targets perhaps 
it would be more accurate to suggest that MAPKAP2 requires a Xaa-Leu-Tyr-Xaa-Ser-
Xaa-Ser motif for catalytic binding. It would thus be interesting to see if mutating this 
sequence  in  TSC2  altered  its  interaction  with,  and  ability  to  be  phosphorylated  by, 
MAPKAPK2. 
5.3.6 Significance of Binding Motifs 
 
Here it is clearly demonstrated that there are potential multi-functional docking 
motifs  present  on  Phosphodiesterase-4  enzymes.  This  discovery,  together  with  the 
identification  of  potential  docking  motifs  on  other  signaling  proteins  [Holland  and 
Cooper, 1999], may imply that multi-functional docking domains have an important 
undiscovered  role  in  cell  signaling.  However  it  still  remains  unclear  the  precise 
functional importance of these domains and a great deal of work needs to be down to 
elucidate what control these sites may have. Indeed it would be interesting to uncover 
whether  the  sites  play  a  functional  role  themselves  or  if  they  may  play  a  larger 
scaffolding role in compartmentalization of cellular signaling. Certainly in the case of 
MAPKAPK2 it would be very interesting to discover the real function of this site as this 
kinase plays a wide-ranging role in a number of cells and it would be interesting to 
ascertain whether its role could be controlled through manipulation of these sites.  
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Chapter 6                   Final Discussion 
 
Phosphodiesterase-4 enzymes hydrolyse the second messenger cyclic 3’5’ AMP 
to 5’-AMP and so inactivate this critical second messenger. As PDEs provide the only 
way the cell has to break down cAMP, therefore members of the ubiquitously expressed 
PDE4 family are set to play an important role in cell signaling. In the worked described 
in this thesis I have investigated the phosphorylation and protein-protein interactions of 
the cAMP phosphodiesterase isoform, PDE4A4/5.  Here I showed that PDE4A4/5 can 
be phosphorylated by the p38 downstream kinase, MAPKAPK2. This phosphorylation 
attenuates  the  activation  of  this  phosphodiesterase  through  Protein  Kinase  A 
phosphorylation. I then went on to show that PDE4A4/5 interacts with the low affinity 
neurotrophin  receptor,  p75NTR  and  that  this  interaction  inhibits  normal  fibrin 
breakdown  in  an  in  vitro  model.  I  also  show  that  phosphorylation  of  PDE4A5  by 
MAPKAPK2 enhances the inhibition of fibrin breakdown. In the final section of this 
thesis  I  have  also  shown  that  long  form  PDE4  isoforms  contain  a  potential  multi-
functional docking site where several partner proteins can bind. The implications of this 
body of work are wide ranging and here I set out to discuss why these may have a 
significant impact on the development of PDE4A directed therapeutics, particularly in 
the case of inflammatory disease directed therapeutics. 
 
6.1  The Role of Phosphodiesterase-4 in Inflammatory Disease 
 
  One of the main focuses of the role of PDE4s in a disease state has been 
the investigation of its role in inflammatory diseases [Spina, 2008]. PDE4 provides the 
primary  means  of  cAMP  degradation  in  cells  of  inflammatory  response,  such  as 
macrophages, eosinophils, neutrophils, T cells and B cells [Saetta et al., 1993; Riise et 
al., 1995; Vassallo et al., 2008]. Due to this, inflammatory diseases such as chronic 
obstructive  pulmonary  disease  (COPD),  asthma,  multiple  sclerosis  and  rheumatoid 
arthritis all are thought to have PDE4 isoenzymes playing a key role in their pathology 
[Houslay et al., 2005].  
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cAMP plays a crucial part in the regulation of primary activating pathways such 
as the cytokine release pathway in T cells and macrophages [Kanda & Watanabe, 2001; 
Duan et al., 2010]. It is therefore thought that if PDE4 is inhibited, leading to an increase 
in intracellular cAMP levels, an attenuation of the pro-inflammatory response in the 
cells may occur. Indeed in macrophages it has been shown that increased intracellular 
cAMP levels, in combination with stimulation of the Toll Like Receptor pathways, leads 
to suppression of the generation and release of the pro-inflammatory cytokine, TNFα 
and the induction of the anti-inflammatory cytokine interleukin 10 [Wall et al., 2009]. 
 
Interestingly, different PDE4 isoforms appear to have different actions in airway 
function. Thus, the specific inhibition of PDE4B has been shown to reduce the release of 
pro-inflammatory cytokines such as TNFα in primary macrophages in response to toll 
like receptor signalling [Jin et al., 2005], whereas PDE4D inhibition has been shown to 
promote airway smooth muscle relaxation [Mehats et al., 2003 and Jin and Conti, 2002]. 
It would therefore appear that inhibition of both PDE4 isoforms leads to relief of some 
of the symptoms of COPD in different cell types. 
 
In a clinical context it has been shown that PDE4A4 is up-regulated in BAL 
macrophages  from  patients  suffering  from  Chronic  Obstructive  Pulmonary  Disease 
(COPD),  and  PDE4B2  has  been  shown  to  be  up-regulated  in  peripheral  blood 
monocytes of smokers [Barber et al., 2004]. These findings, in combination with the in 
vitro discoveries described above, would seem to indicate that PDE4 targeted inhibitors 
might indeed provide therapeutic relief of COPD. Interestingly it has also been shown 
that PDE4A4/5 is also up-regulated in sleep deprivation and can cause cognitive defects 
[Vecsey et al., 2009] and, indeed, in inflammatory conditions such as COPD patients 
exhibit sleep deprivation due to constriction of the airways. It would be interesting to 
see if there is a link between these levels of up-regulation within the two conditions and 
perhaps to see if any of the other, non-lung targeted effects of COPD also may be 
occurring as a result of up-regulated PDE4A. Indeed certain forms of heart disease have 
been found to be more prominent in patients suffering from COPD [Rabe et al., 2007]. 
Could it be that use of phosphodiesterase 4 inhibitors in a condition such as COPD   213 
might provide a multi-faceted therapeutic, relieving not just the obvious prominent lung-
centred symptoms of the disease but also exert beneficial actions elsewhere in the body 
at the same time? 
 
6.2  PDE4 Inhibitors 
 
  Due to the obvious role of phosphodiesterase 4 in inflammatory disease a lot of 
work has been carried out in the pharmaceutical industry to develop successful PDE4 
inhibitors as therapeutics for inflammatory diseases. However until now there has been 
limited success in this research until recently [Spina, 2008; Pages et al., 2009; Houslay 
et al., 2005]. 
 
Non-selective phosphodiesterase inhibitors such as theophylline have been used 
for decades to treat bronchial asthma but have always presented problems with major 
side effects like cardiac dysrhythmmia and nausea [Page, 1999]. The PDE4 selective 
inhibitor Rolipram was originally developed as an anti-depressant [Wachtel, 1982] and, 
subsequently, for the treatment of COPD [Barnette & Underwood, 2000]. However, 
major  side  effects,  namely  nausea,  vomiting  and  enhanced  gastric  acid  secretion 
precluded its clinical use for either indication [Hebenstreit et al., 1989].  
 
It therefore became necessary to develop more specific drugs that did not exhibit 
such severe side effects. So following on from these developments a second generation 
of PDE4 inhibitors was created that included Cilomilast and Roflumilast [Spina, 2009] 
that  have  shown  reduced  side  effects  in  animal  models.  Cilomilast,  developed  by 
GlaxoSmithKline, underwent extensive Phase III clinical trials [Houslay et al., 2005; 
Rennard  et  al.,  2006].  Despite  strong  initial  results  this  drug  failed  to  show  any 
significant improvements in a final clinical trial of COPD patients and was therefore 
denied approval by the Food and Drug Administration (FDA) in the USA [Rennard et 
al., 2008]. Roflumilast is one of the most potent oral PDE4 inhibitors with a longer half 
life than Cilomilast [Houslay et al., 2005]. It was also recently denied approval by the 
FDA although, excitingly, it has very recently been approved within Europe as a once-a-  214 
day treatment for COPD patients with chronic bronchitis under the trade name Daxas 
[Rabe,  2010;  Pages  et  al.,  2009;  
http://www.nycomed.com/en/Menu/Media/News+releases/ Nycomed press release].  
 
  Several  other  generations  of  isoform  specific  PDE4  inhibitors  are  also  in 
development , although phase 3 clinical trials have either yet to be performed for these 
or they have not given clinically significant results in phase 2 studies [Spina, 2008; 
Pages  et  al.,  2009].  One  ‘new’  generation  PDE4  inhibitor  which  is  currently  being 
passed through Phase 2 clinical trials is Apremilast which, unlike many other PDE4 
inhibitors, is being developed for the treatment of psoriasis and arthritis, where it shows 
potential  therapeutic  efficacy  [Schafer  et  al.,  2010;  McCann  et  al.,  2010].  Indeed 
development, and the so far success, of PDE4 inhibitors like Apremilast may imply that 
the pharmaceutical industry has been putting too much emphasis on the development of 
PDE4 inhibitors for COPD alone. This emphasis is understandable because COPD is the 
sixth leading cause of death in the world and is proposed to move up to the fourth 
leading cause of death worldwide by 2030 [Mather and Loncar, 2006]. However with 
advances in PDE4 inhibitors for the treatment of COPD being limited perhaps it is time 
that the development of these therapeutics shifted to focus on other disease states where 
PDE4 is implicated to play an important role, such as the inflammatory disorders just 
mentioned (arthritis and psoriasis) and even CNS diseases whether PDE4s have been 
shown to have a role [Sachs et al., 2007; Millar et al., 2007].  
 
 
 
 
6.3  A potential Role for My Findings in the Development of Novel Therapeutics 
 
  As the development of PDE4 inhibitors has been a complicated and challenging 
task  perhaps  a  better  understand  of  the  enzymes  phosphorylation  states  and  protein 
interaction may open up new opportunities for therapeutic development.  
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6.3.1  PDE4 and MAPKAPK2 in therapeutic development 
 
As I have shown in Chapter 3 of this thesis PDE4A5 can be phosphorylated by 
MAPKAPK2,  a  downstream  kinase  of  the  p38  MAP  Kinase  pathway.  This 
phosphorylation  leads  to  attenuation  of  activation  of  the  PDE  through  PKA 
phosphorylation.  Therefore  in  the  presence  of  p38  MAP  Kinase  signaling  pathway 
activation  I  have  shown  that  there  is  a  sustained,  instead  of  transient,  increase  in 
intracellular cyclic AMP levels. 
 
Interestingly inhibition of the p38 MAPK pathway, like PDE4, has also been 
investigated as a potential therapeutic target for inflammatory diseases as it plays a 
fundamental role in the inflammatory response (see Chapter 3.1.3). Thus, it may be that 
activation of the p38 MAPK-MK2 pathway in the inflammatory response will not only 
promote  the  expression  of  pro-inflammatory  mediators  but  may  simultaneously  also 
increase cAMP levels through PDE4 phosphorylation, which creates a form of negative 
feedback  leading  to  suppression  of  this  pro-inflammatory  response  and  increased 
induction of anti-inflammatory cytokines such as interleukin 10. Indeed this would be 
in-keeping with previous studies mentioned above which showed that stimulation of the 
cAMP pathway in combination with the Toll Like Receptor pathways (that have been 
shown  to  activate  p38  MAPK  downstream),  leads  to  negative  feedback  of  the  pro-
inflammatory  cytokine  response  in  macrophages  and  promotion  of  the  anti-
inflammatory response [Wall et al., 2009].  
 
This  discovery  poses  interesting  questions  about  the  development  of  current 
therapeutics p38 MAPK inhibitors [Cohen, 2009]. While it is thought that blocking the 
p38 MAPK pathway or MAPKAPK2 should lead to loss of pro-inflammatory response 
[Cohen,  2009;  Duraisamy  et  al.,  2008],  the  influence  of  these  inhibitors  on  cAMP 
response may now have to be taken into account. Indeed if MAPKAPK2 is inhibited and 
therefore is no longer available to phosphorylate PDE, this may allow for full activation 
of the phosphodiesterase enzyme, leading to a decrease in intracellular cAMP levels and   216 
a loss of the anti-inflammatory response seen in response to TLR stimulation. Indeed in 
these circumstances the most logical therapeutic to be developed would be a selective 
PDE4 inhibitor as this would allow for promotion of the anti-inflammatory response. 
Therefore, while the discovery of the interaction between PDE4 and MAPKAPK2 may 
not  directly  aid  in  the  development  of  more  specific,  effective  PDE4  inhibitors 
therapeutically, it may provide a valuable insight into understanding the downfall of p38 
MAPK pathway-based inhibitor studies [Cohen, 2010; Hendriks et al., 2010].  
 
6.3.2  PDE4 and p75NTR in therapeutic development 
 
p75NTR  has  also  been  shown  to  play  a  role  in  inflammatory  disease  (see 
Chapter 4.1.5) with it being recently proposed that it may, particularly, have a role in 
fibrosis in inflammatory conditions [Sachs et al., 2007]. Indeed p75NTR can markedly 
inhibit fibrin breakdown (leading to tissue scarring). However here I have shown in 
Chapter 4 that for this to occur it needs to sequester PDE4A5. As stated above PDE4 
selective inhibitors have been developed to treat inflammatory diseases, where fibrosis 
is a major issue and as stated previously a key part of the efficacy of these inhibitors 
relates to their ability to inhibit TNFα  [Houslay et al., 2005; Spina, 2008; Wall et al., 
2009]. TNFα is thought to have a potent pro-fibrotic action [Zhang et al., 2007]. The 
molecular basis of this is not fully understood but it is known that the key signaling 
cascade activated by TNFα is the p38 MAPK pathway [Dent et al., 2003; Uhlik et al., 
2003;  Xu  et  al.,  2006].  Here  I  have  shown  that  MAPKAPK2  can  phosphorylate 
PDE4A5  which  in  a  fibrin  model  system  leads  to  an  almost  total  loss  of  fibrin 
breakdown.  
 
Inappropriate fibrin build up may be responsible for tissue scarring of the lungs 
in COPD and asthma [Nakstad et al., 1990]. From what I have shown in this thesis it 
could  be  implied  that  disruption  of  the  interaction  of  PDE4A5  and  p75NTR  may 
decrease this inappropriate loss of fibrin breakdown. Indeed small molecules targeted to 
disrupt this interaction may provide a more specific therapeutic for the treatment of 
certain aspects of COPD, without the potential side effects seen in PDE4 inhibitors. 
However a great deal of research into this still needs to be carried out as disruption of   217 
this interaction may have significant effects elsewhere in the body.  In this context it 
may also be appropriate for inhibitors of the p38 MAPK pathway to be employed as 
they may also help enhance fibrin breakdown through loss of PDE4 phosphorylation. 
 
6.3.3  The effect of a multifunctional docking domain on therapeutic 
development 
 
In  the  final  study  described  within  this  thesis  I  discovered  a  potential 
multifunctional docking domain on PDE4 long isoforms. The significance of this still 
remains unclear and much more research is needed into this before full conclusions can 
be made. It may be however that the presence of a multi-docking site like this plays 
some role in the adverse effects of PDE4 inhibitors as such inhibitors may be affecting 
the interaction of PDE4 with several partner proteins, not just ones involved in target 
reactions. Indeed it may also be altering compartmentalization of the PDE4 enzymes 
allowing for uncontrolled, unregulated distribution throughout the cell. 
In the context of the work I have done here, and with the development of peptide 
array mapping technology, it would be interesting to speculate what small molecule 
disruption  of  the  complexes  described  throughout  this  thesis  would  result  in 
functionally.  Small  molecule  disruption  targeting  MAPKAPK2s  interaction  with  the 
FLY domain of PDE4A5 may not be an ideal therapeutic target as it would appear that 
disruption of this interaction would lead to increased PDE4 activity, decreased cAMP 
levels  and  therefore  a  loss  of  anti-inflammatory  action.  However,  small  molecular 
disruption of the specific interaction sites for p75NTR with PDE4A5 may have more 
potential as a therapeutic. Indeed it could be speculated that disruption of this complex 
would lead to increased fibrin breakdown, potentially relieving fibrin scarring exhibited 
in conditions such as COPD and spinal cord injury where inappropriate fibrin deposition 
is an issue [Beattie et al., 2002; Sachs et al., 2007].  
 
 
 
6.4  Final Conclusion 
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  In  conclusion,  here  I  have  identified  new  aspects  of  Phosphodiesterase-4 
interaction and regulation. This gives an insight into how this enzyme may function in 
the inflammatory system however its precise mechanism of action appears to be very 
complicated and further research is required to decode its precise role throughout this 
system.  
Issues that I think need to be addressed globally, how my work can help solve these and 
how I would continue this research: 
•  In my opinion the development of PDE4 inhibitors as a therapeutic target is 
currently too broad ranging. Focusing on PDE4 as one single target is clearly not 
working as this research has been ongoing for many years and still too many side 
effects are observed with these inhibitors. Instead perhaps a better option would 
be to focus on very specific PDE4 isoforms and their partner proteins in specific 
disease  states.  Disruption  of  individual  interactions  like  these  may  provide 
highly specific therapeutics lacking adverse side effects. For example, here I 
have shown that interaction between PDE4A4/5 and p75NTR occurs at specific 
sites. If I had more time to further this work it would be interesting to see if these 
sites could be manipulated to produce a small disruptor molecule to stop this 
interaction. This could then be used in cell system models to see how it affects 
fibrin breakdown and, with ethical approval, could then be used in whole animal 
studies to see the effects that this molecule would have on COPD animal models 
and spinal cord injury animal models. 
•  I also think progression of the work on PDE4 and MAPKAPK2 phosphorylation 
may give an interesting insight into the complex inflammatory feedback system 
in the immune system. Indeed if I had time to further this work I would use a 
primary cell system such as Bone Marrow Derived Macrophages (BMDMs) to 
observe  how  loss  of  PDE4A  (through  knock-out)  affects  the  inflammatory 
response of these cells in response to activation of the p38 MAPK pathway. 
Indeed PDE4A, MAPKAPK2 double knockout mice could also be engineered to 
study the effects on inflammation upon loss of both of these signaling pathways. 
I would hypothesise that in PDE4A (-/-) BMDMs there would be an increase in 
the  anti-inflammatory  response  from  these  cells,  counteracting  the  pro-  219 
inflammatory  surge  and  indeed  in  a  MAPKAPK2/PDE  4A  double  knock-out 
system the anti-inflammatory response would be increased as well as the pro-
inflammatory response decreasing. This process could however be complicated 
as  knock-out  of  two  important  signaling  enzymes  such  as  PDE4A  and 
MAPKAPK2 in one mouse model may not be viable.    220 
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